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1.0 The role of granulocytes in chronic inflammatory diseases 
Human granulocytes develop in the bone marrow from myeloid precursor cells that, when 
terminally differentiated, are released into the peripheral blood. There are three types of 
granulocytes: neutrophils, eosinophils and basophils. In this thesis, we have focused on 
eosinophils and neutrophils, the body’s first line of defense against invading 
microorganisms, and are critical effector cells in both innate and adaptive immunity (1-3). 
While neutrophils are critical effector cells in the killing and removal of bacteria (1,2), 
eosinophils are involved in the killing of parasitic worms (4).  
A consequence of granulocyte activation in vivo is the ability to cause tissue damage, as is 
often seen at inflammatory loci. Correct functioning of granulocytes and a controlled 
clearance of these cells contributes to a proper inflammatory response. This is required to 
prevent greater tissue damage than necessary, and enables repair of the tissue over time. 
Long term and/or uncontrolled activation of granulocytes, however, is thought to play an 
important role in the pathogenesis of several inflammatory diseases. These range from 
severe acute diseases, for example adult respiratory stress syndrome (5,6,7) to chronic 
inflammatory diseases, such as chronic obstructive pulmonary disease (COPD) and 
asthma (8,9). Allergic asthma is characterized by an increase predominantly of 
eosinophils in the airways, whereas neutrophils accumulate in this compartment in COPD. 
This thesis focuses on the role of peripheral blood neutrophils in systemic inflammation 
observed in COPD. 
 
1.1 COPD 
Chronic obstructive pulmonary disease (COPD) is characterized by irreversible airflow 
limitation. Airflow limitation results from of aspects of two closely interrelated diseases 
of the respiratory system, chronic bronchitis and emphysema (8,10,11). Chronic bronchitis 
is a chronic inflammatory disease in the airways and is characterized by an excessive 
airway mucus secretion leading to a persistent, productive cough (10). In addition, there 
may also be narrowing of the large and small airways causing dyspnea in these patients. In 
emphysema there is a permanent destruction of the alveoli, due to the irreversible 
degradation of proteins like elastin in the lung. This leads the to loss of structure of 
alveolar walls, and decreased elasticity of the alveolar tissue. Loss of elastin also causes 
collapse and narrowing of the bronchioles, which in turn limits expiratory airflow (10). 
Most patients with COPD suffer from both pathologic entities, but the relative extent of 
emphysema and obstructive bronchitis within individual patients can vary. Smoking is the 
major risk factor to develop COPD in the western world (12). In general COPD develops 
in older individuals with a long smoking history and 15-20% of all smokers will develop 
clinically symptomatic COPD during their lifetime(13).  
Lung function tests and chest radiographs are generally used for routine diagnosis of 
COPD and monitoring of airway obstruction. Because of their simplicity and 
 reproducibility, forced vital capacity (FVC), forced expiratory volume in one second 
(FEV1), the ratio of these two parameters, and the absence of reversibility of airway 
obstruction are the main parameters for monitoring COPD (11). Lung function studies 
have demonstrated that the FEV1 declines slowly with age even in healthy non-smokers, 
but this gradual loss of function will have no significant clinical effects, due to normal 
excess of the lung capacity (Fig. 1)(14). In smokers, however, lung function tends to 
decrease much more rapidly. If a smoker stops smoking before serious COPD develops, 
the rate of decline of the FEV1 may return to almost normal in individuals (15). Other risk 
factors for COPD are continuous exposure to occupational dusts and chemicals, 
infections, and outdoor and indoor air pollution (11). Since not all smokers will develop 
COPD, there must be additional risk factors involved and it is also thought that genetic 
factors will be important. Data suggest that imbalances between proteases and anti-
proteases and oxidants and anti-oxidants contribute to the pathogenesis of the disease. 
Supporting this view, there is a genetic variant of COPD, which is caused by a deficiency 
of alpha-1-antitrypsin (AAT) (16). AAT protects for the destruction of elastin by 
elastases, such as neutrophil elastase. If individuals with a genetic deficiency of AAT also 
smoke, they usually will develop symptoms of COPD by the time they reach early middle 
age.  
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Figure 1: Presumed effect of smoking cessation on decrease in forced expiratory volume at 1 
second (FEV1). FEV1 of individuals who have never smoked or are not susceptible to smoke were 
compared with patients who stopped smoking at different stages in life. Disability occurs at ~30% 
FEV1, and death occurs at ~10%, as indicated by the dotted horizontal lines. Adapted from Fletcher 
et al. (14). 
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The course of the disease can be divided into four different clinical stages according to the 
classification of the GOLD guidelines (Table 1) (11). Stage 0 (“at risk”) refers to patients 
with chronic cough and sputum expectoration, but without any abnormality of the lung 
function as measured by FVC and FEV1. Stage I patients (“mild”) have mild airflow 
obstruction, defined as a ratio of FEV1 to FVC of less than 0.7, but an FEV1 that is still, 
greater than 80%. Stage II (“moderate”) patients with moderate airflow limitation are 
subdivided in group A, which contain patients with an FEV1 between 50 and 80%, and in 
group B, which exists of patients with a FEV1 between 30 and 50%. Usually in stage II, 
patients begin to experience also dyspnea especially upon exertion, and exacerbations of 
symptoms. Stage III patients have severe airflow limitation with an FEV1 less than 30% 
and at this stage quality of life is severly impaired. Exacerbations are typical in moderate 
to severe stages of COPD and are charcterized by increased dyspnea, cough, and sputum 
production lasting days to a few weeks (17,18). These exacerbations may have several 
inciting factors, including viral or bacterial infections, or common pollutants, and 
probably are associated with increased inflammatory changes within the respiratory tract. 
These exacerbations can be life threatening, cause frequent hospitalization and will have a 
negative influence on the prognosis of a COPD patient. Moreover comorbidity like right 
heart failure may aggravate symptoms. 
Table 1.  Classification of COPD according to the GOLD guidelines (10)
0: At risk normal lung function
chronic symptoms (cough, sputum)
I: Mild FEV1/FVC < 70%; FEV1 ≥ 80% predicted.
(With or without symptoms of cough, sputum)
II: Moderate FEV1/FVC <70%;
A:      FEV1 80-50% predicted
B:      FEV1 50-30% predicted
III:Severe FEV1/FVC <70%; FEV1<30% predicted
or FEV1 <50% predicted plus: respiratory failure or
clinical signs of right heart failure
FEV1:   Forced expiratory volume in one second
FVC:    Forced vital capacity
Class Characteristics
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Recently, the definition of COPD has been extended and is now: “a disease state 
characterized by airflow limitation that is not fully reversible. The airflow limitation is 
usually both progressive and associated with an abnormal inflammatory response of the 
lungs to noxious particles and gases” (11). Thus it is now generally accepted that COPD is 
associated with an abnormal inflammation in the airways. It is thought that this abnormal 
inflammatory response is mediated by increased levels of cytokines/chemokines, such as 
TNFα and IL-8, as found in bronchial alveolar lung (BAL) fluid and sputum (19-21). 
Furthermore, increased levels of neutrophils, monocytes and CD8+ cytotoxic lymphocytes 
are found in the lungs (22). Their recruitment is likely to be mediated by the increased 
levels of cytokines/chemokines in the lungs (23-26). Indeed, studies have measured 
neutrophil activation in the lungs of COPD patients (21,23,27,28). This implicates an 
important role for neutrophils in the pathogenesis of COPD. The identification of 
increased concentrations of soluble TNF receptors, which are thought to counteract 
TNFα, in the plasma of COPD patients suggests that the local inflammation in the airways 
communicates with the systemic compartment. Indeed, studies have reported that 
neutrophils in the peripheral blood are characterized by a primed phenotype in COPD 
patients (29,30). These findings suggest that the activation of neutrophils already starts in 
the circulation. However, it is not clear which mediators are involved and whether the 
activation of neutrophils is correlated with the severity of the disease. Therefore, it is 
important to investigate the molecular mechanisms responsible for neutrophil activation in 
peripheral blood, including type of stimuli, regulation of intracellular signaling pathways, 
and changes in the transcriptional program of these cells, for understanding the role of 
neutrophils in the pathogenesis of COPD. 
 
2.0 Granulocytes and their cellular functions 
As previously mentioned, granulocytes kill and remove microorganisms through specific 
cellular functions, such as phagocytosis, release of cytotoxic enzymes and proteins by the 
process degranulation, and production of toxic oxygen metabolites initiated by a 
membrane bound NADPH-oxidase (1). Furthermore, granulocytes also release pro-
inflammatory cytokines and bioactive lipids. These mediators are involved in maintaining 
inflammatory reactions by recruitment of leukocytes, increasing the lifespan of 
granulocytes and enhancing cellular effector functions of granulocytes.  
 
2.1 Migration 
Granulocytes circulate through the body in the blood surveying for invading 
microorganisms. A rapid transition between a circulating non-adherent state and an 
adherent state allows them to migrate into the inflamed tissue (Fig. 2). This first step of 
entering organs or tissue, involves tethering and rolling of leukocytes along the 
endothelial cell layer (Fig. 3). The tether and rolling interactions are mediated by 
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granulocyte L-selectin, and by E- and P-selectins expressed on activated endothelial cells 
(31-34). During this tethering step, granulocytes respond to ligands, such as chemokines 
released or expressed on the membrane of endothelial cells. This results in activation of 
integrin mediated sustained, firm adhesion, spreading, and diapedesis (35). Defective 
neutrophilic recruitment to inflamed sites in leukocyte adhesion deficient (LAD) patients 
and in adhesion molecules-deficient mice demonstrates that migration indeed requires 
selectins and the interactions of integrins, such as CD11b/CD18, with the endothelium 
(36,37). The next step of migration towards the site of inflammation requires the 
migration of the granulocytes through the endothelial layer. This process, called 
diapedesis, requires modifications of endothelial cell-to-cell adherent junctions. Two 
adhesion molecules, including platelet endothelial cell adhesion molecule-1 (PECAM-1) 
and junction adhesion molecule (JAM) have been shown to be involved in this process 
(38,39). Migration within the tissue is mediated by a gradient of immobilized, rather than 
soluble chemoattractants. These chemoattractants, produced by bacteria, or by various 
stromal and epithelial cells of inflamed tissue, are bound to extracellular matrix 
components. This process of migration is defined as haptotaxis. Signals delivered by  “end 
target-derived” chemoattractants, such as formyl peptides (released by bacteria), or 
complement C5a (produced in their immediate surrounding), are thought to be dominant 
and therefore override “regulatory cell-derived” attractants, such as bioactive peptides or 
chemokines (40,41). This allows granulocytes, recruited by endothelial-derived 
chemoattractants, to migrate away from the endothelial agonist source towards their final 
target with a tissue.  
 
2.2 Phagocytosis, degranulation and respiratory burst 
Through the processes described above, granulocytes are mobilized to sites of 
inflammation, where they can destroy invading microorganisms. To accomplish this, 
granulocytes possess an impressive array of “microbicidal weaponary”. Once the 
microorganism is ingested by phagocytosis, the invading microorganism can be destroyed 
by proteolytic enzymes stored in special granules, and by reactive oxygen species, 
produced by the NADPH oxidase complex in the so called “respiratory burst”.  
Ganulocyte phagocytosis is mediated by two different receptor classes, Fc gamma 
receptors (FcRs), such as FcγIIA and FcαRI, and complement receptors (CRs), such as 
CR3 (CD11b/CD18 integrin) (42,43). CR3 binds C3bi on complement-opsonized targets, 
whereas FcγRs and FcαRI bind to immunoglobulin G (IgG) and IgA coated targets, 
respectively. Phagocytosis by these receptor types is driven by reorganization of 
filamentous actin (F-actin), but the mechanisms of uptake appear to be different. FcR 
mediated uptake is accompanied by pseudopod extension and membrane ruffling, whereas 
complement-opsonized targets “sink into” the cell, producing few protrusions. Signaling 
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pathways mediating phagocytosis by these two classes of receptors are also different 
(reviewed in (44).  
Degranulation into the phagolysosome or in the extracellular space is an important event 
for the killing of microorganisms, since inherited granule deficiencies, such as Chediak-
Higashi syndrome (CHS), are marked by frequent and life-threatening bacterial infections 
(45). The contents of granules, which mainly consist of proteolytic enzymes and other 
antimicrobial proteins, directly effect the killing of microorganisms. Four types of 
granules in neutrophils are characterized by the contents and order of appearance during 
maturation (1,46-48). Of the granules, the azurophil granules appear first in neutrophils 
and contain myeloperoxidase, serine proteases, and bactericidal proteins. Later in 
differentiation, specific granules containing lactoferrin and collagenase emerge, followed 
by the tertiary granules containing gelatinase. A fourth type of granule, called secretory 
vesicles, appear at the stage of terminal neutrophil differentiation. Secretory vesicles 
contain mainly serum proteins and therefore the origin is thought to be endocytic.  
The activation of the respiratory burst is mediated by the NADPH oxidase, which is a 
complex of cytosolic and membrane proteins (49) (Fig. 3). The cytosolic proteins are 
p40phox, p47phox, p67phox, and small GTPases Rac and Rap1A, and the flavocytochrome 
b558 complex, containing p22phox, and gp91phox. Upon activation of neutrophils, p47phox 
becomes phosphorylated, resulting in the translocation of the p40phox/p47phox/p67phox 
complex to the membrane, where it interacts via multiple binding sites with 
flavocytochrome b558 (50,51). The active oxidase also requires the translocation of Rac 
(52), which occurs simultaneously, but independent, of the translocation of the 
p40phox/p47phox/p67phox complex (53-56). Rac is thought to support NADPH oxidase 
activity only in its GTP-bound active form (57), however this remains a point of 
controversy (58,59). The generation of superoxide anions via the activation of the oxidase 
complex is followed by the production of many types of reactive oxidant species (ROS), 
such as H2O2 and HO•. In turn, myeloperoxidase (MPO) amplifies the toxic potential of 
H2O2 by producing hypochlorous acid (HOCl). The generation of ROS together with the 
granule contents are critical in the killing of microorganisms. Genetic defects in the phox 
genes (p22-, p47- ,p67- ,gp91phox) results in an immune deficiency: chronic 
granulomatous disease (CGD) (60). This disease is associated with persistent infections as 
a result of the inability of their phagocytes to destroy invading microorganisms. One 
exception to this is the normal killing of microorganisms that themselves produce 
significant quantities of H2O2 (e.g. pneumococci). The severe clinical picture observed in 
CGD clearly demonstrates the vital importance of NADPH oxidase in host defense against 
invading microorganisms. 
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Figure 2: Schematic view of the granulocyte migration towards the site of inflammation and 
subsequent respiratory burst. (A) Neutrophils roll, adhere and spread to the endothelium, which 
release cytokines and chemoattractants. Subsequently, cells move through the endothelium and into 
the tissues by responding to successive combinations of chemoattractant gradients. The direction of 
granulocyte movement is first guided by the steepest local chemoattractant gradient, and is then 
regulated by successive receptor desensitization and attraction by secondary distant agonists. 
Finally, end target attractants dominate over regulatory cell-derived agonists. (adapted from Witko-
sarsat et al (1). (B) Upon full activation of granulocytes, the membrane localized flavo-cytochrome 
b558 complex and the cytoplasmic complex fuse with each other in the membrane of the 
phagosome, resulting in the activation of the NADPH oxidase. 
 
 
2.3 Production of inflammatory molecules 
In recent years it has become obvious that the contribution of neutrophils to host defence 
extends well beyond their traditional effector functions, such as phagocytosis, 
degranulation and production of reactive oxygen species. Indeed, several studies have 
demonstrated that neutrophils not only synthesize proteins that directly participate in their 
effector functions, but that these cells can also produce a broad range of pro- and anti-
inflammatory molecules (Table 2) (61,62). Neutrophils produce mainly pro-inflammatory 
molecules, such as cytokines (e.g. TNFα, IL-1β, IFN-α, G-CSF and IL-12) and 
chemokines (e.g. IL-8, MIP-1α, MIP-1β and GRO-α). Anti-inflammatory cytokines 
expressed by neutrophils are IL1-RA and TGFβ. In addition, neutrophils can express 
membrane receptors (such as IL1-R2, which binds to IL-1α/β) that bind ligand without 
activating the cells (63,64). Expression of these receptors can protect the cell and its 
neighbors against the pro-inflammatory action of the ligand. Recently is has been 
demonstrated that there are also soluble forms of receptors, such as sTNFRs and IL-1R2 
which bind agonist and counteract its function (63,65). Thus, neutrophils are able to 
produce a striking diversity of inflammatory molecules, suggesting that they not only play 
 16 
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a direct role in killing microorgansims, but also contribute to the regulation of immune 
reactions. Indeed, whereas the production of inflammatory mediators by neutrophils is 
less than that produced by monocytes, the amount of neutrophils in the peripheral blood is 
much higher, and at the site of inflammation, neutrophils are the first cells to be recruited 
and largely predominate over monocytes (66).  
The production of inflammatory molecules is induced by a broad range of agents, 
including cytokines (TNFα, IL-1α/β, GM-CSF and IFNγ) and bacterial products (LPS) 
(61,67-69). The pattern of inflammatory molecules generated greatly differs depending on 
the stimulating agent, and for some cytokines co-stimulation is required, e.g. IFNγ plus 
LPS in the case of IL-12 expression (61). In addition, co-stimulation can enhance or 
inhibit regulation of inflammatory molecules. For instance, IFNγ enhances, whereas IL-10 
inhibits LPS induced gene expression of inflammatory molecules. Thus the interaction of 
neutrophils with a given agonist(s) will result in a production of a characteristic pattern of 
inflammatory mediators. Investigation of gene and/or protein expression in neutrophils 
may reveal the agents that these cells have encountered.  
Gene expression of many inflammatory molecules depends on the activation of the 
transcription factor NF-κB. Among the wide range of neutrophil agonists, TNFα, LPS and 
PMA were found to be strong activators of NF-κB, whereas IL-1β, LTB4, fMLP and PAF 
are weaker stimuli (70). In contrast, GM-CSF, G-CSF, and IFNγ are not thought to induce 
NF-κB activation in neutrophils (70,71). These stimuli have in common that they activate 
the STAT transcription factor (72), however it is not clear whether STATs are critically 
involved in regulating transcription of inflammatory molecules by these stimuli. 
Table 2. Expression of inflammatory molecules by neutrophils in vitro
cytokines
Tumor necrosis factor-α
IL-1α, IL-1β
IL-12
Granulocyte colony-stimulating factor (G-CSF)
Interferon-α, (IFNα), IFNβ
chemokines
IL-8
Growth-related gene product-α (GRO-α)
Macrophage inflammatory protein-1α (MIP1α), MIP1β
Cytokine-induced chemoattractants (CINK)
others
Fas ligand
vascular endothelial growth factor (VEGF)
Hepatocyte growth factor (HGF)
cytokines
IL-1 receptor antagonist (IL-1RA)
transforming growth factor-β (TGFβ)
sReceptors
sIL-1R2
Pro-inflammatory Anti-inflammatory
Adapted from Cassatella et al (59)
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2.4 Priming 
The capacity for killing microorganisms can also result in the ability to cause host tissue 
damage inappropriately. Therefore regulation of neutrophil activation is a tightly 
controlled process as is depicted schematically in Figure 3. Normally, resting neutrophils 
in the peripheral blood are poorly responsive to many physiological activators in the 
context of cytotoxicity (73-75). To fully activate granulocytes, a pre-activation step is 
necessary. This pre-activation step is generally referred as “priming” (3,76,77). Priming is 
the amplification of granulocyte functional responses by prior exposure of cells to a 
priming agent. The priming agent itself, however, does not need to cause a noticeable 
functional response, except at very high concentrations (76). Thus priming alters these 
cells from a “non-responsive” to a “responsive” state. Priming agents are mostly 
“regulatory cell-derived” mediators, such as bioactive peptides, chemokines or cytokines 
(73-75,78,79), Products of bacteria, or bacteria covered with immunoglobulins, or 
complement factors are the final activators of the effector functions (80,81). This allows 
granulocytes to activate the killing machine only in the presence of pathogens. At the 
moment it is still not precisely clear, which intracellular molecules allow the distinction 
between a priming and an activation signal, since both priming and final activation signals 
can activate similar signaling pathways. Apart from the activation of specific signaling 
pathways, both the level and kinetics of the activation of signaling molecules might be 
important in modulation of granulocyte functioning.  
 
Resting Primed Complete activation
GM-CSF
TNFα
IL-8
PAF
LPS
fMLP
STZ
Priming: 
• enhancement of the respiratory burst
• increasing the chemotactic response
• cytoskeletal rearangement
• enhancement of the degranulation
• Production of cytokines/chemokines/bioactive-lipids
• Change in survival
Figure 3: Granulocyte priming and activation. Neutrophil activation can be modelled as a two 
step activation mechanism. Agents such as PAF, GM-CSF or TNFα, can bring the cell in a pre-
activated or primed state, which appears to be a reversible event. Subsequent exposure of a primed 
cell to an activating stimulus pushes the cell irreversibly to a fully activated state, whereas non-
primed cells are poorly responsive for the activation stimulus. 
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3.0 Membrane receptors 
Granulocytes display multiple structurally different membrane-associated receptors that 
can regulate cellular functioning. Major groups of receptors are cytokine receptors, G-
protein coupled receptors (GPCRs), integrins, Fc receptors, and Toll-like receptors.  
The cytokine receptor family is divided into 4 classes: (a) the hematopoietin receptor 
family, termed class I, which is further divided into IL-3, IL-2, IL-6, and growth hormone 
subfamilies; (b) the interferon receptor family or called class II; (c) Tumor necrosis 
receptor family; (d) immunoglobulin superfamily receptors, such as IL-1 (82). Most of the 
cytokine receptors are single transmembrane-domain receptors. The receptors of the IL-3 
subfamily, including IL-3, IL-5, and GM-CSF, consist of a cytokine specific α-chain, 
which binds ligand with low affinity, and a common β-chain (83). Heterodimerization of 
these receptors in the presence of ligand results in a conformational change, followed by 
the activation of associated tyrosine kinases, which mediate further downstream signaling. 
Receptors the TNF subfamily, such as the TNF receptors p55 and p75, which bind TNFα, 
and the lymphotoxin receptors, form homotrimers upon ligand binding (84). Subsequently 
signaling proteins, such as TRADD, RIP and TRAF2 are recruited to the cytoplasmic tail 
of the receptor by a 60 amino-acid domain known as the “death domain”. This complex 
can in turn activate caspases (85) and via other proteins, such as NIK, the transcription 
factor NF-κB in granulocytes (70,80). NF-κB mediate survival, while activation of 
caspases has been implicated in inducing apoptosis (86-88). This dual function of TNFα 
might explain the controversial function of TNFα in survival, since TNFα was reported 
by some to have pro-apoptotic and by others to have anti-apoptotic effects on neutrophils 
(89-92). A recent study reported that the outcome of TNFα on survival depends on the 
concentration of TNFα, suggesting that the balance between these pathways is different at 
distinct concentrations of TNFα (93). Furthermore, it is likely that other stimuli can 
influence this balance.  
Generally Fc receptors are single transmembrane-domain molecules that require 
crosslinking for activation, and are expressed on lymphoid and myeloid cells. Fc receptors 
can be divided into two classes. The first class participates in the translocation of plasma 
Ig across epithelial surfaces (poly-Ig receptor,FcRn). The second class of Fc receptors are 
expressed by leukocytes and are involved in immunoglobulin specific activation of 
cellular functions, such as degranulation, cytokine production, phagocytosis and 
respiratory burst (94,95). Most Fc receptors of this second class exist as complexes of a 
ligand-binding α-chain and accessory subunits (β, γ, or ζ-subunits). These subunits, but 
also FcγRII receptors A and C contain immunoreceptor tyrosine-based activation motifs 
(ITAMs) (96). Phosphorylation of ITAMs results in further activation of downstream 
signaling pathways via the activation of tyrosine kinases (44,95,97). Besides Fc receptors 
containing ITAMS, there also Fc receptors including FcγRIIB that contain 
immunoreceptor tyrosine-based inhibition motifs (ITIMS), which requires 
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phosphorylation to obtain its inhibitory activity (95). Co-engagement of an inhibitory Fc 
receptor with an ITAM containing receptor leads to phosphorylation of the ITIM and 
subsequently inhibits the ITAM triggered response. 
The G-protein coupled seven transmembrane glycoproteins, also called serpentine 
receptors, include receptors for complement C5a, formylpeptides, PAF, leukotriene B4, 
and receptors for C-X-C or α-chemokines such as receptors for IL-8. All these ligands 
share the property of being chemoattractants for granulocytes. Binding of these 
chemoattractants to their receptors induce a conformational change of the cytoplasmic tail 
of the receptor resulting in G-protein activation. In an inactive state, G-proteins form a 
complex consisting of an α- and a βγ-subunit, whereas upon GPCRs activation, the α 
subunit binds to GTP, resulting in dissociation of the βγ subunit (98). Subsequently, 
release of these G-protein subunits results in activation of a variety of downstream 
signaling pathways.  
 
4.0 Signaling pathways regulating granulocyte effector functions 
A large amount of research has been performed over the last decade to understand the 
molecular mechanisms responsible for activation of neutrophil effector functions, 
including not only the type of stimuli causing activation, but also unraveling components 
of the signaling pathways responsible for the priming and activation of effector functions 
(Fig. 4). Apart from the activation of signaling pathways, both, duration and localization 
of signaling molecules are important in modulation of granulocyte functioning.  
 
GM-CSF receptorSerpentine Receptors
Differentiation
STAT5
Tyrosine kinases
genistein
Oxidative 
Burst
Survival
LY294002 or
Wortmannin 
PI-3K
Actin
rearrangement
PAF-release Adhesion
MKK3/6
p38
SB203580
Raf
MEK1/2
ERK1/2
PD098059
Ca2+ Rac
Migration
CamK
Figure 4: Simplified model of signaling pathways involved in cytokine and GPCRs induced 
granulocyte functioning. Specific inhibitors are depicted in grey. 
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4.1 Small GTPases 
Many receptors are able to activated small GTPases. The Ras superfamily, which includes 
Ras, Rap1 and Ral (99); and the Rho family, including Rho, Rac, and Cdc42 (100) belong 
to the family of small GTPases. All small GTPases act as molecular switches, alternating 
between a GTP bound and GDP bound states in the relay of signals from receptors. When 
bound to GTP, a conformational change occurs, which unmasks structural motifs, in 
particular the so called effector loop, which can then mediate interactions with target 
proteins or effector molecules. This GDP/GTP cycle is tightly regulated by three main 
classes of proteins: (a) proteins that facilitate the exhange of the hydrolyzed GDP for a 
fresh GTP, guanosine nucleotide exchange factors (GEFs); (b) those that enhance the 
intrinsic hydrolysis activity of the GTPase, (GAPs); (c) and those that inhibit the 
dissociation of the GDP from the GTPase, GDP dissociation inhibitors (GDIs) (101). In 
granulocytes it has been reported that, both Ras and Rap1 are activated by many distinct 
types of receptors, whereas Ral and the Rho family of GTPases are mainly activated by 
GPCRs, integrins, and Fc receptors, but not by cytokine receptors (102-104). Ras is 
known to activate the RAF-MEK-ERK pathway in many cell types as well in eosinophils. 
Using dominant negative Ras, a study showed that Ras attenuates IL-5 mediated cell 
viability in eosinophils (105). Rap1 has been shown to be present in the NADPH complex, 
possibly playing a role in correct targeting or assembly of this complex (102). Rac has 
three isoforms, Rac1, Rac2, and Rac 3 (100). Rac1 is ubiquitously expressed, whereas 
Rac2 is highly restricted to hemopoietic cells and is the most abundant Rac protein in 
neutrophils. In neutrophils, Rac GTPases are activated by GPCRs but not by the receptors 
of the cytokines of the GM-CSF/IL-3/IL-5 family. Rac has been shown to be present 
NADPH oxidase complex of human neutrophils, where it is thought to be critical in the 
production of oxygen radicals, by stabilizing the complex (56). A distinction between 
Rac/Cdc42 and Rho signaling has been reported for their role in phagocytosis. Cdc42 and 
Rac mediate FcγRs phagocytosis, whereas CR3 mediated phagocytosis requires Rho 
activity (Cox 1997;Caron 1998; Massol 1998). Recently, a role of Rho in the process of 
uropod detachment or rear release during migration has been demonstrated in 
granulocytes (106). Thus co-ordination of the activity of these three GTPases might be 
necessary for optimal migration of these cells.  
 
4.2 Intracellular Ca2+  
Upon triggering of many plasma membrane receptors such as GPCRs, intergrin and Fc 
receptors, phospholipase C (PLC)β/γ is activated, which catalyzes the conversion of 
phosphatidylinositol 4,5-biphosphate (PIP2) into diacylglycerol (DAG) and inositol 1,4,5-
triphosphate (IP3) (107,108). DAG activates protein kinase C, whereas IP3 induces Ca2+ 
release from intracellular stores. The increase of intracellular Ca2+ ([Ca2+]i) is later 
followed by an influx of extracellular Ca2+. The effect of increased [Ca2+]i is mediated by 
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EF-hand motif containing proteins, such as calmodulin (109). Binding of Ca2+ to 
calmodulin leads to a conformational change, resulting in the ability to bind to and 
activate proteins that contain a camodulin binding domain (CBD) (110). An important 
group of proteins that are activated by Ca2+/calmodulin are the Ca2+/calmodulin-dependent 
protein kinases (111). Using an inhibitor of calmodulin, it has been demonstrated that 
calmodulin is involved in neutrophil migration and generation of superoxide (112). 
Recently a new calmodulin-dependent kinase, termed CKLiK, was indentified, which is 
predominantly expressed in human granulocytes (113). Furthermore, a role for Ca2+ has 
been suggested in the priming process, since a transient increase in [Ca2+]i, by ionomycin, 
is in itself sufficient to prime granulocytes (114). However, changes in [Ca2+]i is per se a 
requirement, since priming induced by PAF, which increases the level of [Ca2+]i, is only 
partially inhibited under [Ca2+]i-buffering conditions (7). Furthermore, other priming 
agents such as cytokines of the GM-CSF/IL-3/IL-5 family, do not induce a increase in 
[Ca2+]i (115). 
 
4.3 Tyrosine kinases 
Tyrosine kinases have been demonstrated to mediate downstream signaling of several 
receptors, such as those of the GM-CSF/IL-3/IL-5 family, the G-protein coupled receptor 
(GPCR) agonists such as PAF and fMLP as well as Fc receptors such as FcγRII (116-
121). Receptor mediated activation of tyrosine kinases results in the induction of 
intracellular kinase cascades which can amplify and modulate the initial response. In 
neutrophils several protein tyrosine kinases have been identified, including Janus Kinases 
(JAKs) and the Src kinase family. Heterodimerization of cytokine receptors, such as those 
of the GM-CSF/IL-3/IL-5 family (118,122), results in bringing two JAK2 proteins into 
close proximity, enabling cross-phosphorylation and activation of the JAK2 proteins 
themselves as well as the phosphorylation of the cytoplasmic tail of the β-chain. 
Subsequently other signaling proteins, such as Src kinases and Signal Transducers and 
Activators of Transcription (STAT) transcription factors can bind to the β-chain, resulting 
in activation of further signaling pathways. Phosphorylation of STAT proteins by JAKs 
results in dimerization and subsequently STAT proteins translocate to the nucleus to 
induce the expression of target genes. This pathway is important for linking many 
cytokines to gene regulation, but it has not been known whether it is directly linked to 
regulation of granulocyte effector functions.  
Of the Src kinase family, several members such as Lyn, Hck and Fgr are expressed in 
neutrophils (123,124). These Src kinases have also been shown to be activated by various 
cytokine and G-protein coupled receptors (121,125,126). Src kinases are kept in an 
inactive state by the phosphorylation of a C-terminal tyrosine residue (Tyr 507, of c-Src) 
(Fig. 5) (127). Phosphorylation of this site results in binding of the C-terminal region with 
its own SH2 domain and thereby blocking the SH2 and SH3 domain in binding substrates 
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and keeping the kinase domain obscured. Activation of Src kinases is mediated by 
dephosphorylation of this site. In addition, Src kinase are phosphorylated at the tyrosine 
residue 416 (of c-Src), which enables further activation of Src kinases. In human 
neutrophils little is known about the role of Src kinases in downstream signaling pathways 
and effector functions. However by using knock-out mice deficient in the different Src 
kinases, several studies have shown that Src kinases are involved in degranulation (128), 
and migration (129). 
 
Kinase
SH2
SH3
pY527
Y416
SH3
SH2
Kinase
pY416
Y527
Activated kinaseBasal activity
Membrane
A B
Figure 5: Regulation of Src kinase activity. (A) Closed autoinhibited state; (B) open state induced 
either by dephosphorylation of the C-terminal Tyr-527 or by interactions of the SH3 and SH2 
domains with the Src protein partners. This makes Tyr-416 accessible for phosphorylation, resulting 
in enhanced activation. 
 
 
4.4 Mitogen Activated Protein (MAP) Kinases 
One family of tyrosine phosphorylated proteins that has been demonstrated to be activated 
by many inflammatory mediators are the mitogen activated protein kinases, or MAP 
kinases. There are three distinct groups of MAP kinases (130): extracellular signal-related 
protein kinases (ERKs) activated by a large variety of agonist, c-Jun amino-terminal 
kinase/stress-activated protein kinases (JNK/SAPKs) and the p38 MAPK family. The best 
charaterized MAPK pathway consists of Raf, MEK1/2 and ERK1/2 module (131). This 
cascade is regulated by the small GTPase Ras. While ERK is activated by diverse stimuli, 
the other two groups are more specifically activated be environmental stress and pro-
inflammatory cytokines. However, in neutrophils both the pathways ERK and p38 MAPK 
are activated by diverse stimuli, such as LPS, fMLP, GM-CSF, PAF and IL-8, whereas 
TNFα, is a stong activator of p38 MAPK, but weakly activates ERK in neutrophils 
(80,132-135). Inhibitory studies of MEK1/2 have shown that this pathway regulates PAF 
release by serum treated zymosan, whereas variable effects has been shown about the role 
 23 
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of ERK1/2 in migration and fMLP induced superoxide production (78,134,136-138). In 
addition a role for ERK has been shown in regulating neutrophil survival (139). A partial 
decrease in superoxide production and stress induced apoptosis has been reported in the 
presence of p38 inhibitors (140-142). Activation of JNK has only been demonstrated in 
adherent neutrophils and is dependent on beta2 integrin binding (91).  
 
4.5 Phosphatidylinositol 3-kinase (PI3K)/Protein Kinase B (PKB) 
Another signal transduction pathway that appears to play a critical role in both priming 
and activation of granulocyte effector functions involves PI3K (143). At the membrane, 
PI3K phosphorylates phophoinositides at the D-3 position. Class I PI3Ks form 
hetereodimers composed of a regulatory unit and a catalytic subunit. Several isoforms of 
both the adaptor and catalytic subunit have been identified. The best characterized 
catalytic subunits are the p85 adaptor subunit and the catalytic subunit p110α/β, which are 
activated by tyrosine kinase, whereas the p101 adaptor subunit together with the catalytic 
subunit p110γ are thought to be regulated only by G-protein activation. In neutrophils, 
many receptors, including cytokine and G-protein coupled receptors are able to activate 
PI3K either via tyrosine kinases and/or G-proteins (80,144). Utilizing specific 
pharmacological inhibitors of PI3K, wortmannin and LY294002, ourselves and others 
have demonstrated that this kinase plays a critical role in several neutrophil cellular 
functions including the respiratory burst, survival, and migration (80,145-147). Protein 
kinase B (PKB) is one of the major downstream targets of PI3K and is also activated in 
granulocytes in response to both cytokine and G-protein coupled receptors. It has been 
shown in several cell types that PKB can phosphorylate the pro-apoptotic Bcl-2 family 
member BAD, which in turn prevents its association with anti-apoptotic Bcl-2 family 
members, resulting in prolonged survival (148,149). In neutrophils, the PI3K inhibitor 
LY294002 blocked GM-CSF dependent PKB and BAD phosphorylation (150). Thus it 
might be that this PKB/BAD pathway is also involved in regulating neutrophil survival. 
Furthermore, PI3K is involved in other cellular functions of granulocytes, such as the 
respiratory burst. It has been proposed for example that PI3K can mediate the 
phosphorylation of the p47phox, a component of the NADPH oxidase complex (151).  
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5.0 Scope of this thesis 
Granulocytes are thought to play an important role in the maintenance and progression of 
chronic diseases, such as COPD, allergic asthma, and rheumatoid arthritis. Despite the 
importance of granulocytes in these diseases surprisingly little is known about the 
processes occurring in vivo that regulate inappropriate granulocyte functioning. In this 
thesis, gene expression of neutrophils has been analyzed in vitro and in vivo, to 
characterize chronic systemic inflammation and identify mediators that are playing a role 
in the pathogenesis of COPD. To understand the finely tuned process of neutrophil 
functioning in vivo, it is also necessary to define components of the signaling pathways 
responsible for the priming and activation of effector functions in granulocytes. In this 
thesis, several research questions were addressed, concerning granulocyte functioning in 
vitro and in vivo. 
 
Are changes in gene expression of peripheral blood neutrophils a result of the 
pathogenetic mechanisms underlying the development of COPD and can these gene 
profiles be used to define penotypes and severity of the disease? 
Exposure of neutrophils to cytokines or chemokines, results in their activation and 
changes in gene expression profiles. In Chapter 2, we utilise gene array technology and 
real time reverse trancriptase polymerase chain reaction to define the gene expression 
profiles of peripheral blood neutrophils of COPD patients compared with in vitro 
stimulated neutrophils. In Chapter 3, we use the same techniques, to investigate 
differences between peripheral blood neutrophils of COPD patients during a stable phase 
of their disease and during an exacerbation. Furthermore, we investigated the kinetics of 
activation of peripheral blood neutrophils in COPD patients in a longitudial setting. 
 
What is the role of Src kinases and small GTPase Rac in granulocyte functioning?  
To address this question, we use pharmacological inhibitors and a recently developed 
technique of protein transduction. In Chapter 5 we investigate the role of Src kinases in 
neutrophil functioning, whereas in Chapter 6 the role of Rac is investigated in peripheral 
blood eosinophil functioning by introducing a constitutively active mutant into these cells. 
In Chapter 7, we describe an ELISA technique developed for non-radioactive semi-
quantitative analysis of the activation state of several kinases in adherent and suspension 
cells using phosphospecific antibodies. 
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Abstract 
Neutrophils are thought to play an important role in the inflammatory response in COPD 
by activation of their cytotoxic machinery in the lung and airway tissue. In addition, these 
cells are able to synthesize de novo several inflammatory mediators. Therefore, the study 
of gene expression profiles of peripheral blood neutrophils from COPD patients may 
provide unique insights into the mechanisms of activation of neutrophils in vivo. 
Gene expression profiling of peripheral blood neutrophils of moderate to severe COPD 
patients was performed by gene array and real time reverse transcriptase-polymerase chain 
reaction analysis. Expression of many inflammatory genes was regulated indicating that 
these cells were in an activated state. These genes included cytokines (e.g. IL-1β), 
chemokines (e.g. IL-8) and adhesion molecules (e.g. ICAM-1). These genes were also 
regulated in neutrophils in vitro by pro-inflammatory mediators such as TNFα and GM-
CSF. Disease severity as measured by the forced expiratory volume in one second (FEV1) 
in COPD patients correlated with expression of several of these genes, including IL-1β ( r 
= -0.540; p = 0.008), MIP1β (r = -0.583; p = 0.003), CD83 (r = -0.514; p =0.012), IL-1R2 
(r = -0.546; p = 0.007) and IL-1RA (r = -0.612; p = 0.002). These data are consistent with 
a hypothesis that progression of COPD is associated with the activation of neutrophils in 
the systemic compartment. De novo expression of inflammatory mediators by peripheral 
blood neutrophils implicate a pro-inflammatory role for these cells in the pathogenesis of 
COPD.  
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Introduction 
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease of the 
airways, which is characterized by the presence of chronic airflow obstruction and an 
abnormal inflammatory response (1). It is thought that this abnormal inflammatory 
response is mediated by increased levels of cytokines and/or chemokines, such as tumor 
necrosis factor (TNF)-α and Interleukin (IL)-8, which are found in elevated levels in 
bronchoalveolar lavage (BAL) fluid and sputum of COPD patients (2-4). Furthermore, 
increased levels of neutrophils, monocytes and CD8+ cytotoxic lymphocytes are found in 
the pulmonary compartment (5-9). This recruitment of inflammatory cells is likely to be 
mediated by the increased levels of cytokines and/or chemokines in the tissue. Several 
studies have focused on this in COPD by measuring granulocyte activation products at the 
site of inflammation (4, 6, 10, 11).  
In contrast to this local inflammation, little is known concerning the systemic 
inflammatory response in COPD. The identification of soluble TNF receptors, which are 
thought to counteract the function of TNFα, in the plasma of COPD patients, suggests that 
the local inflammation communicates with the systemic compartment (3). Unfortunately, 
direct measurement of many inflammatory mediators such as TNFα is difficult in the 
peripheral blood because of their short half-life, binding to soluble receptors, and renal 
clearance (12-14). A few studies have reported that neutrophils in the peripheral blood of 
COPD patients exhibit characteristics of a primed phenotype (15, 16). Further evidence of 
activation of inflammatory cells in the systemic compartment is suggested by a study 
showing an increased expression of Mac-1 in circulating neutrophils (17). These findings 
suggest that the activation of neutrophils already starts in the circulation. The underlying 
pathogenetic mechanisms remain, however, to be determined.  
Novel methods that allow monitoring of neutrophil activation and analysis of 
inflammatory mediators, are important for the characterization of the systemic 
inflammatory response in COPD. Ourselves an others have shown that in vitro priming of 
neutrophils with for example GM-CSF is associated with the expression of specific gene 
profiles (18, 19). Thus investigation of gene expression profiles of peripheral blood 
neutrophils of COPD patients in comparison with in vitro cytokine-induced gene profiles 
of neutrophils could be a powerful tool for characterization of chronic systemic 
inflammation in COPD. 
In this study the activation status of peripheral blood neutrophils was examined through 
analysis of cytokine-regulated gene profiles in vitro using gene arrays. Gene profiles of 
neutrophils from severe stable COPD patients exhibit characteristics of cells, which are 
activated by pro-inflammatory mediators. Further investigation of differentially expressed 
genes, such as several IL-1 family members, MIP1β and CD83 in mild and severe COPD 
patients demonstrated that expression of these genes in peripheral blood neutrophils 
correlate with the severity of COPD. 
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Materials and Methods  
 
Reagents 
Formyl-methionyl-leucy-lphenylalanine (fMLP) and LPS were purchased from Sigma (St. 
Louis, MO, USA). Recombinant human GM-CSF was from Genzyme (Boston, MA, USA). 
Recombinant human TNFα was purchased from Boehringer Mannheim (Germany). IL-8 
was purchased from Peprotech (Rocky Hill, NJ, USA). Human serum albumin (HSA) was 
obtained from the Central Laboratory of the Netherlands Red Cross Blood Transfusion 
Service (Amsterdam, The Netherlands). RPMI 1640 medium with Glutamax was purchased 
from Life Technologies (Breda, The Netherlands). Ficoll-Paque was from Pharmacia 
(Uppsala, Sweden).  
 
Isolation of human neutrophils 
Blood was obtained from healthy volunteers and COPD patients. Mixed granulocytes were 
isolated from 50-100 ml (normal volunteers) or 20 ml blood (COPD patients), which was 
anti-coagulated with 0.32% sodium citrate as described before (20). In short, blood was 
diluted 2.5:1 with PBS containing 0.32% sodium citrate and human pasteurized plasma-
protein solution (4 g/L). Mononuclear cells were removed by centrifugation over Ficoll-
Pague. The erythrocytes were lyzed in isotonic ice-cold NH4Cl solution followed by 
centrifugation at 4°C. Granulocytes were allowed to recover for 30 minutes at 37°C in 
HEPES buffered RPMI 1640 medium, supplemented with L-glutamine and 0.5% HSA. All 
preparations contained >97% neutrophils.  
 
Subjects 
Twenty three patients with clinically stable moderate to severe COPD were included in 
the study. COPD was defined according to the criteria of the GOLD guidelines (1). 
Inclusion criteria were: FEV1 < 80% and a reversibility of less than 10% or less than 200 
ml after inhalation of a β2-agonist and a FEV1/FVC ratio of less than 70% of the predicted 
value. A history of other concomitant confounding diseases such as diabetes mellitus, lung 
carcinoma, thyroid, cardiovascular disease and bronchiectasis were exclusion criteria for 
the study. Furthermore, patients with an exacerbation due to a respiratory tract infection or 
other respiratory complaints during the 4 weeks prior to the study or patients with a 
history of asthma or atopy were excluded from the study. The mean age of the patient 
group was 64.0 ±2.3 (range 40-79) and their mean FEV1 was 51.7 ± 3.8% of predicted 
(range 19.1%-79.3%). Fourteen of the 23 patients met the criteria for moderate COPD 
(class IIA according to the GOLD guidelines), whereas the other 9 patients suffered from 
moderate to severe COPD (class IIb and III). All patients had a smoking history of more 
than 10 years (pack-years: mean 40 ±4.1, range 14-76). All patients were treated with 
inhaled long-acting β2-agonists (b.i.d) and additional bronchodilating agents if needed, 
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none of them used oral glucocorticosteroids. The study was approved by the Medical 
Ethics Committee of the University Medical Center, Utrecht, and informed consent was 
obtained from all patients. 
 
RNA isolation and cDNA synthesis.  
RNA isolation was performed as previously described (18). Briefly, 2×107 cells were 
washed with ice-cold PBS and lyzed in 0.4 mL of GIT solution (6 mol/L guanidine 
thiocyanate, 25 mmol/L sodium citrate, 0.5% N´-lauroyl sarcosine, 100 mmol/L β-
mercaptoethanol). After storage at –20°C, phenol extraction was performed followed by 
ethanol precipitation. Total RNA was resuspended in a small volume of H20 and treated 
with DNAse for half an hour. After DNAse treatment RNA was again extracted with 
phenol, precipitated with ethanol and RNA was then eluted in 10 µl of RNAse-free H2O. 
cDNA was synthesized using MMLV reverse transcriptase and oligo(dT) primers. 
Samples containing 1 µg of total RNA were heated for 3 minutes at 65°C and quickly 
chilled on ice. A mixture of 25 µl containing 20 µg/ml oligo(dT) primers, 5 µl of 5x RT 
buffer, 20 mM DTT, 2 mM each deoxynucleoside triphosphate, 0.8 U/µl of RNAse 
inhibitor and 400 units of MMLV reverse transcriptase was added and incubated at 37 °C 
for 90 minutes, followed by RT inactivation for 10 min at 65°C. cDNA was stored at -
20°C before further use. All reagents used for cDNA synthesis were obtained from Life 
Technologies (Breda, The Netherlands) 
 
Gene array analysis 
Isolated human neutrophils were incubated in RPMI 1640 supplemented with 0.5% HSA 
for 15 minutes and stimulated for 3 hours at 37°C, followed by RNA isolation as 
described above. RNA was isolated from neutrophils, which were isolated from 10 ml of 
blood of COPD patients. RNA was treated with DNAse to avoid contamination with 
genomic DNA and subsequently analyzed by agarose gel electrophoresis to verify the 
integrity of the RNA preparations. PolyA+ RNA was extracted with magnetic beads 
coated with poly dT using the Atlas Pure Total RNA Labeling System (Clontech, Palo 
Alto, CA, U.S.A.) according to the manufacturer’s protocol. Forty microgram of total 
RNA from neutrophils stimulated with or without cytokines and 20 µg of neutrophils from 
COPD patients or healthy volunteers were used to perform a gene array with. The gene 
array screen was performed with the Atlas Human Hematology/Immunology Array 
#7737-1 (Clontech, Palo Alto, CA, U.S.A.) using reagents supplied and manufactures 
protocol. In short, cDNA probes were generated using specific primers for the genes on 
the array. Reverse transcription of the isolated polyA+ RNA was performed with 
radioactive γ32P-dATP. The two arrays were incubated overnight with the probe at 68 °C. 
The following day, arrays were washed and membranes analyzed by autoradiography. The 
spots on the arrays were quantitated using a PhosphorImager and ImageQuant software 
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(Amersham Biosciences, Uppsala, Sweden). Values were corrected for background and 
housekeeping genes.  
 
Real time PCR 
Primers and probes for CD83 were selected using Primer Express version 1.0 (Applied 
Biosystems, Nieuwerkerk a/d ijssel, The Netherlands). For CD83, a 72 bp (nt 67-139) 
fragment was amplified using the forward primer 5'-TCCTGAGCTGCGCCTACAG-3' 
and the reverse primer 5'-AAGTCCACATCTTCGGAGCAA-3' (Amersham Biosciences, 
Uppsala, Sweden ). The TaqMan probe for CD83, 5'-TCACCTCCGGCGTCGCGG-3' 
was labeled with the fluorescent reporter dye 6-carboxy fluorescein (FAM) at the 5’ end 
and the quencher dye 6-carboxy-tetramethylrhodamine (TAMRA) at the 3’ end (Applied 
Biosystems, Nieuwerkerk a/d ijssel, The Netherlands). A 25-µl PCR was performed using 
0.1 µl of cDNA, 12.5 µl of TaqMan universal PCR master mix containing 6-
carboxyrhodamine (ROX) as a passive reference (PE Applied Biosystems, Nieuwerkerk 
a/d ijssel, The Netherlands), 800 nM of each CD83 primer and 150 nM of CD83 probe. 
All the other genes were analyzed by real time pcr using SYBR green I. For β-actin, a 174 
bp fragment was amplified using the forward primer 5'-AGCCTCGCCTTTGCCGA-3' 
and the reverse primer 5'-CTGGTGCCTGGGGCG-3' as described by Kreuzer et al. (21). 
All other primers were designed using Primer 3 software of the whitehead institute/MIT 
center for genome Research (http://www-genome.wi.mit.edu/cgi-
bin/primer/primer3_www.cgi) and are listed in table 1. Real time PCR with SYBR green I 
was performed in a 25-µl mixture containing 0.1 µl of cDNA, 12.5 µl of SYBR Green 
PCR master mix containing ROX as a passive reference (PE Applied Biosystems, 
Nieuwerkerk a/d ijssel, The Netherlands) and 400 nM of each primer. Amplification and 
detection of both Taqman and SYBR green I pcr were performed with an ABI Prism 7700 
sequence detection system (PE Applied Biosystems, Nieuwerkerk a/d ijssel, The 
Netherlands) under the following conditions: 2 minutes at 50°C, 10 minutes at 95°C to 
activate AmpliTaq Gold DNA polymerase, and 40 cycles of 15 seconds at 95°C and 1 
minute at 60°C. During amplification, the ABI Prism sequence detector monitored real-
time PCR amplification by quantitatively analyzing fluorescence emissions. The signal of 
the dye was measured against the internal reference dye (ROX) signal to normalize for 
non-PCR-related fluorescence fluctuations occurring from well to well. Results were 
normalized for the housekeeping gene β-actin and GAPDH. A reference sample of cDNA 
on every 96 wells plate allowed correction of differences between plates. Results were 
expressed as fold regulation. 
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Reverse primerForward primer
Table 1. Sequences of primers used for real time PCR (SYBR green) 
Target sequence
IL-1β ggtggtcggagattcgtagcgcttattacagtggcaatgaggat
IL-1RA cgcttgtcctgctttctgttcgaagatgtgcctgtcctgtgtc
IL-1R2 tgagatgaacggcaggaaagcaggaggactctggcacctac
GAPDH gaggcattgctgatgatcttgagaaggctggggctcattt
IL-8 gggtggaaaggtttggagtatgagctctgtgtgaaggtgcagtt
MIP-1β agcccattggtgctgagagccatgaagctctgcgtgact
IL-8R1 tcttcagtttcagcaatggtttgtcaagtgccctctagctgttaagt
 
 
Statistics 
Unless otherwise noted, all data are expressed as the mean ± SE, and differences between 
values were compared by the paired t-test. Differences between study groups were 
compared using the Mann-Whitney U test. Statistical significance was defined as p<0.05 
 41 
 
Analysis of systemic inflammation in COPD by gene profiling in neutrophils 
Results 
 
Analysis of gene expression profiles in peripheral blood neutrophils from patients 
with stable COPD 
We investigated peripheral blood neutrophil activation in moderate to severe COPD 
patients utilizing a gene array approach. Atlas gene arrays (Atlas Human 
Hematology/Immunology filters) were hybridized with radioactive labeled cDNA 
synthesized from peripheral blood neutrophils isolated from COPD patients. This type of 
analysis requires many neutrophils, which have typically a low yield of mRNA, 
complicating the use of gene arrays for cohorts of COPD patients. Therefore, we decided 
to identify genes differently regulated in two moderate to severe COPD patients, and 
subsequently validate these findings by real time reverse transcriptase-polymerase chain 
reaction (RT-PCR) in a larger cohort. Gene expression analysis of these two COPD 
patients compared to healthy volunteers indicated that 16 genes were regulated in both 
patients, while 21 genes were regulated in at least one of the two (Table 2). 
Approximately half of the regulated genes encoded for chemokines/cytokines and cell 
surface receptors. Increased expression of IL-8, IL-1β, IL-1RA, and ICAM-1, which are 
known to be upregulated in neutrophils after stimulation with pro-inflammatory 
mediators, such as TNFα, GM-CSF or LPS (22), suggest that these peripheral blood 
neutrophils exhibited an activated phenotype. 
Chemokine/cytokine receptors
IL-8R1
IL-1R2
Chemokines/cytokines
IL1-β
IL-1RA
IL-8
MIP-1β
lymphotoxin-β
Surface antigens
ICAM1
CD58 antigen (LFA3); 
T-lymphocyte maturation-associated prote in MAL
CDW50 antigen ( ICAM3)
CD83 antigen
Transcription factors
STAT5A/B
interferon-stimulated gene factor 3  gamma subunit
interferon regulatory factor 7 ( IRF7)
Protein  kinases/ oncogenes
c-Raf1
EVI2B protein
neutrophil S100 protein
SLP-76; 76-kDa tyrosine phosphoprotein
Others
heat shock 60-kDa protein (HSP60)
lymphocyte cytosolic prote in 1 (LCP1)
-5,4
-5,1
20,5
12,8
12,1
11,2
-17,6
3,2
-9,0
13,1
-6,1
34,8
2,8
-2,7
-7,2
-7,3
-2,5
-2,5
4,1
-6,1
3,6
-16,2
-24,9
29,5
5,1
3,8
20,9
-9,7
3,5
-5,0
-3,4
-5,2
-4,0
-4,0
-2,9
-8,0
-3,4
COPD1
fold-change
COPD2
fold-change
Descrip tion GENBANK
number
M68932
X59770
K02770
M63099
Y00787
J04130
L11015
J03132
Y00636
M15800
X69711
Z11697
U47686
M87503
U73036
X03484
M60830
X97859
U20158
M34664
M22300
Table 2. Genes differently expressed in neutrophils of patients with COPD
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TNFα and/or GM-CSF induce differential expression of inflammatory genes in 
human neutrophils 
To gain further insight into the mechanisms of neutrophil activation we evaluated 
differential gene expression in neutrophils activated with GM-CSF and TNFα in vitro. 
Both cytokines have been implicated in the pathogenesis of chronic inflammatory disease 
including COPD (2, 23, 24). The receptors of these two cytokines are structurally different 
and activate the transcriptional machinery by distinct means.  
Isolated peripheral blood neutrophils were stimulated in the absence or presence of these 
cytokines for three hours. Total RNA was isolated and PolyA+ RNA was prepared and 
used for generating radioactively labeled cDNA. This was hybridized with Atlas gene 
array filters as described in Material and Methods (Atlas Human 
Hematology/Immunology filters). A representative gene array of each condition is shown 
in Figure 1. The lower row of each gene array represent housekeeping genes, which were 
used as an internal reference.  
Unstimulated neutrophils of normal donors expressed 17 % (68 of 402 genes) of the 
spotted genes. Exposure of neutrophils to the cytokines TNFα or GM-CSF and the 
combination of TNFα and GM-CSF resulted in changes in expression of 15, 18, and 19 
genes respectively relative to control (Table 3). These genes belong to several different 
functional classes, but the majority encoded for cytokines/chemokines and cell surface 
receptors. Among the cytokines and chemokines, IL-8, IL-1β, and IL-1RA were clearly 
upregulated by both TNFα and GM-CSF. On the other hand MIP-1β was only induced by 
TNFα, and lymphotoxin-beta by GM-CSF. Moreover, this analysis also revealed that 
TNFα and GM-CSF both induced pro-inflammatory genes such as IL-1β and IL-8, and 
anti-inflammatory genes such as IL-1RA and IL1R2.  
Of the regulated cell surface antigens, most were upregulated by both TNFα and GM-CSF 
except for CD83 and CD69, which were only upregulated by TNFα or GM-CSF, 
respectively. The anti-apoptotic Bcl-2 family member A1 is involved in regulating cell 
survival, and expression was already high directly after isolation, decreasing after 3 hours 
at 37°C in the absence of cytokines. Both TNFα and GM-CSF, maintained the high 
expression.  
The combination of TNFα and GM-CSF resulted in regulation of almost all genes, which 
are regulated by TNFα and GM-CSF individually, however, some genes were regulated 
only by the individual cytokines. MIP-1β, CD83, IL-8R1, and ALP were only regulated 
by TNFα, while GM-CSF alone regulated RAR-alpha, BTG1, lymphotoxin-alpha, CD69, 
MNDA, STAT5A/B, and vav2 (Table 4). Comparison of these cytokine profiles with the 
regulated genes of the COPD patients shows that three out of four TNFα induced genes 
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are similarly regulated in vivo in COPD patients. Of the GM-CSF induced genes, none of 
these seven genes were regulated in these COPD patients. 
 
GM-CSF TNFα + GM-CSF
IL-1RA
CD83
Control TNFα
 
Figure 1: Gene arrays analysis of TNFα stimulated peripheral blood neutrophils. Neutrophils 
were incubated without or with TNFα (100 U/ml) and/or GM-CSF (0.1 nM) for 3 hours in vitro. 
RNA was isolated and used for generating radioactively labeled cDNA, which was hybridized with 
Atlas array filters (Atlas Human Hematology/Immunology filters). CD83 and ICAM-1 were boxed 
with a circle and square respectively. Membranes were analyzed using a PhosphorImager and Image 
Quant software. All genes of the array were spotted in duplo. 
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TNFα
fold-change
GM-CSF
fold-change
TNFα +GM-CSF
fold-change
Descrip tion GENBANK
number
Table 3. Genes regulated by several stimuli in neutrophils
* regulated in one of the two performed gene arrays
-8.6 -6.4IL8 receptor alpha M68932
11.5* 13.6 4.4IL1R-beta X59770
Chemokine/cytokine receptors
5.1antileukoprote inase 1 (ALP) X04470
15.0retinoic acid receptor a lpha (RAR-alpha) M73779
-10.3 -9.2*B-cell translocation gene 1 (BTG1) X61123
-4.5 -6.4 -5.8NOTCH 1 M73980
-3.1 -6.9 -16.3*fli1 proto-oncogene M93255
Blood d isorder proteins
106.7 98.5 227.6IL-1RA M63099
7.1 9.3 22.2IL-8 Y00787
6.0 4.1*MIP-1β J04130
3.2lymphotoxin-β L11015
Chemokines/cytokines
15.4 5.0 18.1ICAM1 J03132
2.8 9.5* 4.5*CD14 antigen M86511
8.7 21.6 16.6CD44 antigen M59040
3.4 6.7* 3.5*CD58 antigen Y00636
12.5 10.3*CD83 antigen Z11697
17.4 8.2CD69 antigen L07555
Sur face antigens
-4.4 -11.8*MNDA M81750
-5.7STAT5A/B U47686
Transcription factors
12.0 10.7vav2 S76992
3.3 15.2 15.1SLP-76 U20158
8.2ras-like small GTPase TTF Z35227
Protein  kinases/oncogenes
13.9 4.7 19.2*BCL2-related protein-A1 (BCL2-A1) U29680
Apoptosis
13.0* 27.3*IL-1β K02770
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Table 4. Specif ic cytokine regulated genes of  neutrophils
TNFα 
(fold-change) 
GM-CSF 
(fold-change) 
TNFα +GM-CSF
(fold-change) 
TNFα and/or GM-CSF
(12.5) NOTCH 1 (-)CD83 antigen BTG1 (-10.3)
SLP-76 (+)
ICAM1 (+)vav2 (12.0)
CD14 antigen (+)
STAT5A/B (-5.7) IL-8 (+)
IL-1RA (+)MNDA (-4.4)
MIP-1β RAR-alpha TTF(6.0) (15) (8.2) IL-1R2 (+)
IL-8R1 lymphotoxin-β(-8 .6) (3.2) Fli1-proto-ocogene (-)
CD44 antigen (+)
CD58 antigen (+)
Bcl2-A1 (+)
ALP CD69 antigen(5.1) (17.4) IL-1β (+)
 
 
Modulation of inflammatory genes in neutrophils by different inflammatory 
mediators 
We utilized several physiological stimuli to analyze the expression of inflammatory genes, 
such as CD83, IL-8R1 and MIP-1β in peripheral blood neutrophils in vitro. Expression of 
these genes was measured by a real time RT-PCR as described in Materials and Methods. 
Specific primers were used to amplify only cDNA generated from mRNA and not 
genomic DNA. Gene expression was normalized for β-actin and GAPDH expression. 
Analysis revealed that IL-8 and fMLP did not induce any of the genes investigated, 
whereas TNFα, GM-CSF, LPS and the combination TNFα/GM-CSF modified 
upregulated of IL-1RA and IL-1β, (Fig 2 and Table 5). IL-1R2 was down-regulated by all 
stimuli. Similar to the data obtained with the gene arrays CD83 and MIP-1β were 
upregulated by TNFα and LPS and not by GM-CSF.  
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CD83
MIP-1β
IL-1RA
IL-1β
IL-1R2
IL-8
IL-8R1
TNFα +
 GM-CSF
1.9
5.0
7.7
4.3
2.8
2.4
-3.8
IL-8
-2.7
-0.8
-0.7
-1.0
-0.7
-0.6
-1.0
fMLP
-2.2
0.8
-0.2
-1.4
-1.5
-0.3
-2.2
LPS
4.8
6.7
5.6
3.8
1.3
4.1
-2.7
4.0
4.4
4.9
2.1
0.0
0.4
-3.2
TNFα GM-CSF
-3.4
-0.6
4.7
0.8
1.3
0.2
-3.7
Table 5. Genes regulated ( fold-change (log2)) by several stimuli in neutrophils
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no stim TNFα GM-CSF IL-8 fMLP TNFα + GMCSF LPS
MIP1 beta
IL-1RA
IL-1β
IL-1R2
IL-8
IL-8R1
LO
G
2
-4
-2
0
2
4
6
8
10
CD83
 
Figure 2: Gene expression in peripheral blood neutrophils, stimulated by several mediators in 
vitro. Peripheral blood neutrophils are incubated with several physiological stimuli for 3 hours in 
vitro at 37°C (TNFα, 100U/ml; GM-CSF, 0.1 nM; IL-8, 10 nM; fMLP, 1 µM; LPS, 10 ng/ml). 
Expression of indicated genes were measured by real time RT-PCR. Results are expressed as LOG2 
fold change ±S.E.M. (n=3). 
 
 
Expression of TNFα and GM-CSF regulated genes in patients with stable COPD  
Investigation of the expression of genes preferentially induced by specific cytokines will 
help to determine which mediators play a role in the activation of neutrophils in patients 
with COPD. cDNA was prepared from total RNA from healthy volunteers and from the 
aforementioned COPD patients and used for real time RT-PCR analysis of indicated genes 
(Fig. 3). Data of the moderate COPD patients (GOLD class IIa) indicated that only the IL-
8R1 gene was significantly decreased compared to healthy volunteers. Neutrophils of the 
more severe COPD patients showed a significant increase of CD83, MIP-1β, and IL-1β 
compared to healthy volunteers. Furthermore, CD83, IL-1β, MIP-1β, but also IL-1RA 
were significantly increased in severe COPD patients compared to mild COPD patients. 
This suggests that a pro-inflammatory mediator such as TNFα is involved in systemic 
activation of neutrophils from patients with severe COPD.  
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Healthy controls
Moderate stable COPD
(Class IIA)
Moderate to severe stable COPD
(Class IIB and III)
IL-1R2
-2
-1
0
1
2
3
4
A
IL-8
-5
-4
-3
-2
-1
0
1
2
3
A
IL-8R1
-3
-2
-1
0
1
2
3
A
p < 0.05
CD83
A
-2
-1
0
1
2
3
4
LO
G
2
p < 0.001
p < 0.002
IL-1β
-2
-1
0
1
2
3
4
5
A
LO
G
2
p < 0.01
p < 0.023
IL-1RA
-2
-1
0
1
2
3
4
5
A
p < 0.05
p < 0.001
MIP-1β
-4
-2
0
2
4
6
8
A
p < 0.01
LO
G
2
p < 0.003
 
 
Figure 3: Gene expression analysis in peripheral blood neutrophils of COPD patients. 
Peripheral blood neutrophils were isolated from healthy volunteers (Filled squares), moderate (class 
IIA) COPD patients (open diamonds), and moderate to severe (class IIB and III) stable COPD 
patients (filled triangles). Expression of indicated genes were measured using real time RT-PCR and 
expressed as LOG2 fold-change compared to the group of healthy controls. Differences between the 
study groups were compared using the Mann-Whitney U test.  
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TNFα regulated genes correlate with severity of disease in patients with stable 
COPD 
Our findings that patients with severe stable COPD had an increased expression of CD83, 
MIP-1β and IL-1RA compared to mild stable COPD patients suggest that these genes 
might correlate with the severity of COPD. Indeed, these genes, CD83 (r = -0.51), MIP-1β 
(r = -0.58) and IL-1RA (r = -0.61), but also IL-1β (r = -0.54) and IL-R2 (r = -0.546) 
correlated with the severity of COPD as measured by FEV1 (Fig 4). In contrast, no 
correlation between FEV1 and the expression of IL-1β, IL-8 and IL-8R1 was found 
(results not shown).  
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Figure 4: Correlation of gene expression in peripheral blood neutrophils of COPD patients 
with FEV1 (% predicted). Expression of indicated genes were measured using real time RT-PCR 
and expressed as LOG2 fold-change compared to the group of healthy controls. Correlations 
between the FEV1 and expression of indicated genes in neutrophils from stable COPD patients were 
evaluated using Pearson’s rank correlation analysis. 
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Discussion 
 
Peripheral blood neutrophils of COPD patients exhibit an activated phenotype. 
Activation of neutrophils plays an important role in the pathogenesis of several chronic 
inflammatory diseases such as COPD and rheumatoid arthritis (25, 26). Therefore, 
investigation of gene expression profiles of peripheral blood neutrophils of COPD patients 
could provide a unique insight into the molecular mechanisms modulating chronic 
systemic inflammation. Furthermore, these gene profiles compared with in vitro cytokine-
induced gene profiles of neutrophils from normal donors can be used as fingerprints for 
mediators that are critical in disease pathogenesis. In this study the activation status of 
peripheral blood neutrophils was examined through gene array analysis and real time RT-
PCR. 
Gene expression analysis of peripheral blood neutrophils from patients with severe stable 
COPD indicated that peripheral blood neutrophils exhibited an activated phenotype. 
Several genes, including IL-1β, IL-1RA, IL-8, ICAM1, CD44, CD69, and MIP1β which 
have been previously reported to be regulated by pro-inflammatory mediators, such as 
TNFα, GM-CSF or LPS (Fig. 2)(22, 27-31), were clearly regulated in neutrophils from 
moderate to severe COPD patients (Class IIB and III). Upregulation of CD83, which is 
described as a specific marker for dendritic cells, has recently been described to also be 
expressed on neutrophils in vitro by TNFα and in vivo by acute infection (32, 33). These 
data are consistent with hypothesis that circulating neutrophils in severe COPD patients 
have encountered pro-inflammatory mediators.  
Comparison of cytokine induced gene expression profiles of neutrophils with the gene 
expression profiles of neutrophils isolated from patients with stable severe COPD 
revealed that gene expression profiles of circulating neutrophils from COPD patients were 
very similar to that of in vitro TNFα or LPS, but not that of GM-CSF stimulated 
neutrophils of normal donors. The gene profile of neutrophils from COPD patients is not 
identical to that of individual mediators such as TNFα or LPS. This demonstrates that it is 
unlikely that dominant single mediators drive systemic inflammation in COPD but rather 
a combination of inflammatory mediators. Indeed, a combination of inflammatory 
mediators can lead to enhancement (Fig. 2) or inhibition of transcription of genes (see 
Chapter 3). For instance, IFNγ enhances the production of cytokines/chemokines of 
neutrophils stimulated by LPS, whereas IL-10 inhibits the production of inflammatory 
mediators of (27). In addition, the kinetics of gene expression is important. Genes that are 
expressed late upon activation might not be found in peripheral blood, but only in the 
tissues.  
Investigation of expression of several of these genes, including IL-1β, IL-1RA, IL-8, 
CD83 and MIP-1β, in patients with different stages of COPD, revealed that these genes 
were significantly increased in the more severe COPD patients (Class IIb and III) and a 
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significant negative correlation was present between the extent of the gene expression and 
the lung function. This was not a generalized finding, since the expression of several 
genes did not demonstrate this correlation. These data show a close correlation between 
disease status in the pulmonary tissue and the systemic inflammatory reaction as measured 
in the peripheral blood. The status of systemic inflammation can thus be measured as an 
additional read-out for the health status and may also helpful for the prognosis of a COPD 
patient.  
 
Gene expression of peripheral blood neutrophils of COPD patients show 
upregulation of functional groups of genes 
Among the regulated genes of severe COPD patients, several cytokines and chemokines 
were upregulated. It has been described that besides the traditional functions, such as 
phagocytosis, degranulation and production of superoxide, neutrophils can express a 
variety of inflammatory mediators (reviewed by (27)). These findings suggest that 
circulating neutrophils not only participate in airway damage in COPD patients, but also 
participate in the regulation of systemic inflammation. In addition, it is likely that these 
cells can also regulate local inflammation after migration into the airways of COPD 
patients. Here they can act in a pro-and anti-inflammatory fashion depending on the mix 
of genes that is transcribed (see below). 
Other genes that are regulated, such as CD58, CD44, ICAM3, ICAM1, and CD69 point at 
a putative change in neutrophil adhesion properties in these COPD patients. The change in 
adhesion properties is in agreement with data showing that peripheral blood neutrophils of 
COPD patients have increased levels of Mac1 (17). Thus a change in adhesion properties 
of neutrophils might facilitate the recruitment of cells into the lung tissue of COPD 
patients, and contributes to the sequestration of neutrophils in the airways of COPD 
patients.  
 
Balance between anti- and pro-inflammatory mediators 
TNFα, GM-CSF but also LPS can induce the expression of pro-inflammatory mediators 
in neutrophils and, thereby, enhance the inflammatory response. However, at the same 
time TNFα, GM-CSF and LPS downregulated the responsiveness of neutrophils and 
bystander cells towards other pro-inflammatory mediators. IL-1RA and IL-1R2 are 
natural inhibitory proteins for IL-1β. IL-1RA exerts its inhibitory action by binding to IL-
1 receptors without triggering any intracellular signaling responses, whereas IL-1R2 binds 
IL-1β without giving a biological response (34, 35). The upregulation of IL-1RA and IL-
1R2 in neutrophils in vivo is likely involved in dampening of the inflammatory response 
initiated by IL-1β. Similarly, TNFα or GM-CSF down-regulated the expression of IL-8R1 
which is likely to result in reduced responsiveness to this pro-inflammatory chemokine. 
Other studies have shown that systemic inflammation can cause functional down-
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regulation of serpentine receptors in vitro and in vivo (36-38). Thus activated neutrophils 
can not only induce an inflammatory response, but also an anti-inflammatory response, 
generating a negative feedback loop. The outcome of these two processes may be 
determined by differences in the levels and kinetics of the responses. Thus neutrophils are 
not only effector cells, but might also play a role in the regulation of the duration of an 
inflammatory reaction.  
Interesting is that the balance between the pro-inflammatory mediator IL-1β and the anti-
inflammatory mediators IL-1RA and IL-1R2 is disturbed in patients with severe stable 
COPD compared to in vitro stimulation of neutrophils by inflammatory mediators. Real 
time RT-PCR analysis showed that the expression of IL-1RA is much higher than that of 
IL-1β in neutrophils stimulated with TNFα (Fig. 2), compared to neutrophils from severe 
stable COPD patients (Fig. 3). Apparently, the regulation of natural inhibitory genes is 
disturbed in peripheral blood neutrophils from severe COPD patients. In addition, 
expression of IL-1R2 is not upregulated in these COPD patients, while in vitro GM-CSF 
or LPS induced the expression of IL-1R2. Thus the balance of expressed genes, has been 
shifted towards a pro-inflammatory state. In contrast to rheumatoid arthritis, in COPD 
little is known concerning the function of IL-1 family proteins. In the rheumatoid 
synovium, an imbalance exists in the pro- and anti-inflammatory mediators since the 
relative levels of production of IL-1RA are not adequate to effectively block the pro-
inflammatory effects of IL-1 (39). Injection of IL-1RA in the synovium, significantly 
reduced the signs and symptoms of rheumatoid arthritis at 24 weeks (40). So the 
imbalance between anti- and pro-inflammatory genes, including the IL-1 family, of 
circulating neutrophils of COPD patients, might therefore also contribute to the 
development of a chronic inflammatory response in COPD. 
In conclusion, this study indicates that activated neutrophils can be found in the peripheral 
blood of stable COPD patients and this activation correlates with the severity of the 
disease. Inflammatory mediators such as TNFα, are likely involved in the activation of 
neutrophils in these stable COPD patients. Interestingly, there is an imbalance in 
expression of pro- and anti-inflammatory mediators, including the IL-1 family, in 
neutrophils of the more severe COPD patients. This imbalance towards a pro-
inflammatory response may contribute to the systemic inflammation observed in these 
COPD patients. Greater understanding of these mechanisms by fine-tuning analysis of the 
gene profiles may increase our understanding of the systemic inflammation in COPD and 
may result in better markers for disease staging. 
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Abstract 
 
Chronic obstructive pulmonary disease (COPD) is associated with systemic inflammation, 
which is in part mediated by increased levels of inflammatory cytokines/chemokines and 
by (pre)activation of peripheral blood neutrophils. To investigate systemic inflammation 
during acute exacerbations of the disease, we analyzed the expression of cytokine-induced 
inflammatory genes in peripheral blood neutrophils from frequently exacerbating COPD 
patients during a stable phase of the disease compared to an exacerbation. Data were 
obtained by using real time reverse transcriptase-polymerase chain reaction.  
The expression of several pro-inflammatory genes, including CD83, IL-1β, IL-1RA, IL-8 
and MIP-1β was increased in patients with moderate to severe COPD (Gold class IIa and 
III). In contrast to our expectation the expression of these genes was actually decreased in 
peripheral blood neutrophils during an exacerbation of the disease to levels similar to that 
of neutrophils obtained from normal donors. This was most evident for CD83 and, 
therefore, we utilized this marker for an in vitro mechanistic study. TNFα induced CD83 
mRNA in a dose and time dependent manner in neutrophils in vitro. Interestingly, CD83 
was dramatically down-regulated by simultaneous incubation of neutrophils with 
granulocyte-macrophage colony-stimulating factor (GM-CSF) and TNFα. This effect was 
dose dependent and optimal at 100 pM GM-CSF. This GM-CSF-induced effect is 
independently of IκBα phosphorylation. Thus, acute exacerbations of COPD are 
associated with a clear down-regulation of inflammatory genes in circulating neutrophils, 
which might be caused by a change in the levels of systemic inflammatory mediators.  
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Introduction 
 
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease of the 
airways, which is characterized by the presence of chronic airflow obstruction and chronic 
inflammation in the lower airways. Several studies have monitored local inflammation in 
COPD by measuring granulocyte activation at the site of inflammation (1-3). Additional 
studies have measured cytokine levels in the sputum to monitor disease progress (4-6).  
In contrast to this relatively well-studied local inflammation, little is known concerning 
the systemic inflammatory response in COPD. A number of studies provide evidence that 
local inflammation is reflected by cytokine release into the systemic circulation. However, 
several inflammatory mediators such as tumor necrosis factor (TNF)-α are difficult to 
detect in the peripheral blood because of their short half-life, binding to soluble receptors, 
and renal clearance from the peripheral blood (7-9). Recent studies showed that levels of 
soluble TNF-receptor (sTNF-R)55 and sTNF-R75 were increased in the peripheral blood 
of patients with COPD, which is thought to reflect TNFα induced inflammation (9-11). 
Other studies reported increased levels of eosinophil cationic protein (ECP) and 
myeloperoxidase (MPO) in the serum of COPD patients (12), which are indirect 
measurements for pre-activation of granulocytes. Indeed, initial data have shown that 
inflammatory cells in the peripheral blood of patients with chronic pulmonary diseases are 
characterized by a primed phenotype (13-15). Despite the increasing evidence that 
granulocytes are activated in the peripheral blood from patients with COPD, little is 
known regarding the identity of the inflammatory mediators and the type and kinetics of 
the inflammatory response. Even less is known regarding systemic inflammation during 
exacerbations of COPD. 
In this study the activation status of peripheral blood neutrophils was examined as read-
out for the chronic inflammatory response during acute exacerbations of COPD. This was 
achieved by analysis of the expression of inflammatory genes in peripheral blood 
neutrophils in vivo and in vitro using real time RT-PCR. We compared gene profiles of 
neutrophils, stimulated with the pro-inflammatory cytokine TNFα in vitro with the gene 
profiles of neutrophils isolated from patients with COPD before and at time of 
exacerbation of their disease. Pro-inflammatory genes such as CD83, IL-1β and MIP-1β 
were upregulated in neutrophils obtained from severe COPD patients. These genes are 
typically induced by TNF in vitro (see Chapter 2). Surprisingly, these genes were down-
regulated in peripheral blood neutrophils during acute exacerbation of the disease. These 
findings demonstrate a change in systemic inflammation during an acute exacerbation of 
COPD. 
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Materials and Methods  
 
Reagents 
Formyl-methionyl-leucyl-phenylalanine (fMLP) and LPS were purchased from Sigma (St. 
Louis, MO, USA). Recombinant human GM-CSF was from Genzyme (Boston, MA, USA). 
Recombinant human TNFα was purchased from Boehringer Mannheim (Mannheim, 
Germany). IL-8 was purchased from Peprotech (Rocky Hill, NJ, USA). Human serum 
albumin (HSA) was obtained from the Central Laboratory of the Netherlands Red Cross 
Blood Transfusion Service (Amsterdam, The Netherlands). RPMI 1640 medium with 
Glutamax was purchased from Life Technologies (Breda, The Netherlands). Ficoll-Paque 
was from Pharmacia (Uppsala, Sweden). Anti-phospho-IκBα (ser32) was from New 
England Biolabs (Bevery, MA, USA). Actin (I-19) polyclonal antiserum was from Santa 
Cruz Biotechnology Inc. (Santa Cruz, CA, USA). 
 
Subjects 
Six patients were enrolled into the study with unstable moderate to severe (class IIb and 
III) COPD according to the inclusion criteria of the GOLD guidelines (16). All patients 
had in the year prior to the inclusion to the study at least two exacerbations requiring 
hospital admission. Patients also had to meet the following additional inclusion criteria: a 
FEV1 < 80% and a reversibility of the airway obstruction of less than 10% or less than 
200 ml after inhalation of a β2-agonist and a FEV1/FVC of less than 70%. A history of 
other concomitant confounding diseases such as diabetes mellitus, lung carcinoma, 
cardiovascular disease and bronchiectasis were excluded from the study. Also patients 
with a history of asthma or atopy were excluded. Patients were on standardized therapy 
with a muscnismic receptor antagonist (b.i.d), long acting β2-agonist (b.i.d.), inhalated 
cortico-steroids if neccecary, and they were allowed to use a short acting β2-agonist for 
rescue medication. These COPD patients were followed for nine months and disease 
status was monitored every two weeks during a visit to the out patient clinic. During every 
visit a medical history, Borg score (17), lung function (FEV1 and FVC), and routine 
laboratory tests were performed. Blood samples were taken during these visits to 
investigate peripheral blood neutrophil gene expression during an exacerbation(s) before 
treatment of the exacerbation and during stable phases of their disease. The presence of an 
acute disease exacerbation was diagnosed according to Anthonisen (18), being an increase 
of dyspnoea, cough, or sputum production resulting in hospital admission. During 
exacerbations patients were treated with antibiotics (levofloxacin 500 mg once a day for 
fourteen days) and glucocorticosteroids intravenously (Di-Adreson F-aquosum 50 mg for 
7 days). A stable phase was defined as at least 4 weeks before or after an acute 
exacerbation and no presence of a respiratory tract infection or respiratory complaints 
during 4 weeks prior or after sampling. The mean age of the patient group was 63.3 ±4.9 
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(range 48-78).The mean FEV1 was 29.8 ± 3.4% (range 19.1%-39.9%). Eleven healthy 
subjects with a normal lung function were enrolled as controls. The study was approved 
by the Medical Ethics Committee of the University Medical Center, Utrecht, and informed 
consent was obtained from all subjects. 
 
Isolation of human neutrophils 
Blood was obtained from healthy volunteers and COPD patients. Mixed granulocytes were 
isolated from 50-100 ml blood (normal volunteers) or 20 ml (COPD patients), which was 
anti-coagulated with 0.32% sodium citrate. Blood was diluted 2.5:1 with PBS containing 
0.32% sodium citrate and human pasteurized plasma-protein solution (4 g/L). 
Mononuclear cells were removed by centrifugation over Ficoll-Paque for 20 minutes at 
2000 rpm. The erythrocytes were lyzed in isotonic ice-cold NH4Cl solution followed by 
centrifugation at 4°C. Granulocytes were allowed to recover for 30 minutes at 37°C in 
Hepes buffered RPMI 1640 medium, supplemented with L-glutamine and 0.5% HSA. All 
preparations contained >97% neutrophils.  
 
RNA isolation and cDNA synthesis.  
RNA isolation was performed as previously described (19). Briefly, 2×107 cells were 
washed with ice-cold PBS and lyzed in 0.4 mL of GIT solution (6 mol/L guanidine 
thiocyanate, 25 mmol/L sodium citrate, 0.5% N´-lauroyl sarcosine, 100 mmol/L β-
mercaptoethanol). After storage at –20°C, phenol extraction was performed followed by 
ethanol precipitation. Total RNA was resuspended in a small volume of H20 and treated 
with DNAse for half an hour. After DNAse treatment RNA was again extracted with 
phenol, precipitated with ethanol and RNA was then eluted in 10 µl of RNAse-free H2O. 
cDNA was synthesized using MMLV reverse transcriptase and oligo(dT) primers. 
Samples containing 1 µg of total RNA were heated for 3 minutes at 65°C and quickly 
chilled on ice. A mixture of 25 µl containing 20 µg/ml oligo(dT) primers, 5 µl of 5x RT 
buffer, 20 mM DTT, 2 mM each deoxynucleoside triphosphate, 0.8 U/µl of RNAse 
inhibitor and 400 units of MMLV reverse transcriptase was added and incubated at 37 °C 
for 90 minutes, followed by RT inactivation for 10 min at 65°C. cDNA was stored at -
20°C before further use. All reagents used for cDNA synthesis were obtained from Life 
Technologies (Breda, The Netherlands) 
 
Real time reverse transcriptase-polymerase chain reaction (RT-PCR) 
CD83 gene was analyzed by Taqman real time pcr as described in Chapter 2. All the other 
genes were analyzed by real time pcr using SYBR green I (Chapter 2). Amplification and 
detection of both Taqman and SYBR green I pcr were performed with an ABI Prism 7700 
sequence detection system (PE Applied Biosystems, Nieuwerkerk a/d ijssel, The 
Netherlands) under the following conditions: 2 minutes at 50°C, 10 minutes at 95°C to 
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activate AmpliTaq Gold DNA polymerase, and 40 cycles of 15 seconds at 95°C and 1 
minute at 60°C. During amplification, the ABI Prism sequence detector monitored real-
time PCR amplification by quantitatively analyzing fluorescence emissions. The signal of 
the dye was measured against the internal reference dye (ROX) signal to normalize for 
non-PCR-related fluorescence fluctuations occurring from well to well. Results were 
normalized for the housekeeping gene β-actin and GAPDH. A reference sample of cDNA 
on every 96 wells plate allowed correction of differences between plates. Results were 
expressed as fold regulation. 
 
Western blotting  
Cytosolic extracts were prepared by the same method as for obtaining nuclear extracts in the 
section EMSA. Samples were normalized for protein content and boiled for 5 min at 95°C in 
the presence of Laemmli sample buffer. Proteins were analyzed on 10% SDS-polyacrylamide 
gels and transferred to Immobilon-P. The blots were blocked in hybridization buffer (10 mM 
Tris, 150 mM NaCl and 0.3% Tween-20) containing 5% BSA for 1 hour followed by 
incubation with polyclonal anti-phospho-IκBα (ser32) (1/2000) in hybridization buffer with 
0.5% BSA for 1 hours at room temperature. Second antibody was incubated in hybridization 
buffer for 1 hour. The western blots for hybridization with anti-actin were blocked in 
hybridization buffer containing 5% non-fat milk for 1 hour followed by incubation with anti-
actin (1/1000) in hybridization buffer with 0.5% non-fat milk for 2 hours at room temperature. 
Second antibody was incubated in hybridization buffer containing 0.5% non-fat milk for 1 
hour. Detection of all western blots was performed by enhanced chemiluminescence (ECL; 
Amersham, UK).  
 
Statistics 
Unless otherwise noted, all data are expressed as the mean ± SE, and differences between 
values were compared for significance by the paired t-test. Differences between study 
groups were compared using the Mann-Whitney U test. The Wilcoxon signed rank test 
was used for comparisons within an individual between their stable phase and 
exacerbation. Statistical significance was defined as p<0.05 
 
Chapter 3 
 63 
Results 
 
Exacerbations of COPD are associated with down-regulation of cytokine inducible 
genes in peripheral blood neutrophils.  
Neutrophils isolated from patients with moderate to severe COPD appeared to have a 
markedly increased expression of several inflammatory genes, compared to cells obtained 
from normal control donors (see Chapter 2). These genes are typically induced by pro-
inflammatory cytokines, such as TNFα. We tested the hypothesis that exacerbations of 
COPD would be reflected in a more pronounced expression of these genes, since 
increased levels of inflammatory cytokines have been found in the airways of patients 
with acute exacerbations of COPD as compared to a stable phase of their disease (1). We 
focused on a small set of regulated genes, including IL-1β, IL-1RA, IL-8, IL-8R1, MIP1β 
and CD83 to analyze their expression during stable phases and during exacerbations of 
COPD patients. cDNA was prepared from total RNA of cells from healthy volunteers and 
of above mentioned COPD patients, and was used for real time RT-PCR analysis of the 
indicated genes (Fig 1). Pro-inflammatory genes such as CD83, MIP-1β, and IL-1β were 
significantly increased in severe COPD patients compared to healthy volunteers (Fig 1, 
see also Chapter 2).  
Interestingly, neutrophils isolated from these patients were characterized by a clear and 
significant decrease in CD83, MIP-1β, IL-1β, and IL-8 expression at the time of an 
exacerbation of their disease compared to the stable phase (Fig.1). The expression of IL-
1RA and IL-1β returned to the level of healthy volunteers. Expression of CD83, MIP-
1β and IL-8 was reduced to a level even lower than that of healthy volunteers. Not all 
analyzed genes were down-regulated in neutrophils from COPD patients with an 
exacerbation. For example the IL-8R1 gene was not significantly influenced.  
 
Kinetics of TNFα induced CD83 expression in neutrophils in vitro.  
The results obtained with CD83 were the most striking of all genes analyzed. To gain 
more insight into the mechanism underlying this phenomenon, we studied expression of 
CD83 under different conditions in vitro. We and others have shown that this gene is 
specifically induced by inflammatory mediators that activate the transcription factor 
NFκb, including TNFαand LPS (see Chapter 2,(20-24). We first set out experiments to 
study the characteristics of TNFα-induced activation of neutrophils in terms of expression 
of CD83 mRNA in these cells. Neutrophils were stimulated with TNFα for various 
periods of time to analyze the kinetics of TNFα-mediated upregulation of CD83 
expression. CD83 expression was measured by real time RT-PCR as described in 
Materials and Methods. Specific primers were used to amplify only cDNA generated from 
CD83 mRNA and not genomic DNA. CD83 expression was normalized for β-actin 
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expression. Increased CD83 expression was already observed within 30 minutes of TNFα 
stimulation, and was further elevated over time (Fig. 2A). Maximal increase of CD83 
expression was reached between 2-3 hours. Next, neutrophils were incubated with 
increasing concentrations of TNFα for 3 hours to determine the dose dependency of CD83 
induction (Fig. 2B). A significant increase of CD83 expression of 7- and 14-fold was 
found at a concentration of 10 and 100 U/ml, respectively. These data demonstrate that the 
increase in CD83 mRNA expression by TNFα is time and concentration dependent. These 
findings are consistent with a role for cytokines such as TNFα in systemic inflammation 
in COPD, but do not shed light on the down-regulation of CD83 mRNA in neutrophils 
from COPD patients during an acute exacerbation of their disease. 
 
Healthy controls
Mild to severe COPD
(Class IIB and III) 
without exacerbation
and
during an exacerbation
MIP-1β
-4
-2
0
2
4
6
8
IL-8
-5
-4
-3
-2
-1
0
1
2
3
CD83
-2
-1
0
1
2
3
4
IL-1RA
-2
-1
0
1
2
3
4
5
IL-1β
-2
-1
0
1
2
3
4
5
LO
G
2
IL-8R1
-3
-2
-1
0
1
2
3
LO
G
2
p < 0.05p < 0.05p < 0.05
p < 0.05p < 0.05
p < 0.001
p < 0.05
p < 0.005
p < 0.05
p < 0.05
 
Figure 1: Gene expression analysis in peripheral blood neutrophils of COPD patients. 
Peripheral blood neutrophils were isolated from healthy volunteers (Filled squares) and moderate to 
severe (class IIB and III) COPD patients during their stable phase (open circles) and at time of 
exacerbation (filled circles). A line connected the stable phase and exacerbation of the same patient. 
Expression of indicated genes were measured using real time RT-PCR and expressed as LOG2 fold-
change compared to the group of healthy controls. Differences between the study groups were 
compared using the Mann-Whitney U test. Differences between stable phase and exacerbation were 
compared using the Wilcoxon signed rank test. 
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Figure 2: TNFα induced CD83 expression is time and dose dependent. Peripheral blood 
neutrophils were stimulated with TNFα (100U/ml) for several time points (A) or with several 
concentrations of TNFα for 3 hours in vitro (B). RNA was isolated and real time RT-PCR for CD83 
was performed. Results were normalized for the housekeeping gene β-actin. Results were expressed 
as relative levels of CD83 ±S.E.M. (n=4). For statistical analysis the paired T-test was used 
(*p<0.05 versus 3 hrs no stimulation; **p<0.001 versus 3 hrs no stimulation). 
 
GM-CSF down-regulates TNFα-induced CD83 mRNA in neutrophils  
Besides TNF-α, a role for GM-CSF in the pathogenesis of COPD has been proposed (4, 
25, 26). Therefore, we designed experiments to study the effect of co-stimulating 
neutrophils with GM-CSF and TNFα on the expression of CD83 mRNA. In Chapter 2 we 
demonstrated that TNFα but not GM-CSF could induce CD83 expression. Neutrophils 
were stimulated with increasing concentrations of TNFα in the presence or absence of 
GM-CSF (0.1 nM). RNA was isolated and CD83 expression was determined by real time 
RT-PCR (Fig 3A). Co-incubation with GM-CSF caused a dramatic inhibition of TNFα 
(100 U/ml) induced CD83 expression in human neutrophils. This inhibition was complete 
in neutrophils stimulated with 1 or 10 U/ml TNFα. 
Neutrophils were subsequently stimulated with TNFα and increasing concentrations of 
GM-CSF to determine the dose dependency of the inhibition. As shown in Figure 3B, 
increasing concentrations of GM-CSF results in decreasing TNFα induced CD83 
expression. Complete inhibition of 10 U/ml of TNFα induced CD83 expression was 
obtained at a concentration of 0.1 nM GM-CSF. These findings demonstrate that a 
combination of pro-inflammatory cytokines can result in down-regulation of a pro-
inflammatory gene.  
 
 
 
 
 65 
 
Exacerbations of COPD correlate with down-regulation of genes in neutrophils 
GM-CSF-induced down-regulation of CD83 mRNA is not associated by changes in 
NFκB signaling 
As previously mentioned both activators of CD83, TNFα and LPS (see Chapter 2), are 
strong activators of the transcription factor NF-κB in neutrophils (27). In addition, TNFα 
induced CD83 expression in T-cells is NF-κB dependent (20, 21). Therefore, we 
investigated whether the effect of GM-CSF might be mediated through inhibition of NF-
κB signaling. As a read out for this signaling pathway, the phosphorylation state of IκBα 
was studied. In an unphosphorylated state, IκB associates with NF-κB, retaining it in the 
cytoplasm and subsequently preventing translocation of NF-κB to the nucleus. TNFα but 
not GM-CSF stimulation was sufficient to induce phosphorylation of IκBα in neutrophils 
(and thus activation of NFκB) (Fig 3C). Stimulation of neutrophils with TNFα in the 
presence GM-CSF resulted in IκBα phosphorylation to a similar level as TNFα alone. 
Thus, the inhibitory effect of GM-CSF on TNFα-induced CD83 expression is independent 
of IκBα phosphorylation in human neutrophils. 
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Figure 3: TNFα induced CD83 expression in peripheral blood neutrophils is inhibited by GM-
CSF. (A) Isolated neutrophils were incubated with increasing concentrations of TNFα (as indicated) 
and simultaneously without (black bars) or with GM-CSF (0.1 nM) (empty bars) for 3 hours in 
vitro. CD83 expression was measured by performing real time RT-PCR and results are expressed as 
relative levels of CD83 ±S.E.M. (n=4). For statistical analysis the paired T-test was used.*p<0.05. 
(B) Neutrophils were incubated with TNFα (10 U/ml) and simultaneously with increasing 
concentrations of GM-CSF for 3 hours in vitro. Results are expressed as relative levels of CD83 ±
S.E.M. (n=4). For statistical analysis the paired T-test was used.*p<0.05 versus TNFα (10 U/ml). 
(C) Neutrophils were incubated with TNFα (10 U/ml) and/or GM-CSF (10-10 M) for the times 
indicated. After stimulation, cytosolic extracts were prepared, normalized for protein content and 
analyzed by SDS-PAGE followed by Western blotting with anti-phospho-IκBα (ser 32) or anti-
actin. Data is representative of three independent experiments. 
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Discussion 
 
At chronic inflammatory loci, such as bronchial tissue in COPD, neutrophils migrate to 
the site of inflammation and can become activated even in the absence of microbial 
derived triggers. Several studies have monitored inflammatory diseases by measuring 
granulocyte activation at the site of inflammation (1-3). In contrast to local inflammatory 
sites, little is known about systemic inflammation associated with granulocyte activation 
in peripheral blood in COPD. Furthermore, it is not clear which inflammatory mediators 
are playing a role in the activation of granulocytes in the systemic compartment. The 
analysis of gene profiles of cytokine-induced genes in neutrophils (in vitro) can be used as 
an indication for the action of these cytokines in vivo. Indeed, we have found several 
differentially expressed genes in neutrophils from the blood of patients with moderate to 
severe COPD compared to normal donors (see Chapter 2). 
Here we focused on a set of genes that were found to be regulated in vivo in COPD 
patients, and are also induced by cytokines in neutrophils in vitro (see Chapter 2). The 
expression of CD83, MIP-1β, and IL-1β were significantly enhanced in peripheral blood 
neutrophils from COPD patients in a stable phase of their disease (Fig. 1). However, to 
our surprise, the expression of CD83, MIP-1β, IL-1β, and IL-8 was dramatically down-
regulated in peripheral neutrophils from COPD patients during an acute exacerbation of 
their disease (Fig. 1). This unanticipated result may have important consequences 
concerning the insight into the mechanisms of the chronic systemic inflammatory 
response in COPD. Apparently, either a quantitative (excess of inflammatory signals) 
and/or a qualitative (different inflammatory mediators) change reflects itself in a gene 
profile that fits more with a reduced inflammatory phenotype. It is tempting to speculate 
that neutrophils act as pro-inflammatory cells at the onset of an inflammatory reaction, but 
can have a more anti-inflammatory function at later stages of an acute exacerbation. This 
altered neutrophil phenotype might then be more involved in dampening the inflammatory 
reaction. Support for this hypothesis is the finding that peripheral blood neutrophils are 
found to be primed directly after post-injury multiple organ failure, but become 
unresponsive to several pro-inflammatory chemoattractants after 48 hours (28, 29) 
TNFα is thought to be an important cytokine in the pathogenesis of COPD, has been 
implicated in many chronic inflammatory diseases (30) and is a strong activator of 
neutrophils (31). Besides TNFα, GM-CSF has also been implicated in the pathogenesis of 
COPD (25, 26). Interestingly, GM-CSF induces a distinct profile of expressed genes in 
neutrophils compared to TNFα (see Chapter 2). Not much is known regarding GM-CSF 
in systemic inflammation, but we did not find clear indications of specific GM-CSF 
induced genes in neutrophils isolated from the peripheral blood of COPD patients (see 
Chapter 2). Based on these findings we designed experiments to study the down-
regulation of CD83 mRNA in an in vitro setting. We focused on TNFα-induced CD83 
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expression in neutrophils in vitro as a model for processes occurring in vivo in patients 
with COPD.  
Time course experiments showed that CD83 expression was significantly induced by 
TNFα after one hour and was maximal after three hours. Concentrations between 1 and 10 
U/ml of TNFα were sufficient to induce CD83 mRNA expression. These concentrations 
are likely to be found near chronic inflammatory sites (4, 11, 32). The expression of CD83 
induced by TNF is likely to be mediated by NFκB, since mediators such as LPS and 
TNFα, that are well known activators of NFκB, induce CD83 in neutrophils (26), whereas 
mediators that do not activate NFκB in neutrophils (like GM-CSF and IL-8) do not 
increase CD83 mRNA. In addition, a recent study provides evidence that NF-κB mediates 
TNFα induced CD83 expression in Jurkat T cells (20).  
The effect of a combination of pro-inflammatory cytokines, TNF and GM-CSF, revealed 
the surprising observation that GM-CSF inhibits TNFα induced CD83 expression. This 
finding is consistent with the hypothesis that cytokines such as GM-CSF can cross-
modulate the expression of pro-inflammatory genes in neutrophils in vivo. Indeed, GM-
CSF levels were markedly increased in serum and sputum from chronic bronchitic 
patients with an exacerbation, as compared with patients under baseline conditions (25). 
The precise molecular mechanism by which GM-CSF inhibits CD83 expression remains 
to be determined. However, our IκBα phosphorylation data demonstrated that GM-CSF is 
inhibiting CD83 expression independently of IκBα phosphorylation.  
Another explanation for the down-regulation of genes at the time of exacerbation may be 
that the “hyper” activation of neutrophils causes enhanced homing to inflammatory loci. 
This hypothesis is supported by studies describing that circulating neutrophils are 
(pre)activated during the first 24 hours after major trauma and that a subsequent activation 
of these cells during this period can lead to enhanced sequestering in the organs and 
induction of an intense, cytotoxic, inflammatory response resulting in multiple organ 
injury (33, 34).  
Interestingly, the periods of exacerbation were characterized by neutrophilia rather than 
neutropenia (results not shown). Previous studies have also demonstrated an increase of 
neutrophils in the airways (25, 35-37). A consequence of this is that neutrophils obtained 
during an exacerbation in the periphery were likely recently released from the bone 
marrow. These neutrophils may not have encountered pro-inflammatory mediators such as 
TNFα. This might also explain why the expression of some genes decreases to below that 
of healthy volunteers. Most likely these processes occur simultaneously. The resulting 
phenotype of neutrophils obtained from patients during an exacerbation of COPD is the 
result of a very delicate balance between recruitment of neutrophils from the bone 
marrow, cross-modulation by multiple cytokines and enhanced homing to inflammatory 
sites. 
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In conclusion, our data indicate that combinations of cytokines in vivo can result in the 
production of specific gene profiles dependent on the combination and concentrations of 
cytokines. This suggests that cytokine/chemokine induced gene expression profiles may 
provide novel insights into the mechanisms of systemic inflammatorion in COPD in terms 
of type of inflammatory response, participation of unique combinations of cytokines and 
kinetics of the presence of different phenotypes of leukocytes in the peripheral blood. 
Thorough analysis of these gene profiles will allow characterization of different stages of 
COPD and possibly better timing of appropriate therapy. 
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Abstract 
 
Chronic inflammation of the airways is a hallmark of Chronic Obstructive Pulmonary 
Disease (COPD). We investigated the kinetics of priming of inflammatory cells in 
peripheral blood as a consequence of this process. 
Priming of leukocytes was determined by measuring the expression of priming epitopes 
by novel antibodies designated A17 and A27, CD83 mRNA expression and activation of 
intracellular signaling proteins in a cross sectional and a longitudinal study. Leukocytes 
were obtained from COPD patients (GOLD class IIa, b and III) and healthy controls. In a 
longitudinal study of six patients with moderate to severe COPD (GOLD class IIb and III) 
and six normal controls, the kinetics of priming was determined every two weeks for a 
period of nine months.  
In the cross sectional study, the priming of neutrophils in the context of expression of 
priming epitopes was not increased in COPD patients (31.6 ± 4.8 AU (A17) and 31.6 ± 
5.1 AU (A27) respectively), as compared to healthy controls (29.3 ± 5.2 AU (A17) and 
29.7 ± 4.2 AU (A27) respectively). For eosinophils, a slight but significant decrease in 
priming epithopes A17 was observed in COPD patients (45.7 ± 6.9 AU (A17) and 46.7 ± 
6.5 AU (A27) respectively) compared to healthy controls (58.2 ± 5.3 AU (A17) and 61.4 
± 5.2 AU (A27) respectively). The absence of priming of neutrophils was unanticipated 
and was evaluated in more detail in a small group of severe COPD patients (GOLD class 
IIb and III). In this group further characteristics of neutrophil priming were evaluated: 
expression of CD83 mRNA by real time PCR and activation of intracellular signaling 
molecules. This was studied in a longitudinal setting and all priming markers in 
combination with clinical characteristics were measured every two weeks during a period 
of nine months. Priming of neutrophils in this group of severe COPD patients was 
variable with regard to all priming markers compared with normal controls (coefficient of 
variation for A27 on neutrophils in COPD patients: 0.50, in healthy controls: 0.24 
(p<0.0001)). No correlation was found between clinical parameters and priming of 
peripheral blood neutrophils. 
We conclude that patients with advanced COPD show characteristics of a highly variable 
systemic inflammation, which does not reflect itself in individual clinical symptoms. 
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Introduction 
 
Chronic Obstructive Pulmonary Disease (COPD) is defined as a disease state 
characterized by irreversible, usually progressive airflow limitation (1). Central in the 
pathogenesis of COPD is the inflammatory reaction found in the airways and the alveolar 
structures, which leads to persistent injury. COPD is a slowly progressive disease and the 
damage to the lungs can be ascribed to years of exposure to noxious particles in cigarette 
smoke being the most important risk factor for the development of COPD in the western 
world (1). These particles can evoke direct damage to the lung parenchyma, but are also 
involved in the initiation of an inflammatory reaction in the lungs of COPD patients (2-4). 
The induction of this inflammatory reaction is accompanied by an imbalance in 
protease/antiprotease and oxidative/anti-oxidative mechanisms. These processes can lead 
to pulmonary damage and are not restricted to COPD (5-7). In the peripheral and central 
airways of COPD patients but also in `healthy` smokers inflammatory changes are found 
characterized by an increase in the number of neutrophils, monoyctes and T lymphocytes 
(3, 8, 9). 
Progression of COPD is characterized by a decline in lung function and development of a 
systemic response. Systemic effects are initiated by the local persistent inflammatory 
response in the lungs of COPD patients. Mediators originating form the local 
inflammatory response such as cytokines, chemokines and acute phase proteins are found 
in the peripheral circulation (10, 11). Activation of peripheral leukocytes, the occurrence 
of cachexia and muscle wasting are often observed in patients with severe COPD (12, 13). 
Sputum and bronchoalveolar lavage (BAL) studies have been performed to gain more 
insight into the processes of inflammation induced tissue damage in COPD. These studies 
showed increased levels of pro-inflammatory cytokines and chemokines in the bronchial 
compartment (10, 14, 15). In addition increased levels of inflammatory cytokines and 
chemokines as well as their receptors on leukocytes have been observed in the peripheral 
circulation. These circulating cytokines and chemokines mediate part of the systemic 
inflammatory reaction and are thought to prime inflammatory cells in the peripheral 
blood. This will facilitate the margination, extravasation and accumulation of 
inflammatory cells in to the tissues. Therefore, only partially primed cells can be found in 
the blood (11). Insight into the mechanism of priming of peripheral blood leukocytes of 
patients with COPD will contribute to the understanding of the kinetics of the systemic 
inflammatory processes, which are associated with the disease. 
We performed a cross-sectional study of COPD patients to determine whether there was 
inflammation-associated priming of neutrophils and eosinophils in the peripheral blood 
compared with cells obtained from normal control donors. An additional longitudinal 
study was undertaken to determine the kinetics of priming in COPD patients and in 
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normal controls. We show that systemic neutrophilic inflammation is variable in patients 
with severe COPD in contrast to mild to moderate patients and healthy controls. 
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Materials and Methods  
 
Reagents 
Recombinant human GM-CSF was from Genzyme (Boston, MA, USA). Recombinant 
human TNFα was purchased from Boehringer Mannheim (Mannheim, Germany). Human 
serum albumin (HSA) was obtained from the Central Laboratory of the Netherlands Red 
Cross Blood Transfusion Service (Amsterdam, The Netherlands). RPMI 1640 medium with 
Glutamax was purchased from Life Technologies (Breda, The Netherlands). Ficoll-Paque 
was from Pharmacia (Uppsala, Sweden). Polyclonal anti-phospho-PKB (ser473), anti-
phospho-ERK1/2 (Thr202/Tyr204). 
 
Study population and design 
For the cross-sectional study twenty-three patients with clinically stable, smoking related 
COPD (class IIa, IIb and III according to the GOLD criteria (1) were recruited from the 
outpatient clinic of the Heart Lung Center Utrecht. Patients with a FEV1 < 80% and a 
reversibility of less than 10% or less than 200 ml after administration of an inhaled β-
agonist were included. Patients with other concomitant confounding diseases such as 
diabetes mellitus, lung carcinoma and cardiovascular disease and those with bronciectasis 
were excluded from the study. Also patients with a history of asthma or atopy and patients 
with a respiratory tract infection or respiratory complaints during 4 weeks prior to the 
study were excluded. The mean FEV1 was 51.7 ± 3.8 % (range 19.1% - 79.3%). All 
patients had a previous history of at least 14 years of smoking (mean 40.0 ± 4.1, range 14 
– 76). The mean age of the patients was 64.0 ± 2.3 years (range 40 – 79). Eleven patients 
were currently smoking, other patients stopped smoking at least one year prior to the 
inclusion in the study. Regular use of oral glucocortico-steroids was also an exclusion 
criterion. Patients were treated with a long-acting β2 agonist, inhaled corticosteroids twice 
a day (when needed) and were prescribed bronchodilating agents if necessary. The 
priming state of neutrophils and eosinophils in the context of expression of priming 
epitopes on granulocytes was determined in all participants essentially as described before 
(11) (see also below). 
For the longitudinal study six patients with moderate to severe (class IIb and III) COPD 
according to the GOLD criteria, were investigated every two weeks during a period of 
nine months. Inclusion criteria were moderate (class IIB) to severe (class III) COPD, no 
other concomitant diseases or history of asthma or atopy. In the year prior to the inclusion 
to the study these patients experienced minimally two exacerbations requiring hospital 
admission. During every visit medical pulmonary history, severity of dyspnea was 
determined with the Borg score (16), lung function (FEV1 and FVC) and routine 
laboratory tests (Hb, Hct, Leukocyte count, CRP and BSE) were performed. All COPD 
patients were treated according a standardized protocol with a muscarinic receptor 
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antagonist (b.i.d.) and a long acting β2-agonist (b.i.d.). As rescue medication a short 
acting β2-agonist was used. During exacerbations not requiring admittance to the hospital 
patients were treated with antibiotics (levofloxacin 500 mg once a day for seven days) and 
oral glucocorticosteroids (prednison 30 mg). Severe exacerbations, requiring hospital 
admission were treated intravenously with glucocorticosteroids (Di-Adreson-F aquosum 
50 mg for 7 days) and antibiotics (levofloxacin 500 mg once a day for fourteen days). 
Exacerbations were diagnosed based on the major and minor criteria, being an increase in 
dyspnea, increased sputum volume, or sputum purulence, minor symptoms of 
exacerbation included cough, wheeze, sore throat, nasal discharge or fever (17, 18) For 
the diagnosis of an exacerbation the patients required two symptoms for the diagnosis, one 
of which had to be a major symptom(17). Sputum samples were obtained during 
exacerbations if possible and checked for bacterial growth. During exacerbations serum 
was obtained for virus PCR. Eight healthy subjects with a normal lung function were 
enrolled as controls and followed for six month. In the patient group and in the healthy 
controls the priming of leukocytes was measured every two weeks and also the expression 
of CD83 mRNA in neutrophils and activation of signaling molecules. In addition, for 
monitoring the patients thoroughly clinical parameters like borg score, lung function, 
medical history and routine laboratory tests (Hb, Hct, Leukocyte count, BSE and CRP) 
were determined at every visit. 
The study was approved by the Medical Ethics Committee of the University Medical 
Center, Utrecht, and informed consent was obtained from all subjects. 
 
Procedure for staining phagocytes with FITC labeled MoPhabs A17 and A27 
Two human monoclonal phage antibodies were isolated from a synthetic bacteriophage 
antibody library. These phage antibodies recognize epitopes that are upregulated on 
neutrophils and eosinophils present in whole blood, these epitopes are expressed on the 
cells at low priming concentration of cytokines such as GM-CSF and TNFα (11). Blood 
was collected on ice immediately after venapuncture and kept at 4 °C.100µl of FITC-
labeled MoPhab (A17 and A27 (11)) was added to 50µl of whole blood and incubated for 
90 min on ice. After incubation red cells were lysed in ice cold NH4Cl. Hereafter, the cells 
were washed and taken up in PBS/1%HSA, cells were analyzed in a FACS vantage 
flowcytometer (Becton & Dickinson, Mountain View, CA, USA). The different 
phagocytes were identified according to their specific side-scatter and forward-scatter 
signals (14). 
 
Isolation of human neutrophils 
Blood was obtained from healthy volunteers and COPD patients. Mixed granulocytes 
were isolated from 50-100 ml (normal volunteers) or 20 ml blood (COPD patients), which 
was anti-coagulated with 0.32% sodium citrate as described before (15). In short, blood 
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was diluted 2.5:1 with PBS containing 0.32% sodium citrate and human pasteurized 
plasma-protein solution (4 g/L). Mononuclear cells were removed by centrifugation over 
Ficoll-Pague. The erythrocytes were lyzed in isotonic ice-cold NH4Cl solution followed 
by centrifugation at 4°C. Granulocytes were allowed to recover for 30 minutes at 37°C in 
HEPES buffered RPMI 1640 medium, supplemented with L-glutamine and 0.5% HSA. 
All preparations contained >97% neutrophils. Isolated human neutrophils were incubated 
in RPMI 1640 supplemented with 0.5% HSA for 15 minutes and stimulated with or 
without TNFα (100U/ml) or GM-CSF (10 –10 M) for 3 hours at 37°C, followed by RNA 
isolation or protein lysation as described below. 
 
Isolation of Total RNA and PCR 
Total RNA form cells was obtained using the method described by Pals et al (19). cDNA 
was synthesized with use of a Pro Star First Strand reverse transcription-PCR kit as 
described by the manufacturers protocol (Stratagene, La Jolla, USA). Relative levels of 
CD83 expression were measured using primers and probes for CD83 designed by the 
Primer Express(TM) version 1.0 (Applied Biosystems, Nieuwerkerk a/d IJssel, The 
Netherlands). cDNA samples were measured by real-time quantitative PCR using a 
Perkin-Elmer Applied Biosystems Prism 7700 sequence detection system. (For details see 
also Chapter 2).  
 
Western blotting  
Neutrophils (106 cells) were pre-incubated with several concentrations of inhibitor for 20 
minutes followed by stimulation for the indicated time points, washed in ice-cold PBS and 
immediately lysed in Laemmli sample buffer. Total cell lysates were boiled for 5 min at 95°C 
and analyzed on 10% SDS-polyacrylamide gels. Proteins were transferred to Immobilon-P. 
The blots for hybridization with phospho-specific antibodies were blocked in hybridization 
buffer (10 mM Tris, 150 mM NaCl and 0.3% Tween-20) containing 3% BSA for 1 hour 
followed by incubation with phospho-specfic antibody (1/1000) in hybridization buffer with 
1% BSA for 2 hours at room temperature. Second antibody was incubated in hybridization 
buffer for 1 hour. The western blots for hybridization with all other antibodies were blocked in 
hybridization buffer (10 mM Tris, 150 mM NaCl and 0.3% Tween-20) containing 5% non-fat 
milk for 1 hour followed by incubation with antibody (1/1000) in hybridization buffer with 
0.5% non-fat milk for 2 hours at room temperature. Second antibody was incubated in 
hybridization buffer containing 0.5% non-fat milk for 1 hour. Detection of all western blots 
was performed by enhanced chemiluminescence (ECL; Amersham, UK).  
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Statistics 
Data are presented as mean ± SEM. Comparison of data was performed with using the 
Mann-Whitney U-test. Coefficient of variation was calculated as SD/mean. Probability 
values of < 0.05 were considered significant. 
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Priming of peripheral leukocytes in COPD and controls 
Peripheral venous blood was obtained from 23 patients with stable COPD (GOLD class 
IIa-IIb and III) and a group of 23 healthy non-smoking controls. The characteristics of the 
patients and controls are listed in Table 1. Figure 1 shows the priming of neutrophils and 
eosinophils recognized by moPhabs A17 and A27 in all COPD patients and in the healthy 
controls. These two human phage antibodies isolated from a synthetic bacteriophage 
antibody library recognize epitopes that are upregulated on neutrophils present in whole 
blood activated with low priming concentrations of cytokines, such as GM-CSF and 
TNFα (11). Surprisingly no significant differences were observed in the priming of 
neutrophils between COPD patients and healthy controls. A slight but significant decrease 
in eosinophil priming was observed in patients with stable COPD. In the COPD study 
group no relation between current smoking status and priming of granulocytes was 
observed (results not shown). 
COPD controls
0
50
100
150
200
ph
ag
e 
A
17
ne
ut
ro
ph
ils
(a
rb
itr
ar
y 
un
its
)
COPD controls
0
50
100
150
200
ph
ag
e 
A
27
ne
ut
ro
ph
ils
(a
rb
itr
ar
y 
un
its
)
COPD controls
0
50
100
150
200
p < 0.05
ph
ag
e 
A
17
eo
si
no
ph
ils
(a
rb
itr
ar
y 
un
its
)
COPD controls
0
50
100
150
200
DC
BA
ph
ag
e 
A
27
ne
ut
ro
ph
ils
(a
rb
itr
ar
y 
un
its
)
ph
ag
e 
A
17
ne
ut
ro
ph
ils
(a
rb
itr
ar
y 
un
its
)
ph
ag
e 
A
27
ne
ut
ro
ph
ils
(a
rb
itr
ar
y 
un
its
)
ph
ag
e 
A
17
eo
si
no
ph
ils
(a
rb
itr
ar
y 
un
its
)
ph
ag
e 
A
27
ne
ut
ro
ph
ils
(a
rb
itr
ar
y 
un
its
)
Figure 1. Expression of priming epithopes on neutrophils and eosinophils recognized by the 
phage antibodies A17 and A27 in patients with COPD and healthy controls. Comparison of the 
priming of neutrophils (COPD ■, controls □) (panels A and B) and eosinophils (COPD ●, controls 
○) (panels C and D) in peripheral blood of all COPD patients irrespective of the smoking status and 
healthy non-smoking controls. The priming was measured with two directly labeled monoclonal 
phage antibodies defined A17 (A and C) and A27 (B and D). The statistic analysis was performed 
by the Mann-Whitney U-test.  
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Table 1. Patient characteristics of the cross-sectional part of the study
number
Age, yr
Sex, M/F
FEV % predicted
VC % predicted
pack years
COPD 
23
62.8 ± 11.1
14/9
52.9 ± 3.8
81.3 ± 3.5
38.0 ± 4.7
Controls
23
33.3 ± 6.4
11/10
100.9 ± 2.5
100.7 ± 1.9
-
 
Variable neutrophil priming in stable COPD 
During the follow-up period the priming of neutrophils was highly variable in COPD 
patients compared to healthy controls (Fig. 2). The characteristics of the patients and 
controls are listed in Table 2. Figure 2 shows representative examples of the neutrophil 
priming in the follow-up period of three patients compared to three healthy controls. The 
priming of neutrophils expressed by moPhab A17 and A27 was highly variable in all six 
patients. No relation with individual clinical data, such as signs of exacerbations, bacterial 
or viral infections, colonization, increase in dyspnea and sputum production could be 
found. Table 4 shows the variation coefficient of leukocyte priming over a period of nine 
months. The variation coefficient for neutrophil priming is significantly increased in the 
COPD patients compared to the healthy controls.  
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Figure 2. Highly variable 
expression of priming 
epithopes in neutrophils 
during follow-up of patients 
with COPD. Representative 
example of the neutrophil 
priming measured every two 
weeks in three patients with 
COPD (panels A and C) 
compared to three healthy 
controls (panels B and D). The 
monoclonal phage antibody 
named A17 was used in panels 
A and B, whereas the 
monoclonal phage antibody, 
A27, was used in panels C and 
D. No relation with clinical 
symptoms was observed; one 
patient shown in the graph, 
marked with closed circles (•) 
had no signs of a clinical 
exacerbation during the follow-
up period. 
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Table 2. Patient characteristics of the longitudinal study
 
number
age, yr
sex M/F
FEV % predicted
VC % predicted
pack years
COPD 
6
62.1 ± 4.3
4/2
30 (19 –40) 
63 (46-88)
42.5 ± 6.0
Controls
8
34.8 ± 2.6
5/3
101 (94-113) 
100 (86-113) 
-
 
 
Table 3. Coefficient of variation in COPD cohort compared to the healthy controls
COPD cohort 
(SD/mean) 
A17 neutrophil
A27 neutrophil
A17 eosinophil  
A27 eosinophil
0.37 (p < 0.05) 
0.50 (p< 0.0001) 
0.49 (p < 0.05) 
0.54 (p< 0.005)
0.25 
0.24
0.31
0.37 
Control cohort 
(SD/mean) 
 
 
Expression of CD83 mRNA is variable in neutrophils obtained from COPD patients 
Expression levels of CD83 in neutrophils can be induced by stimulation of neutrophils 
with cytokines such as TNFα (Chapter 2)(20). PCR was performed to determine CD83 
mRNA expression in neutrophils and was visualized by agarose gel electrophoresis, as 
well as by real time quantitative PCR (Fig. 3 A and B). The expression of CD83 mRNA 
on neutrophils isolated from patients showed a high, but variable expression during the 
follow-up period. The two patients analyzed had no signs of an exacerbation during the 
observation period for CD83 shown in Figure 3. As control CD83 expression is shown in 
isolated neutrophils from a healthy donor unstimulated and stimulated with TNFα. 
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Figure 3: CD83 mRNA expression in peripheral blood neutrophils of COPD patients. In panel 
A, CD83 mRNA expression in neutrophils, during the follow-up of two patients, is visualized by gel 
electrophoresis, in panel B the quantitative expression of CD83 mRNA is measured via real-time 
PCR. In both panels the expression of CD83 in a healthy control is shown and also after stimulation 
of neutrophils with TNF (10 U/ml). Both patients had no clinical signs of an exacerbation during the 
period of CD83 mRNA measurement shown in the panels.  
 
 
Variable activation of PKB and ERK1/2 in neutrophils of COPD patients 
Some chronic inflammatory diseases are characterized by constitutive activation of 
intracellular signaling pathways in peripheral blood granulocytes (21). We evaluated the 
phosphorylation/activation status of two kinases ERK1/2 and Protein Kinase B (PKB). 
Both kinases require phosphorylation for activation (22). Application of phosphospecific 
antibodies allows the study of activation of these kinases by Western Blotting. As can be 
seen in Figure 4 these kinases are activated in neutrophils obtained from COPD patients. 
Again a high, but variable pattern of activation of ERK/PKB was found in COPD. 
Particularly PKB can be highly phosphorylated during the course of the disease, and 
phosphorylation of this kinase in non-cytokine treated cells from COPD patients can be as 
high as that found in control cells in vitro after cytokine stimulation.  
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Figure 4: Phosphorylation of PKB and ERK1/2 in neutrophils of COPD patients. A 
representative example of the phosphorylation of PKB and ERK1/2 in two patients with COPD 
during the follow-up period is shown in I and II. Human neutrophils were isolated from peripheral 
blood of patients with COPD. Cells were lysed and western blotting was performed as described in 
Materials and Methods. Phosphospecific antibodies were used for ERK1/2-p and PKB-p. Also 
shown is kinase phosphorylation in neutrophils obtained form a healthy control and after stimulation 
with GM-CSF (10-10 M). 
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Discussion 
 
The present study was undertaken to investigate chronic and systemic inflammation in 
COPD patients in a unique context. Analysis of leukocyte priming in peripheral blood by 
inflammatory mediators is an elegant method to study the kinetics of these processes. In 
this study we showed highly variable priming of neutrophils in patients with moderate to 
severe COPD, which is unrelated to individual clinical symptoms. This is in line with a 
hypothesis that the systemic inflammatory response in the airways of COPD patients is 
highly variable (18). Apparently clinical symptoms are not a good measure for the degree 
of systemic inflammation. In addition, this response is not very sensitive for cortico-
steroids, which is in line with the findings that chronic treatment of COPD with these 
drugs has a limited effect (23-25). 
The inflammatory changes observed in COPD patients include increased numbers of 
mucosal macrophages and sputum neutrophils (26, 27). The initial inflammatory insult is 
usually mediated by cigarette smoke. These inflammatory processes can be generated 
directly via cigarette smoke induced chemokine release by fibroblasts and resident tissue 
macrophages, and indirectly via the oxidative stress and proteases-induced damage (28). 
Chemokines are thought to contribute to inflammatory cell recruitment to the lungs and 
are, therefore, involved in the inflammatory processes in the lung parenchyma (3). These 
processes can occur in all smoking individuals (29) and the inflammation is to a large 
extent reversible upon smoking cessation (30). In patients with COPD, however, several 
studies showed a continuing inflammatory response (10, 26). The development of COPD 
in a minority of `healthy` smokers is caused by a switch to a chronic and exaggerated 
inflammatory response to noxious particles in cigarette smoke. More follow-up research 
in COPD patients as well as in `healthy` smokers has to be performed to elucidate the 
mechanisms underling the switch to persistent inflammation in COPD patients.  
It is tempting to speculate that the continuous activation of neutrophils is critical for the 
occurrence of a chronic irreversible inflammatory process observed in COPD. These cells 
are pre-activated in the peripheral blood of more severe COPD patients (see Chapter 2) 
and are found in enhanced numbers in the tissue of COPD patients (31, 32). Previous 
studies on peripheral blood neutrophils isolated from COPD patients showed an increase 
in respiratory burst and the increased expression of adhesion molecules (33). Studies with 
bronchial biopsies and sputum induction also showed an increase in the number of 
neutrophils and degranulation products of neutrophils in patients with COPD (32, 34-36). 
This methodology for studying neutrophils and neutrophil function in COPD has many 
disadvantages, the induction of sputum, bronchial lavage and biopsies in patients with 
moderate to severe COPD (classes IIb and III, GOLD guidelines) are often not possible 
(37). 
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Despite the importance ascribed to the neutrophil in COPD, surprisingly we found no 
difference in the priming of peripheral neutrophils of patients as measured by expression 
of priming epitopes compared to controls. However, it could not be ruled out that 
expression of surface markers is not sensitive enough to sense alterations in peripheral 
blood neutrophils induced by low amounts of cytokines, such as TNFα and/or IL-8. Gene 
expression profiles in neutrophils with gene array technology in patients with COPD 
revealed an increase in mRNA’s for pro-inflammatory genes such as CD83 (38). CD83 is 
a dendritic cell marker, which can be induced in neutrophils activated with TNF-α and 
IFN-γ (39). Previous studies performed in our laboratory showed an increase in CD83 
mRNA expression in neutrophils obtained from COPD patients. In addition, a positive 
correlation was observed between neutrophil CD83 expression and FEV1 (see Chapter 2). 
These data demonstrate that an increase in neutrophil activation coincides with 
deterioration of COPD. Therefore, a longitudinal study was set up to study the kinetics of 
expression of inflammatory markers to obtain a better insight into inflammatory processes 
in patients with COPD. This longitudinal study was performed with six patients with 
moderate to severe COPD. Despite the best clinical treatment the neutrophil priming 
during this follow-up period in patients was variable and unrelated to individual clinical 
symptoms (Fig. 2). A similar variability was also observed for CD83 expression in 
neutrophils during follow-up of these patients (Fig. 3). Detailed analysis showed that the 
expression of CD83 mRNA significantly decreased during a clinical exacerbation of 
COPD (see Chapter 3). Apart from this finding we observed in this study a high but 
variable expression of CD83, also outside periods of a clear clinical exacerbation. This 
variability shows that the chronic systemic inflammatory process in COPD patients cannot 
be considered as a “stable” process.  
It is tempting to speculate that the high variability in neutrophil priming is related to a 
discontinuous production of pro-and anti-inflammatory cytokines/chemokines (see also 
Chapter 3). To explore this hypothesis we evaluated the function of two protein kinases 
that are activated by both chemokines and cytokines. We have previously reported that 
hyperactivation of PKB in eosinophils of patients with asthma coincided with the 
enhanced priming status of these cells (21). Application of phosphospecific antibodies 
allows the study the activation status of these kinases by Western Blot analysis (22). In 
neutrophils stimulation with cytokines such as GM-CSF results in the phosphorylation of 
ERK1/2 and PKB (see figure 4 and (40-42)). In neutrophils from patients with COPD 
these signaling pathways were, and remained, activated after isolation and, increased 
phosphorylation of both PKB and ERK1/2 was observed. Again the pattern of activation 
was variable. The activation of both kinases has important consequences for granulocytes, 
particularly activation of PKB points at prolonged activation of the PI-3 kinases signaling 
pathway. This pathway has been shown to be essential in several granulocyte responses 
including inside-out control of Fc-receptors and integrins (40), priming of cytotoxicity, 
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enhanced survival (43) and priming of adhesion and migration (22, 44). It is tempting to 
speculate that neutrophils from more severe COPD are activated in a cycle of high/low 
priming that reflects itself in a variability of priming markers. High priming might be 
associated with enhanced homing, activation and survival. Low priming on the other hand 
might be associated by an anti-inflammatory phenotype (see Chapter 2). 
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Abstract 
Tyrosine phosphorylation is thought to be critical in the regulation of neutrophil 
functioning and members of the Src-family of tyrosine kinases have recently been shown 
to be regulated in activated granulocytes. We have utilized a specific pharmacological 
inhibitor of Src-kinases, pyrazolpyrimidine 1 (PP1), to evaluate the role of Src-kinases in 
cytokine/chemoattractant induced regulation of neutrophil function. PP1 inhibits PKB 
phosphorylation, but not STAT5 phosphorylation or the activation of MAP kinases by 
either fMLP or GM-CSF. Pre-treatment of neutrophils with PP1 and also with the PI3K 
inhibitor LY294002 resulted in a strong inhibition of fMLP induced superoxide 
production and cytokine-mediated survival, but not fMLP induced migration. 
Interestingly, the kinetics of inhibition of actin polymerization and the respiratory burst 
are very similar. While initiation of both processes was not effected, sustained activation 
was inhibited by PP1. Taken together, our results demonstrate a critical role for Src-
kinases in regulating neutrophil cytotoxic effector functioning through PI3K-PKB.  
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Introduction 
Neutrophils are critical effector cells in the killing and removal of microorganisms 
through the regulation of specific effector functions (1). The recruitment of neutrophils 
from peripheral blood to the inflammatory locus is mediated by several processes, 
consisting of rolling, and later firm adhesion to the vascular endothelium, followed by 
transmigration through the endothelium and migration to the specific site (2). At the 
inflammatory locus, the killing of microorganisms is mediated by different cytotoxic 
effector mechanisms including phagocytosis, release of cytotoxic proteins, and production 
of toxic oxygen metabolites initiated by a membrane bound NADPH-oxidase (3). 
Furthermore, these leukocytes are also involved in maintaining inflammatory reactions by 
the release of cytokines and bioactive lipids.  
A consequence of activation of neutrophils is the ability to cause tissue damage during 
inflammatory reactions and, therefore, the activity of neutrophils must be tightly 
controlled. For this reason the activation of neutrophils occurs in a multistep process. 
Resting neutrophils in the peripheral blood are poorly responsive to many activators 
including naturally occurring formyl peptides such as fMet-Leu-Phe (fMLP). However, 
when these cells are exposed to several pre-activating or "priming" agents such as 
cytokines, effector functions such as the respiratory burst, phagocytosis and degranulation 
are greatly enhanced (4,5). To understand the mechanism by which specific agents 
activate or prime granulocytes it is important to define components of signaling pathways 
responsible for the activation of effector functions in granulocytes. 
Recently several intracellular signal transduction cascades have been found to be activated 
in human neutrophils in response to cytokines such as GM-CSF, as well as G-protein 
coupled receptor (GPCR) agonists such as PAF and fMLP. One family of proteins that has 
been demonstrated to be activated by many priming agents are the mitogen activated 
protein kinases or MAP kinases (6-10). There are three distinct groups of MAP kinases: 
extracellular signal-related protein kinases (ERKs) activated by a large variety of agonist, 
stress-activated protein kinases (JNK/SAPKs) and the p38 MAPK family. Another signal 
transduction pathway that appears to play a critical role in both priming and activation of 
granulocyte effector functions involves the lipid kinase phosphatidylinositol 3-kinase 
(PI3K). Utilizing specific inhibitors of PI3K, wortmannin and LY294002, ourselves and 
others have recently demonstrated that this kinase plays a critical role in several 
neutrophil effector functions including the respiratory burst and migration (7,11-13).  
Despite the fact that in neutrophils cytokine and G-protein coupled receptors can activate 
the signaling cascades mentioned above, little is known about the specific mechanism by 
which these receptors initiate these cascades. During the last few years increasing 
evidence shows that tyrosine kinases are involved in transducing signals from both 
cytokine and G-protein coupled receptors to downstream signal cascades (14). In 
granulocytes, it has been shown that tyrosine kinases are involved in cytokine and G-
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protein coupled receptor agonist signaling (15-18). In neutrophils several protein tyrosine 
kinases have been identified, including Janus Kinases (JAKs) and the Src kinase family. 
The JAKs, which are activated by cytokine receptors but not by G-protein coupled 
receptors, phosphorylate the STAT transcription factors (19-21). This pathway is 
important for linking many cytokine receptors to gene regulation but is not involved in 
activation of cytotoxic mechanisms. Of the family of Src kinases, several members like 
Lyn, Hck and Fgr are expressed in neutrophils (22,23). These Src kinase members have 
also been shown to be activated by several cytokine and G-protein coupled receptors 
(18,24,25). Data from cell lines and knock-out mice show that Src kinases are involved in 
many cellular processes including differentiation, adhesion/spreading, migration, 
apoptosis, gene transcription and cell cycle (26,27).  
The development of a pharmacological Src family-selective tyrosine kinase inhibitor, PP1, 
has allowed the investigation of the role of this tyrosine kinase family (28). In this study 
we have utilized this inhibitor to evaluate the role of Src-kinases in cytokine and 
chemoattractant signaling regulating neutrophil functions. Our results demonstrate that 
Src kinases are involved in PKB but not in MAPK activation in neutrophils. Furthermore, 
we show that Src kinases play a role in fMLP-induced superoxide production, migration, 
actin polymerization and cytokine mediated survival. 
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Materials and Methods 
 
Reagents and Antibodies 
N-formyl-methionyl-leucyl-phenylalanine (fMLP) was purchased from Sigma (St. Louis, 
MO, USA). Recombinant human GM-CSF (2.5 x 108 U/mg) was from Genzyme (Boston, 
MA). Human serum albumin (HSA) and human pasteurised plasma-protein solution (40 
g/L) were obtained from the Central Laboratory of the Netherlands Red Cross Blood 
Transfusion Service (Amsterdam, The Netherlands). Hepes buffered RPMI 1640 medium 
with L-Glutamine and Hyclone were purchased from Life Technologies, Breda, The 
Netherlands. Ficoll-Paque was from Pharmacia (Uppsala, Sweden). Polyclonal anti-
phospho-PKB (ser473), anti-phospho-p44/42 MAPK (Thr202/Tyr204), anti-phospho-p38 
MAPK (Thr180/Thr182) and anti-phospho-STAT5 (Tyr694) antibodies were from New 
England Biolabs (Westburg, Leusden, The Netherlands). ERK-1 (C-16), ERK-2 (C-14), 
Hck (N-30) and c-Fgr (N-47) polyclonal antisera were from Santa Cruz Biotechnology Inc. 
(Santa Cruz, CA). Monoclonal anti-Lyn was purchased from Transduction Laboratories 
(Lexington, KY). Anti-PKB anti-sera has been described previously (29). The inhibitors 
PP1, PD098059, and LY294002 were from Biomol (Plymouth, PA). 
 
Isolation of human neutrophils 
Blood was obtained from healthy volunteers. Mixed granulocytes were isolated from 50-
100 ml blood, which was anti-coagulated with 0.32% sodium citrate as described before 
(7). Blood was diluted 1.4 times with phosphate-buffered saline (PBS) containing 0.32% 
sodium citrate and 10% human pasteurized plasma-protein solution (40 g/L). Mononuclear 
cells were removed by centrifugation over Ficoll-Pague for 20 minutes at 2000 rpm. The 
erythrocytes were lysed in isotonic ice-cold NH4CL solution followed by centrifugation at 
4°C. Granulocytes were allowed to recover for 30 minutes at 37°C in Hepes buffered 
RPMI 1640 medium Technologies, supplemented with L-glutamine and 0.5% HSA. All 
preparations contained >97% neutrophils. Before stimulation, neutrophils were 
resuspended in incubation buffer (20 mM Hepes pH 7.4, 132 mM NaCl, 6 mM KCl, 1 mM 
MgSO4, 1.2 mM KH2PO4, 5 mM glucose, 1 mM CaCl2 and 0.5% (v/v) HSA) for 15-30 
minutes at 37°C. 
 
Lyn, Hck and Fgr kinase activity 
Neutrophils were isolated as described above and incubated at 37°C for 30 minutes. After 
stimulation with fMLP, cells (5 × 106 cells) were lysed in 20 mM Tris-Cl pH 7.5, 150 mM 
NaCl, 50 mM NaF, 5 mM EDTA, 0.1% SDS, 0.5% sodium deoxycholaat, 1 mM Na3VO4, 
1% NP-40, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 1 mM PMSF and benzamidine. 
Lysates were pre-cleared for 30 minutes at 4°C with protein G-sepharose and 
 
Src kinases regulate PKB activation and modulate neutrophil functioning 
 98 
subsequently, Lyn, Hck and Fgr kinase was immunoprecipitated with 1 µg of Lyn, Hck or 
Fgr antibody for 1 hour at 4°C on a rotating-wheel. To immunoprecipitate Lyn monoclonal 
antibody, protein G-sepharose was added for a further 1 hour at 4°C, while protein A-
sepharose was used to immunoprecipitate Hck and Fgr antibodies. After washing twice 
with lysis-buffer and twice with wash buffer (25 mM Tris pH 7.5, 150 mM NaCl and 0.1 
mM Na3VO4), precipitates were incubated in 30 µl kinase buffer (20 mM Hepes pH 7.5, 10 
mM MnCl2, 1 µM rATP, and 0.3 µCi [γ32P]ATP) with increasing concentrations of PP1 for 
2 minutes at room temperature. The Hck and Fgr kinase reactions contained 10 µg of 
enolase. Reaction was stopped by the addition of 5x Laemmli sample buffer and boiled for 
5 minutes. Samples were separated by electrophoresis on 15% SDS-polyacrylamide gels. 
Kinase activity was detected by autoradiography. 
 
MAP kinase activity in vitro 
MAP kinase activity was measured as described before (7). In short, neutrophils were 
isolated as described above and incubated at 37°C for 30 minutes. After pre-treatment with 
PP1 or PD98059 and stimulation with fMLP or GM-CSF, cells (5 × 106 cells) were lysed 
in 50 mM Tris-Cl pH 7.5, 100 mM NaCl, 50 mM NaF, 5 mM EDTA, 40 mM β-
glycerophosphate, 1 mM Na3VO4, 1% Triton X-100, 10 µg/ml aprotinin, 10 µg/ml 
leupeptin, 1 mM PMSF and benzamidine. Lysates were pre-cleared for 30 minutes at 4°C 
with protein A-sepharose and subsequently, MAP kinase was immunoprecipitated with 1 
µg of both ERK-1/ERK-2 or p38 polyclonal antisera for 1 hour at 4°C on a rotating-wheel. 
Protein A-sepharose was then added for a further 1 hour at 4°C. After washing twice with 
lysis-buffer, samples were washed twice with kinase buffer (30 mM Tris-Cl pH 8.0, 20 
mM MgCl2, 2 mM MnCl2, 10 µM rATP, 10 µg myelin basic protein and 0.3 µCi 
[γ32P]ATP) without ATP and MBP. Precipitates were then incubated in 25 µl kinase buffer 
for 20 minutes at room temperature. Reaction was stopped by the addition of 5x Laemmli 
sample buffer. Samples were separated by electrophoresis on 15% SDS-polyacrylamide 
gels. MBP phosphorylation was detected by autoradiography. 
 
Western blotting  
Neutrophils (106 cells) were pre-incubated with several concentrations of inhibitor for 20 
minutes followed by stimulation for the indicated time points, washed in ice-cold PBS and 
immediately lysed in Laemmli sample buffer. Total cell lysates were boiled for 5 min at 95°C 
and analyzed on 10% SDS-polyacrylamide gels. Proteins were transferred to Immobilon-P. 
The blots for hybridization with phospho-specific antibodies were blocked in hybridization 
buffer (10 mM Tris, 150 mM NaCl and 0.3% Tween-20) containing 3% BSA for 1 hour 
followed by incubation with phospho-specfic antibody (1/1000) in hybridization buffer with 
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1% BSA for 2 hours at room temperature. Second antibody was incubated in hybridization 
buffer for 1 hour. The western blots for hybridization with all other antibodies were blocked in 
hybridization buffer (10 mM Tris, 150 mM NaCl and 0.3% Tween-20) containing 5% non-fat 
milk for 1 hour followed by incubation with antibody (1/1000) in hybridization buffer with 
0.5% non-fat milk for 2 hours at room temperature. Second antibody was incubated in 
hybridization buffer containing 0.5% non-fat milk for 1 hour. Detection of all western blots 
was performed by enhanced chemiluminescence (ECL; Amersham, UK).  
 
F-actin measurement 
Fluorescent F-actin staining was performed as described previously (30). In short, 
neutrophils (2.5 x 106 cells/ ml) were stimulated for the indicated time points and 
subsequently fixed and permeabilized with ice-cold 3% formaldehyde in PBS, containing 
100 µg/ ml lysophosphatidylcholine for 10 minutes at room temperature. F-actin was 
stained with 30 U/ml NBD-phalloidin for 30 minutes at room temperature. The 
intracellular fluorescence was determined by FACS-analysis (FACSvantage, Becton 
Dickinson, San Jose, CA), by measuring a total cell count of 5000 cells per sample. 
 
Measurement of neutrophil migration 
Neutrophil migration was measured using a modification of the method according to 
Boyden as described before (7); using a 48-well microchemotaxis chamber (Neuroprobe, 
Cabin John, MD). Chemoattractants or incubation buffer (30 µl) were added to the lower 
compartments. Two filters were placed between lower and upper compartments. The lower 
filter had a pore width of 0.45 µM (Millipore, Bedford, MA), while the upper filter 
(cellulose nitrate) had a pore width of 8 µM (thickness 150 µM; Sartorius, Gottingen, 
Germany). Before use the filters were soaked in incubation buffer. Neutrophils were 
placed in the upper compartment (25 µl of 2 x 106 cells/ml). The chambers were 
subsequently incubated for 1.5 hours at 37°C. The upper filters were removed, fixed in 
butanol/ethanol (20/80% v/v) for 10 minutes and stained with Weigert solution 
(composition: 1% v/v haematoxylin in ethanol mixed with a 70 mM acidic FeCl3 solution 
at 1:1 ratio). The filters were dehydrated with ethanol, made transparent with xylene and 
fixed upside down. All migratory responses were quantified with an image analysis system 
(Quantimet 570C, Leica Cambridge Ltd.) using Quantimet 570 Control Software (QUIC 
version 2.02) together with custom made software. An automated microscope, Leitz 
DMRXE (Leica, Weitzlar, Germany) was used to step through the filters in the Z direction 
with 16 intervals of 10 µM. Neutrophils were counted at each level and the total migration 
to each level was calculated. The results are expressed as migration index, which is 
calculated by the cumulative migration of all intervals (µm) divided by the total number of 
cells multiplied by the amount of migrated cells. The mean of four randomly chosen points 
on each filterspot was calculated. 
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Measurement of NADPH-oxidase activation 
Superoxide was measured by cytochrome c reduction according to a modified method 
described by Pick and Mizel (31). In short, neutrophils (4 x 106 cells/ml) were pre-
incubated for 5 min at 37OC in incubation buffer. Subsequently, neutrophils were pre-
incubated with inhibitors and/or cytokines for the indicated periods of time. Hereafter, the 
cells (200 µl) were transferred to a microtitre plate in a thermostat-controlled microtitre 
plate reader (340 ATTC; SLT LabInstruments, Austria), mixed with cytochrome c (75 
µM) and the incubation was continued for 5 min, the plates shaken every 3 seconds. The 
cells were then stimulated with fMLP (1 µM) and cytochrome c reduction measured every 
12 seconds as an increase in absorbance at 550 nm.  
Oxygen consumption was measured as describe before (32). In short, granulocytes were 
resuspended (3×106 cells/ml) in the incubation buffer and pre-incubated with GM-CSF 
(10-10M) for 30 min. After incubation, cells were brought in a stirred and thermostated 
airtight vessel and inhibitor was added for 5 min. Subsequently, fMLP (1µM) was added to 
activate the respiratory burst and oxygen consumption was continually measured with an 
oxygen probe (Yellow Springs Instrument) for several minutes. 
 
Measurement of neutrophil apoptosis 
Apoptosis of neutrophils was measured by analyzing Annexin V-FITC binding (Alexis; 
Kordia bv, The Netherlands). In short, freshly isolated neutrophils (0.5 × 106/ml) were 
resuspended in Hepes buffered RPMI medium supplemented with 8% Hyclone serum. 
After treatment with inhibitors/cytokines, cells were incubated for the indicated times at 37
°C. At the end of incubation, cells were stored at 4°C until the last incubation time point 
had been reached. Subsequently, cells were washed with ice-cold PBS and resuspended in 
binding buffer (10 mM Hepes/NaOH, pH 7.4, 140 mM NaCl and 2.5 mM CaCl2). Annexin 
V-FITC (1/40) was added to the cells and incubated for 10 min at room temperature. After 
washing, cells were resuspended in binding buffer containing 1 µg/ml propidium iodide. 
The fluorescence was determined by FACS-analysis (FACSvantage, Becton Dickinson, 
San Jose, CA), by measuring a total cell count of 10000 cells per sample.  
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Results 
 
PP1 inhibits Lyn and Hck kinase activity but not STAT5 phosphorylation in 
neutrophils 
To analyze the role of Src kinases in neutrophil signaling and effector functions we utilized 
the recently identified inhibitor pyrazolpyrimidine (PP1) (28). This compound has been 
described to specifically inhibit Src kinases including Fyn and Lck but not ZAP-70, JAK2 
and EGF-R protein kinases. As previously mentioned, several members of the Src kinase 
family including Lyn, Hck and Fgr are expressed in neutrophils and have been shown to be 
activated by several cytokine and G-protein coupled receptors (18,22,23). Furthermore, a 
recent study found that the sensitivity of the various members of the Src kinase family to 
PP1 was different (33). To characterize the inhibition of Lyn, Hck and Fgr by PP1 we 
stimulated neutrophils with fMLP and an immunocomplex kinase assay was performed in 
the presence of different concentrations of PP1. Whereas Lyn and Hck demonstrated 
kinase activity, no Fgr kinase activity could be found in fMLP stimulated neutrophils (data 
not shown). As shown in Figure 1A and 1B, increasing concentrations of PP1 resulted in a 
concentration-dependent decrease in Lyn and Hck kinase activities.  
Recently it has been suggested that Src kinases are critically involved in the activation of 
STAT transcription factors in many cell types (34). c-Src was found to be involved in IL-3 
mediated activation of STAT3 and it has been shown that Lyn can enhance STAT5 
activation (35,36). To investigate whether Src kinases may be involved in STAT activation 
in neutrophils, cells were pre-incubated with increasing concentrations of PP1 and 
subsequently stimulated with GM-CSF. After stimulation, samples were analyzed by 
performing a western blot utilizing an activation-specific phospho-STAT5 antibody. 
Figure 1C shows no inhibition of STAT5 phosphorylation by PP1 at a concentration of 50 
µM PP1, demonstrating that Src kinases are not involved in GM-CSF induced STAT5 
phosphorylation in neutrophils. This observation also establishes that PP1 does not 
aspecifically inhibit other tyrosine kinases.  
 
Activation of MAPKs by GM-CSF or fMLP is not inhibited by PP1 
Stimuli such as GM-CSF and fMLP have been described to transiently activate MAPKs in 
neutrophils (6-10,37). Whereas Src kinases have been proposed to be important regulators 
of MAPKs in several cell types (38-41), very little is known about the role of Src kinases 
in neutrophils. To determine whether fMLP and GM-CSF activate MAPKs via Src kinase 
we performed two different assays to measure the activation state of MAPKs, an in vitro 
kinase assay (Fig. 2A and C) and western blotting using phospho-specific antibodies to 
ERK1/2 and p38 (Fig. 2B and D respectively). Before stimulation, neutrophils were pre-
incubated with increasing concentrations of PP1 for 20 minutes. As shown in Figure 2 
neither ERK1/2 nor p38 kinase activities were inhibited by the highest concentration of 50 
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µM PP1 in both the in vitro kinase assay as well as the western blots using activation-
specific phospho-antibodies against p38 and ERK1/2. However a specific inhibitor of 
MEK (PD098059), the upstream activator of ERK1/2, completely blocks ERK1/2 kinase 
activity. Thus in neutrophils neither the GM-CSF nor fMLP receptors require Src kinases 
in the regulation of ERK1/2 and p38 MAPK activation. 
 
Figure 1: Src-kinase inhibitor PP1 
inhibits Lyn and Hck kinase activity in 
vitro but not STAT5 phosphorylation in 
neutrophils. Neutrophils were stimulated 
with fMLP (10-6 M) for 2 min, lysed and 
immunoprecipitated with a Lyn or Hck 
antibody. Kinase assays were performed 
in the presence of increasing 
concentrations of PP1 as indicated. (A) 
Autophosphorylation of Lyn was detected 
by autoradiography. (B) Kinase activity of 
Hck was measured using enolase as 
substrate. Phosphorylation of enolase was 
detected by autoradiography. (C) 
Neutrophils were pre-treated with DMSO 
or increasing amounts of PP1 before 
stimulation with GM-CSF (10-10 M). 
Protein lysates were analyzed by SDS-
PAGE followed by Western blotting with 
anti-phospho-STAT5. Data is 
representative of three independent 
experiments. 
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A role for Src kinases in GM-CSF- and fMLP-induced PKB activation 
Recent studies have shown that both cytokines and chemoattractants activate PI3K which 
plays a critical role in regulating a variety of neutrophil effector functions (7,12,13,42-45). 
A role for tyrosine kinases in activation of the PI3K has also been proposed in neutrophils 
(17,18,46). To investigate the role of Src kinases in PI3K activation in neutrophils, we 
used the phosphorylation status of PKB, a downstream target of PI3K (29,47), as a 
measurement of PI3K activation. Firstly, we analyzed the ability of fMLP and GM-CSF to 
induce PKB activation in neutrophils using an activation-specific phospho-antibody 
against serine 473 of PKB. Figure 3A shows a transient phosphorylation of PKB upon 
either GM-CSF or fMLP stimulation. fMLP induced PKB phosphorylation is much 
stronger and more rapid than by GM-CSF, similar to the kinetics of MAPK and PI3K 
activation by these two stimuli (7,18). As shown in Figure 3B, increasing concentrations of 
PP1 resulted in a decrease in both GM-CSF and fMLP induced PKB phosphorylation with 
a half-maximal inhibition of approximately 1-5 µM of PP1 and a complete block at 5-20 
µM of PP1 respectively. Addition of the specific PI3K inhibitor LY294002 (48), also 
completely blocks GM-CSF and fMLP induced PKB phosphorylation, indicating that PKB 
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activation requires PI3K. Furthermore we have found that PP1 does not directly inhibit 
PKB kinase activity (data not shown). Taken together, our data demonstrate that Src 
kinases are critical in activation of the PI3K-PKB signaling.  
A
fMLP GM-CSF 
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Figure 2: Activation of ERK1/2 and p38 MAPK by fMLP and GM-CSF do not require Src 
kinases. Freshly isolated neutrophils were pre-incubated with DMSO, PD-98059 (50 µM) or 
increasing concentrations of PP1 for 20 min and subsequently stimulated with GM-CSF (10-10 M) 
and fMLP (10-6 M) for 10 and 2 min respectively. (A and C) After stimulation, 5x106 cells were 
lysed and 1/25th was used for Western blotting with anti-ERK1/2 and anti-p38 MAPK antibodies to 
confirm as equal amount of protein. The remainder of the sample was used for immunoprecipitation 
with a mixture of ERK1 and ERK2 (1:1) antibodies or with p38 MAPK antibody. Kinase activity of 
both ERK1/2 and p38 MAPK was measured for 20 minutes at room temperature using Myelin Basic 
Protein (MBP) as substrate. Phosphorylation of MBP was detected by autoradiography. (B and D) 
Neutrophils (106 cells) were treated as above and immediately lysed in Laemmli sample buffer. 
Proteins were analyzed by SDS-PAGE followed by Western blotting with indicated antibodies. Data 
is representative of three independent experiments. 
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Figure 3: Src kinases are critical for fMLP and GM-CSF induced PKB activation. (A) Isolated 
neutrophils were incubated with GM-CSF (10-10 M) and fMLP (10-6 M) for the times indicated. 
After stimulation, cells were immediately lysed in Laemmli sample buffer and samples were 
analyzed by SDS-PAGE followed by Western blotting with anti-phospho-PKB (ser 473) or with 
anti-PKB. (B) Neutrophils were pre-treated with DMSO, increasing concentrations of PP1 or 20 µM 
of LY294002 followed by stimulation with GM-CSF (10-10 M) and fMLP (10-6 M) for 10 or 2 min 
respectively. All samples were analyzed as previous described. Data is representative of three 
independent experiments. 
 
Src-kinase activity is required for activation of the respiratory burst in neutrophils 
Stimulation of neutrophils with the chemotactic peptide fMLP induces the rapid formation 
of microbicidal oxidants, a process termed the respiratory burst and is dependent on prior 
priming of cells with cytokines, chemoattractants or lipopolysaccharide (1,4,5,7). 
Previously we have shown a role for PI3K but not ERK in this process (7). Taken this 
finding together with our result that PKB but not ERK activation is inhibited by PP1, 
suggests a possible role for Src kinases in fMLP-induced superoxide production. We 
analyzed the effect of pre-incubation of neutrophils with various concentrations of PP1 on 
the fMLP induced respiratory burst using GM-CSF as a priming agent.  
As shown in Figure 4A, GM-CSF and fMLP individually do not activate the respiratory 
burst in neutrophils, whereas neutrophils treated with GM-CSF prior to fMLP activation 
show a large increase in superoxide production which is markedly decreased by both 50 
µM PP1 and 20 µM LY294002. Neutrophils incubated with increasing concentrations PP1 
show that the maximum decrease of superoxide production is already reached at 5 µM of 
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PP1 (Fig. 4B). The same decrease in fMLP-induced respiratory burst was observed in 
cells first primed with GM-CSF, followed by treatment with different concentrations of 
PP1 before finally being activated with fMLP (Fig. 4C). This demonstrates that indeed Src 
kinases are involved in superoxide production, but it is not apparent whether Src kinases 
are critical for GM-CSF mediated neutrophil priming. Interestingly, PMA, which strongly 
induces the respiratory burst independently of priming, is not inhibited by 50 µM of PP1 
(Fig. 4D). This demonstrates that under certain conditions, activation of the respiratory 
burst can occur independently of Src-kinases.  
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Figure 4: PP1 inhibits fMLP induced respiratory burst, but not PMA stimulated respiratory 
burst. (A and B) Neutrophils were pre-incubated with DMSO, increasing amounts of PP1 or 20 µM 
of LY294002 for 20 min before incubation of GM-CSF (10-10 M) for 30 min followed by 
stimulation with fMLP (10-6). (C) Neutrophils were incubated with GM-CSF (10-10 M) for 30 min, 
before treatment with DMSO or increasing amounts of PP1 for 20 min followed by stimulation with 
fMLP (10-6). (D) Neutrophils were pre-incubated with DMSO or with 50 µM PP1 for 20 min 
followed by stimulation with PMA (0.1 µg/ml). Superoxide production was monitored continuously 
by measurement of cytochrome c reduction. Results are expressed as the OD at a wavelength of 550 
nm and are representative of four independent experiments.  
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Src kinases are not involved in fMLP induced neutrophil migration 
To reach the site of infection, chemoattractants guide neutrophils to the inflammatory 
locus by a process termed chemotaxis. In order to investigate the role of Src kinases in 
neutrophil migration we utilized a modification of the method described by Boyden with a 
48-well microchemotaxis chamber where the stimuli was placed in the lower chamber and 
migratory activity was measured as described previously (7). To induce migration we 
used the chemoattractant fMLP, which is able to potently induce neutrophil migration 
(Fig. 5A). 
To determine the role of Src kinases in neutrophil migration, we pre-incubated neutrophils 
with various concentrations of PP1 before performing Boyden-chamber migration assays. 
As is shown in Figure 6B, fMLP induced migration is not blocked by PP1. Similar results 
were also obtained by incubating the cells with 20 µM of LY294002 (Fig. 5B).  
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Figure 5: Src kinases are not involved in fMLP induced neutrophil migration. Neutrophil 
migration was monitored in microchemotaxis Boyden chambers in response to buffer or fMLP (10-8 
M) as described in the Materials and Methods. Stimulus was placed in the lower compartment and 
cells were left to migrate for 1.5 hours at 37 °C. Neutrophils were pre-incubated with DMSO (A), 
increasing amounts of PP1 (B) or 20 µM of LY294002 (B). Results are expressed as migration 
index ±S.E.M. (n=3) 
 
PP1 and LY294002 prevent GM-CSF mediated neutrophil survival 
The life span of circulating neutrophils is relatively short compared to other leukocytes 
and cannot be dramatically extended (49). However, several stimuli can delay apoptosis 
including GM-CSF and LPS (50), whereas other stimuli, such as TNF-α, accelerate 
neutrophil apoptosis (51,52). In several cell lines it has been shown that the PI3K-PKB 
pathway plays an important role in cell survival (53). Since, we have demonstrated in this 
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 study that Src kinases regulate PI3K-PKB activity it is reasonable to conclude that Src 
kinases might also play a role in inhibiting neutrophil apoptosis. To investigate the role of 
Src kinase and PI3K in apoptosis of neutrophils, we incubated freshly isolated neutrophils 
for 20 min with various concentrations of PP1 or 20 µM of LY294002 before addition of 
GM-CSF. To measure apoptosis we utilized Annexin-V, which binds to 
phosphatidylserine (PS), present on the outer leaflet of the plasma membrane only in those 
cells which have initiated an apoptotic program. In Figure 6A, dot plots are shown in 
which the lower left corner represents living cells and the lower right corner represents 
early apoptotic cells. Few apoptotic cells were observed in freshly isolated neutrophils 
whereas after 12 hours approximately 50% of the cells were apoptotic. Stimulating cells 
with GM-CSF results in a decrease of the number of apoptotic cells from 50% to 20%, 
while PP1 completely blocks this GM-CSF rescue (Fig. 6A). In Figure 6B we analyzed 
different time points of apoptosis using several concentrations of PP1. Figure 6B shows 
that neutrophils initiate the apoptotic program after 4-8 hours of isolation and that this 
process is not blocked but delayed by GM-CSF for approximately 4 hours. This delay is 
completely blocked with PP1 at a concentration of 20 µM, as well as with 20 µM of 
LY294002. Neutrophils treated with PP1 alone give similar kinetics for apoptosis as 
neutrophils without treatment (data not shown). 
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Figure 6: Src-kinases and PI3K are involved in GM-CSF mediated survival. Neutrophils were 
pre-incubated for 20 min with DMSO or increasing concentrations of PP1 before adding GM-CSF. 
Apoptosis of the cells was measured using Annexin-V in combination with propidium iodide 
followed by FACS analysis. Cells positive for Annexin-V represent cells in apoptosis. FACS results 
are presented in dot plots (A) or (B) cells positive for Annexin-V were plotted in a graph. Results of 
the graph are expressed as percentage apoptosis. (n=3) 
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PP1 inhibits fMLP induced actin polymerization in neutrophils with the similar 
kinetics as for respiratory burst 
Cytoskeletal rearrangement, which involves changes in levels of filamentous actin (F-
actin) is considered to be an essential event for several neutrophil effector functions 
including the respiratory burst and migration. In neutrophils, chemoattractants like fMLP 
and PAF induce a rapid increase in relative F-actin content (54,55). To determine whether 
Src kinases may also be involved in actin polymerization in neutrophils, cells were pre-
incubated with different concentrations of PP1 and subsequently stimulated with fMLP. 
Actin polymerization was determined by measuring F-actin content using NBD-phalloidin 
followed by FACS analysis as described in Materials and Methods. Cells pre-treated with 
20 µM PP1 demonstrate a similar rapid increase of F-actin as control cells, however the 
decline in F-actin, which normally occurs after several minutes of fMLP stimulation, 
occurs much more rapidly (Fig. 7A). This suggests a possible role for Src-kinases in 
regulating the depolymerization reaction.  
A link between actin polymerization and correct functioning of the NADPH oxidase has 
recently been proposed (56). Furthermore, we also observe inhibition of both F-actin 
polymerization and superoxide production by PP1 (Fig. 4 and 7A). Utilizing an oxygen 
probe we analyzed the detailed kinetics of fMLP induced oxygen consumption (Fig. 7B). 
Interestingly, similar to actin polymerization, while the overall respiratory burst is reduced 
dramatically, the initial phase of activation appears to be unaffected. Although indirect this 
supports a link between sustained actin polymerization and activation of the respiratory 
burst complex. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
 
BA
GM-CSF
GM-CSF + LY 
GM-CSF + PP1
1 min
Time
O
2 c
on
su
m
pt
io
n
Time (min)
%
 A
ct
in
 p
ol
yn
er
m
isa
tio
n
fMLP
fMLP + 20 µM PP1
50
150
250
350
1 2 3 4 5 
 
Fig. 7: Kinetics of PP1 inhibition of F-actin polymeriza-tion and oxygen consumption in 
neutrophils. (A), Human neutrophils were pre-treated with DMSO or PP1 (20 µM) for 20 min 
before stimulation with fMLP (1µM). At the indicated time-points cells were fixed an F-actin 
staining was performed followed by FACS analysis. The results are expressed as the relative F-actin 
content ±S.E.M. (n=3) (B), Respiratory burst was measured as oxygen consumption by neutrophils 
as described in Materials and Methods. Cells were stimulated with GM-CSF (10-10M) for 30 min 
before the addition of DMSO, 50 µM of PP1 or 20 µM of LY294002 for 5 min. Subsequently, 
fMLP (1µM) was added to activate the respiratory burst and oxygen consumption was continually 
measured for several min. ∧ Represents addition of fMLP 
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Discussion 
During the last few years increasing evidence has demonstrated that tyrosine kinases are 
involved in the coupling between cytokine and G-protein coupled receptor activation of 
agonist effector functions in granulocytes (57-59). Among the tyrosine kinases, the family 
of Src kinases are activated upon stimulation of several cytokine and G-protein coupled 
receptors in neutrophils (18,24) and therefore might play an important role in neutrophil 
signaling and effector functions. Data obtained utilizing knock-out mice of different Src 
family members demonstrate that these kinases are involved in degranulation (60), and 
migration (61) in human neutrophils, whereas other studies have shown a role of Lyn in 
superoxide production (33) and in regulation of neutrophil survival by cytokines (62). 
Furthermore a link between Src kinases and PI3K (18) (63) and p38 MAPK (64) has been 
proposed in human neutrophils. Recently a specific Src family kinase inhibitor called PP1 
has been developed (28). By using this inhibitor we have been able to determine the role 
of Src kinase in regulating human neutrophil signal transduction and effector functions.  
Recent studies show that PP1 can inhibit several members of the Src kinase family 
including Fyn, Lck, Lyn, slightly Fgr, but not Hck in vitro (28) (33). In our study we 
found that Lyn kinase was slightly more sensitive to PP1 than Hck kinase (Fig. 1A and 
1B). The finding that Hck is also inhibited is in contrast with a previous study (33). 
However in this study only 2 µM PP1, was utilized, whereas we found inhibition of Hck 
kinase activity between 2.5 and 10 µM PP1. Previous studies have shown that neutrophils 
stimulated with GM-CSF have enhanced phosphorylation of STAT1, STAT3 and STAT5 
(65,66). Whereas Src kinases have recently been implicated in cytokine induced STAT 
activation in various cell types (34-36,67), little is known in neutrophils. In this study we 
have demonstrated that Src kinases are apparently not involved in GM-CSF induced 
STAT5 phosphorylation in human neutrophils (Fig. 1C). This also demonstrates that PP1 
is not a general tyrosine kinase inhibitor since cytokine-induced tyrosine phosphorylation 
of STAT is not perturbed. Importantly, responses such as fMLP induced migration and 
also PMA activated respiratory burst, are not sensitive for the inhibitor PP1, indicating 
that PP1 is not simply toxic to these cells. 
Both the cytokine GM-CSF and G-protein coupled receptor agonist fMLP are able to 
transiently activate ERK, p38 and PI3K-PKB signaling cascades in neutrophils (6-
9,17,18,37,68). Currently little is known about the specific upstream signals by which 
receptors activate these cascades. In Figure 2 and 3B we demonstrate that PP1 inhibits 
PKB phosphorylation but not ERK1/2 and p38 MAPK activities upon both fMLP and 
GM-CSF stimulation. Our observation that PP1 does not inhibit ERK, correlates well with 
data showing that in neutrophils the tyrosine kinase inhibitors, genistein and erbstatin, and 
also PP1 do not inhibit activation of the small GTPase p21ras whose activity is critical as 
a regulator of ERK (69,70). In the case of activation of p38, opposing data has been 
published showing that fMLP stimulated neutrophils from Hck-/-Fgr-/-Lyn-/- mice are 
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unable to activate p38 MAPK (64). This contradictory finding is difficult to reconcile with 
our data but may be due to functional differences between murine and human derived 
neutrophils. The inability of Hck-/-Fgr-/-Lyn-/- mice to activate p38 could also be through a 
variety of alternative mechanisms not directly linked to receptor mediated stimulation. 
Furthermore, the same study also demonstrates a partial inhibition of p38 MAPK 
phosphorylation with PP1 in human neutrophils. An alternate explanation for this 
opposing result might be due to the different concentrations of fMLP used in these assays.  
We have also demonstrated that both fMLP and GM-CSF require Src kinases to activate 
the PI3K effector kinase PKB. It is likely that activation PI3K is mediated by Src kinases 
since pre-incubation of cells with either PP1 or the PI3K inhibitor LY294002 inhibited 
PKB activation. This is supported by data showing that a member of the Src family 
kinases, Lyn, can bind to the GM-CSF receptor and to the p85 subunit of PI3K in 
neutrophils (18,71). The observation that Src kinases are involved in fMLP-mediated 
activation of PKB is supported by data showing that in neutrophils stimulated with 
agonists of G-protein-coupled receptors, PI3K is activated through a genistein-sensitive 
target, presumably a protein tyrosine kinase (16,46).  
The observation that Src kinases are involved in PI3K-PKB activation together with 
previous data showing that PI3K is involved in several neutrophil effector functions, also 
predicts a role for Src kinases in these processes (42). Indeed, we observed a decrease of 
fMLP-induced respiratory burst with PP1 incubated either before or after GM-CSF 
priming, but we did not observe inhibition of the PMA induced response. This 
demonstrates that Src kinases are involved in fMLP activation of the respiratory burst but 
that these kinases are not essential for the assembly of the NADPH oxidase per se. 
Furthermore, we found a similar inhibition of fMLP induced respiratory burst with 
LY249002 (Fig. 4A), suggesting that Src kinases may act through PI3K-PKB to regulate 
fMLP induced respiratory burst.  
Again supporting a functional link between Src kinases and PI3K-PKB signaling, we 
demonstrated that both PP1 and LY294002 inhibit GM-CSF mediated survival (Fig. 6). 
This data is supported by a study demonstrating a role of Lyn in GM-CSF delayed 
apoptosis (62) and by a recent study showing that the PI3K inhibitor LY294002 blocked 
GM-CSF dependent PKB and BAD phosphorylation in neutrophils (72). It has been 
shown in several cell types that PKB can phosphorylate the pro-apoptotic Bcl-2 family 
member BAD, which in turn prevents its association with anti-apoptotic Bcl-2 family 
members by association with 14-3-3 proteins, resulting in prolonged survival (73,74). 
Thus it is tempting to speculate that Src-kinases act through PKB to inhibit pro-apoptotic 
Bcl-2 family members resulting in a delay in neutrophil apoptosis.  
The effector functions, migration and superoxide production, involve cytoskeletal 
rearrangement requiring actin polymerization. Previous studies have shown that fMLP 
induces actin polymerization in neutrophils in suspension (54,75). Here we demonstrate 
that while the rapid induction of F-actin formation is not inhibited by PP1, the decline in 
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F-actin content is more rapid in PP1 treated neutrophils (Fig. 7A). This suggests that Src 
kinases may play a role in the stabilization and duration of actin polymerization. This 
finding might be considered in contrast with our data that Src kinases and PI3K do not 
affect fMLP induced migration, which also involves cytoskeletal rearrangement. The role 
of PI3K in regulating migration however is still controversial. Whereas some studies, 
including utilization of PI3Kγ knockout mice, show that PI3Ks play an important role in 
neutrophil migration (12,13,45,76), other studies demonstrate that PI3K inhibitors do not 
inhibit fMLP induced migration (77,78). Furthermore, the small GTPase p21Rac, which is 
an upstream regulator of actin polymerization, superoxide production and migration 
(79,80), does not appear to require Src-kinases or PI3Ks in neutrophils (76,81). This 
feature might be cell type specific since in several cell lines p21Rac is regulated by PI3K. 
Thus it might be that Src-kinases and PI3K/PKB act in parallel with p21Rac regulating 
actin depolymerization and superoxide production in neutrophils. The kinetics of PP1 
inhibition of actin polymerization (Fig. 7A) are very similar to that of inhibition of the 
respiratory burst, see also Figure 4 and 7B. In both cases, PP1 does not block the initiation 
of the response, but rather the maintenance of the signal. One model might be that Rac is 
involved in initiating of actin polymerization and superoxide production, whereas Src 
kinases and PI3K/PKB are necessary in maintaining these responses. A recent report has 
shown that neutrophil NADPH oxidase could be deactivated by actin depolymerization 
agents in a cell-free system, suggesting that actin filaments, which grow during the 
activation of NADPH oxidase, prolong the lifetime of the oxidase (56). This might 
indicate a mechanism by which Src kinases act via PI3K/PKB to regulate fMLP-induced 
respiratory burst through maintenance of actin polymerization.  
The difference in sensitivity of the respiratory burst and GM-CSF delayed apoptosis and 
also between fMLP and GM-CSF activation of PKB might suggest that different Src 
kinases are involved in these processes. Therefore we tested the sensitivity of Lyn and 
Hck kinases to PP1. However the difference between the sensitivity of Lyn and Hck to 
PP1 is too small to draw any definitive conclusions. Furthermore the sensitivity of Lyn 
and Hck to PP1 is probably different whether PP1 is added to an in vitro kinase assay 
compared to adding PP1 to cells, as has been suggested by others (28). This difference 
may be attributed in part to permeability of PP1 and its distribution within the cell.  
The finding that Src kinases are involved in PKB phosphorylation but not in MAPK 
activation together with the comparison of data of the Src kinase inhibitor PP1 with those 
of PI3K inhibitor LY294002, suggests that Src kinases and PI3K-PKB act in the same 
pathway that is responsible for GM-CSF induced survival, prolonging the fMLP induced 
respiratory burst and regulating F-actin polymerization. Thus the regulation of Src kinase 
family members by both cytokine and chemoattractant receptors provides a critical 
upstream control point modulating human neutrophil function. 
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Abstract 
The small GTPase Rac has been implicated in various cellular processes, including 
cytoskeletal reorganisation, chemotaxis, proliferation and the production of reactive 
oxygen species. However, little is known about the precise role of Rac in human 
granulocyte functioning. Here we have investigated downstream Rac-dependent functions 
by introducing a constitutively active Rac(Q61L) into human eosinophils. Rac(Q61L) 
fused to a Tat protein-transduction domain entered cells rapidly and with a high 
efficiency. Introduction of Rac(Q61L) into eosinophils did not itself lead to the induction 
or enhancement of superoxide production or migration. However, we found that 
Rac(Q61L) induced IgA binding to the Fcα Receptor (CD89), a process normally 
requiring cytokine mediated inside-out signaling. This finding was confirmed in Ba/F3 
cells stably overexpressing constitutively active Rac(G12V). Since the regulation of 
ligand binding to Fc receptors on eosinophils is similar to that of integrins, we also 
investigated the activation of integrins by Rac(Q61L). However, STZ binding, which is 
mainly mediated by the CR3 integrin, was not increased by Rac(Q61L). Utilizing the 
technique of fluorescence recovery after photobleaching, we further demonstrated that that 
the lateral mobility of the FcαRI in the plasma membrane is decreased by constitutively 
active Rac or IL-3. This is not due to a decrease of the rate of diffusion, but to an increase 
in the immobile pool of FcαRI. These results show that Rac activation in eosinophils is 
not itself sufficient for priming or activation of superoxide production, but is sufficient for 
the modulation of FcαRI resulting in enhanced ligand binding. 
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Introduction 
Granulocytes are critical effector cells for the killing and removal of microorganisms 
through specific effector functions, such as phagocytosis, degranulation, and activation of 
the respiratory burst (1). A consequence of granulocyte activation is the ability to cause 
tissue damage, as is often seen at inflammatory loci. Therefore, the regulation of 
granulocyte activation must be a tightly controlled, multistep process. Resting 
granulocytes in the peripheral blood are poorly responsive to many physiological 
activators (2-4). When these cells encounter pre-activating mediators, effector functions 
are greatly potentiated in a process generally referred to as “priming” (5, 6). Genetic 
defects, such as hereditary chronic granulomatous disease (CGD), resulting from a defect 
in the oxidase system (7, 8) and leukocyte adhesion deficiency (LAD) results in abnormal 
neutrophil functioning and immunodeficiency (9). Patients with disorders of neutrophil 
functioning suffer from severe infections, which shows the importance of correct 
granulocyte functioning for normal host defence. 
To function appropriately in response to extracellular signals, granulocytes use a plethora 
of intracellular signal transduction pathways to link receptors for extracellular stimuli with 
effectors in the cytoplasm and nucleus. The Rho family of GTPases, members of the Ras 
superfamily of small signalling molecules, has been implicated in the control of neutrophil 
functioning. One of the members of the Rho family, Rac, has been implicated in several 
granulocyte effector functions (10-12). Rac has three isoforms, of which Rac1 is 
ubiquitous expressed, Rac2 is predominantly expressed in hematopoietic cells, and Rac3 
in heart, placenta, brain, kidney and pancreas. Utilising overexpression of dominant-
negative and constitutively active mutants in cell lines, Rac has been implicated in cellular 
processes including migration, superoxide production, cytoskeletal reorganisation and 
proliferation (13-18). 
Until recently, the inability to manipulate granulocytes by standard molecular biological 
techniques, due to their short-life and quiescent state, has made it difficult to investigate 
the specific role of signalling pathways eosinophils and neutrophils. The role of Rac in 
primary cells has thus mainly been investigated in Rac-deficient animal models, which 
have implicated Rac2 in neutrophil migration and respiratory burst (11, 14). Furthermore, 
evidence suggesting for a role of Rac in migration and respiratory burst in human 
neutrophils has been provided by analysis of a patient with neutrophil immunodeficiency 
as a result of a Rac2 mutation, resulting in production of a dominant-negative protein (19, 
20). We have used a recently developed technique of protein transduction for elucidating 
the role of Rac in eosinophil functioning. 
Protein transduction methodology has previously been used with success in eosinophils 
(21, 22) to investigate the role of signal transduction molecules in effector functions. The 
protein transduction domain of the HIV Tat protein (YGRKKRRQRRR) (23-26), was 
fused to the gene coding for an activating Rac with point mutation (Q61L), resulting in a 
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constitutively active Rac (27, 28). Incubation of this fusion protein with eosinophils 
resulted in Tat-Rac(Q61L) rapidly entering eosinophils (within 5 minutes) and efficienct 
(±99%). Introduction of Tat-Rac(Q61L) into eosinophils was not sufficient to activate or 
enhance superoxide production or migration. Interestingly, constitutively active Rac alone 
resulted in enhanced IgA binding to FcαR, a process that normally requires prior 
cytokine-stimulation. In contrast, Rac was not found to be involved in CR3 integrin 
(CD11b/CD18) activation. These findings demonstrate a novel and specific function for 
Rac in eosinophils. 
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Materials and methods 
 
Reagents 
Human serum albumin (HSA) was from the Central Laboratory of the Netherlands Red 
Cross Blood Transfusion Service (Amsterdam, The Netherlands). Ficoll-Paque was from 
Pharmacia (Uppsala, Sweden). Purified human serum IgA (>20 mg/ml) was obtained 
from Cappel (Malvern, PA). It contained no detectable trace of IgG, IgM or non-
immunoglobulin serum proteins. Recombinant human IL-5 was a gift from Dr M. 
McKinnon, GlaxoSmithKline (Stevanage, UK). Recombinant mouse IL-3 was produced 
in COS cells (29). STZ was prepared as described (30). PAF and 3-amino propyl-
triethoxysilane was purchased from Sigma (St. Louis, MO, USA). Tat-Rac(Q61L) vector 
was a kind gift of Dr. S. Dowdy (Howard Hughes Medical Institute, Dept. of Pathology, 
Washington University School of Medicine, St Louis, Missouri 63110, USA)  
 
Isolation of human eosinophils 
Blood was obtained from healthy volunteers. Mixed granulocytes were isolated from 50-
100 ml blood, which was anti-coagulated with 0.32% sodium citrate as described before 
(31). Blood was diluted 1.4 times with a PBS2+ buffer (phosphate-buffered saline PBS 
containing 0.32% sodium citrate and 10% human pasteurised plasma-protein solution (40 
g/L)). Mononuclear cells were removed by centrifugation over Ficoll-Pague. The 
erythrocytes were lysed in isotonic ice-cold NH4CL solution followed by centrifugation at 
4°C. Granulocytes were washed with PBS2+ buffer and eosinophils were purified from 
granulocytes by negative immunomagnetic selection with anti-CD16-conjugated 
microbeads (MACS;Miltenyi Biotec,(32)). To avoid mononuclear cell contamination also 
anti-CD3- and anti-CD14-conjugated microbeads were added to the granulocyte 
suspension. Purity of eosinophils was >97%. Before stimulation, eosinophils were 
resuspended in incubation buffer (20 mM Hepes pH 7.4, 132 mM NaCl, 6 mM KCl, 1 mM 
MgSO4, 1.2 mM KH2PO4, 5 mM glucose, 1 mM CaCl2 and 0.5% (v/v) HSA) for 15-30 
minutes at 37°C. 
 
Tat-Rac(Q61L) protein isolation 
A polyhistidine-tagged Tat-RacQ61L construct was expressed in BL21 bacteria 
(Novagen, Madison, WI). Expression and isolation of Tat-RacQ61L was performed 
similarly as has been described by Hall et al (21), except that the isolation of the protein 
was performed under non-reducing conditions. Briefly, expression of Tat-RacQ61L in 
bacteria was induced by IPTG for 3-4 hours at 37 C, before the bacteria pellet was 
solubilized in lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, 10% 
glycerol, 1mM PMSF, pH 8.0). Lysozyme (1mg/ml) and DNAse I (5 µg/ml) was added to 
the bacteria solution and incubated for 30 minutes on ice. Solution was sonicated for 6-8 
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times for 10 seconds each, and centrifuged twice at 15 000 RPM for 20 minutes. 
Supernatant containing the fusion protein was added to Ni-NTA beads and rotated for 30 
minutes at 4°C. Beads were incubated with lysis buffer, twice with wash buffer 1 (50 mM 
NaH2PO4, 300 mM NaCl, 20 mM imidazole, 0.5% Tween-20, 10% glycerol, pH 8.0) and 
3-4× with wash buffer 2 (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, 0.5% 
Tween-20, 10% glycerol, pH 8.0). Protein was eluted from the beads with elution buffer 
(50 mM NaH2PO4, 300 mM NaCl, 500 mM imidazole, 0.5% Tween-20, 10% glycerol, pH 
8.0). LPS was removed from the protein elution by a method described previously (33). In 
short, 0.1 volume of LPS removal buffer (50 mM NaH2PO4, 300 mM NaCl, 10% glycerol, 
10% Triton X-114, pH to 7.5) was added and rotated at 4°C for 10 minutes. After 
transferring the solution to 37°C for 5 minutes, solution was centrifuged at 3000 RPM for 
5 minutes. Upper layer was transferred to a new tube and the procedure was repeated 4× 
and twice with the LPS removal buffer without Triton X-114. Imidazole, and last traces of 
Triton X-114, were removed from the resultant protein solution by dialysing twice against 
PBS (pH 7.4) containing 10% glycerol for at least 4 hours at 4ºC each time, using Slide-
A-Lyzer dialysis cassette (extra strength), 3-12ml, MW cut off is 10 kDa, (Pierce).  
Protein concentration was measured and purity of Tat-RacQ61L was approximately 95%, 
as determined by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-
PAGE) and subsequent Coomassie blue staining. Protein expression of the Tat-RacQ61L 
protein was confirmed by SDS-PAGE and immunoblotting using anti-HA and anti-Rac 
antibodies. Protein solution was aliquoted and frozen at –80°C 
 
Generation of stable transfectants 
Ba/F3 cells were cultured at a cell density of 105-106 cells/ml in RPMI 1640 supplemented 
with 8% Hyclone serum (Gibco) and recombinant mouse IL-3. Ba/F3_FcαRI cells, 
expressing FcαRI-VSV, were generated as previously described by Bracke et al (34). 
Furthermore, FcαRI was tagged with EGFP and transfected in Ba/F3 cells to generate 
stable Ba/F3_FcαRI_EGFP cells. Subsequently Ba/F3_FcαRI cells were used for 
transfection of pLXSN (neo) containing the Rac(G12V) mutant. Cells were cultured with 
mouse IL-3 and 500 mg/ml G418 (Bhoeringer Mannheim, Germany) to select resistance. 
Stable cells were grown continually on mouse-IL-3, G418 and hygromycin. Expression of 
FcαRI was analyzed regularly by FACS. 
 
Transduction of eosinophils and Ba/F3 cells by Tat-RacQ61L 
Tat-RacQ61L, or a control protein (bovine serum albumin, BSA), was labeled with FITC 
(1:3 wt/wt) in PBS with 100 mM NaHCO3 (pH9.0) for 1 hour at room temperature. 
Excess of free FITC was removed by dialysis with PBS. Eosinophils and Ba/F3 cells were 
attached to poly-L-lysine coated coverslips and incubated in incubation buffer containing 
10 µg/ml FITC labeled Tat-Rac61L or BSA for 5 min. After washing the coverslips with 
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incubation buffer without FITC-labeled proteins, cells were fixed with 1% of 
paraformaldehyde. Presence of FITC-labeled protein in eosinophils and Ba/F3 cells was 
measured by confocal laser scanning microscopy.  
 
IgA binding assays 
IgA-binding assays were performed either with purified human eosinophils or with 
cytokine starved Ba/F3_FcαRI cells as described previously (34). Briefly, for IL-3 
starvation, Ba/F3_FcαRI cells were washed twice with PBS and left in medium (RPMI 
1640 with 0.5% HY clone) without IL-3 for 4 hrs. Prior to performing a binding assay, 
Ba/F3_FcαRI cells or purified eosinophils were washed with Ca2+-free incubation buffer 
containing 0.5 mM EGTA and brought to a concentration of 8×106 cells/ml. Ba/F3_FcαRI 
cells (0.4×106 cells) were incubated with Tat-Rac(Q61L) (20 µg/ml) or with IL-3 for 15 
min, whereas eosinophils were activated with either Tat-Rac(Q61L) (20 µg/ml), PAF (10-
6M) or IL-5 (10-9M) for 15, 5 and 15 min respectively at 37°C. After stimulation of the 
cells, dynabeads pre-coated with serum IgA (10 mg/ml), were added in a ratio of 3.5 
beads/cell and incubated for 20 min for PAF, and 30 min for Tat-Rac(Q61L), IL-5, or IL-3 
treated cell. After incubation, cells were resuspended vigorously and IgA-binding was 
evaluated under a microscope. All cells that had bound two beads or more were defined as 
rosettes. One hundred cells (bound and unbound to beads) were counted and the amount of 
beads bound to rosettes was designated as the rosette index.  
 
Fluorescence recovery after photobleaching (FRAP) assay 
Ba/F3_FcαRI-YFP cells were cytokine starved and attached to poly-L-lysine coated 
coverslips. Cells were incubated with 20 µg/ml Tat-Rac61L, with IL-3 (1:1000) or with 
incubation buffer for 15 min at 37°C. FRAP was performed on a Zeiss LSM510 META 
confocal microscope equipped with an Argon/ML laser, and images were acquired with 
standard YFP settings (512 x 512, 16 bit deep 2x line-averaged images). All FRAP 
experiments were performed at 37°C. In each individual experiment, about 20 cells were 
partially bleached using with the following protocol. The first two frames were taken as 
pre-bleach images, and following bleaching for 40 iterations with maximal laser power, 
time lapse sequences of 50 images with an interval of 3.2 seconds were taken. Analysis 
was done with image analysis software (Optimas 6.1, Media Cybernetics, Silver Spring, 
Maryland U.S.A.) using custom written macros. Background bleaching during the course 
of imaging was corrected for bleaching profiles were fitted with Sigma plot (version 4.0, 
SPSS Inc, Chicago, Illinois U.S.A.) using the following equation: y = y0 + a(1 – e -bx) 
where a is the asymptotic plateau and b the recovery time constant.  
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Migration assay 
Migration experiments were performed as described previously (22). Glass coverslips (0.3 
mm) were treated with 3-amino propyl-triethoxysilane, washed with PBS, blocked with 
0.5% glutaraldehyde for 30 min at room temperature and coated with fibronectin (100 
µg/ml). Eosinophils, suspendend in incubation buffer, were allowed to attach to the 
coverslip for 15 minutes at 37°C. Medium was removed and the cells were washed twice 
with incubation buffer. The coverslip was inverted in a droplet of incubation buffer 
containing PAF (10-7M) and sealed with a mixture of beeswax, paraffin and pertroleum 
jelly (1:1:1, wt/wt/wt). Cell tracking was monitored by time-lapse microscopy at 37 C and 
analyzed by custum-made macro (A.L.I.) in the image analysis software (Optimas 6.1, 
Media cybernetics, Silver Spring, MD). Cell migration was followed for 10 minutes 
capturing an image every 20 seconds. 
 
STZ binding assay 
STZ binding was measured as previously described (35). STZ particles were stained green 
fluorescent with FITC (1000:1, wt/wt) in a buffer containing 100 mM NaHCO3 (pH 8.5) 
for 30 minutes at room temperature. Eosinophils (4×106 cells/ml) were resuspended in 
incubation buffer. The FITC coupled STZ particles retained the same ability to stimulate 
the respiratory burst as did the orginal STZ particles (data not shown). Eosinophils were 
resuspended in the incubation buffer (3×106 cells/ml) and brought in a stirred and 
thermostated airtight vessel. Cells were stimulated with Tat-Rac(Q61L) (20 µg/ml), or 
with PAF (10-6M) for 15 and 5 min respectively. Subsequently, STZ-FITC (1mg/ml) was 
added and after 5 min a 100 µl cell aliquot was taken, fixed with ice-cold 
paraformaldehyde (1% w/v) and analyzed in a FACScan flowcytometer (Becton 
Dickinson). Eosinophils were gated from the free STZ-FITC particles and fluorescent 
eosinophils (that had bound at least one particle) were expressed as percentage of total 
number of eosinophils. This percentage is an underestimation of the amount of cells that 
actually have bound an STZ-FITC particle, because an aggregate of cells (bridged by STZ-
FITC particles) is detected as a single double-coloured event. 
 
Measurement of NADPH-oxidase activation  
Oxygen consumption was measured as previously described (36). In brief, granulocytes 
were resuspended in the incubation buffer (3×106 cells/ml) and transferred to in a stirred 
and thermostated airtight vessel. Cells were stimulated with Tat-Rac(Q61L) (20 µg/ml), 
with PAF (10-6M) or with incubation buffer for 15, 15 and 5 min respectively. 
Subsequently, STZ (1mg/ml) was added to activate the respiratory burst, and oxygen 
consumption was continually measured with an oxygen probe (Yellow Springs Instrument) 
for several minutes. 
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Results 
 
Transduction of cells with FITC-labeled Tat-Rac(Q61L) 
Until recently, it was not possible to utilize standard molecular biological techniques to 
investigate the function of specific signaling molecules in human granulocytes. Recently, 
however, the novel technique of protein-transduction has been utilized to introduce 
protiens into eosinophils at an efficiency of more than 95%. Proteins are fused to 11 
amino acids of the HIV Tat protein, a protein transduction domain known to allow fusion-
proteins to enter mammalian cells in a receptor independent way (37). We utilized 
Rac(Q61L) a constitutively active form of Rac, which was fused with the Tat-protein 
transduction domain. This was expressed in bacteria, and isolated as previously described 
(21). Due to protein aggregation during the isolation, we adapted the method and 
performed the isolation under non-reducing conditions (see materials and methods). To 
determine whether Tat-Rac(Q61L) fusion protein entered cells, protein was labeled with 
FITC and incubated with eosinophils, or a bone-marrow derived B-cell line Ba/F3, for 5 
minutes at 37°C. Localization of FITC labeled Tat-Rac(Q61L) was analyzed by confocal 
microscopy. As shown in Figure 1, both eosinophils and Ba/F3 cells, incubated with 
FITC-labeled Tat-Rac(Q61L), demonstrated strong intracellular fluorescence. FITC 
labeled Tat-Rac(Q61L) entered cells in a rapid manner, as has previously been reported 
(21). In addition, transduction of these cells by FITC labeled Tat-Rac(Q61L) was 
maintained for at least 90 minutes (data not shown). In contrast, incubation of eosinophils 
or Ba/F3 cells with FITC-bovine serum albumin, not linked to the Tat peptide, resulted in 
no intracellular staining, demonstrating only the Tat-linked fusion protein are capable of 
entering cells (Fig. 1; upper panels). 
BSA-FITC
TAT-Rac
(Q61L)-
FITC
Eosinophils Ba/F3 cellsA B
 
Figure 1: Transduction of eosinophils and Ba/F3 cells by Tat-Rac(Q61L). Isolated human 
eosinophils (A) or Ba/F3 cells (B) were incubated for 5 minutes with 10 µg/ml FITC labeled BSA or 
Tat-Rac(Q61L) proteins. Fluorescence of cells was analyzed by confocal laser scanning microscopy.  
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Eosinophil superoxide production and migration in the presence of constitutively 
active Tat-Rac(Q61L) protein. 
Rac has been implicated in several granulocyte effector functions including superoxide 
production (10, 11, 14). Here we investigated the role of Rac in superoxide production by 
transduction of eosinophils with constitutively active (Q61L) Rac. Eosinophils were 
incubated with Tat-Rac proteins for 15 minutes at 37°C before stimulation. Superoxide 
production was initiated by STZ, and could be primed by pre-incubation with PAF for 2 
minutes (38). PAF is a strong activator of Rac proteins, but does not activate the oxidase 
complex itself (31). Superoxide production was measured by oxygen consumption using 
an oxygen probe. Although superoxide production was induced by STZ and this was 
enhanced by PAF, transduction of eosinophils with Tat-Rac(Q61L) alone was not 
sufficient to induce superoxide production, nor enhance STZ induced superoxide 
production (Fig. 2A). 
 
A
STZ
Rac(Q61L)
 + STZ
PAF + STZ
Rac(Q61L) +
PAF  +  STZ
PAF STZ
B
1 min
• • 0
10
20
30
40
50
60
70
80
90
100
_ PAF
%
 c
el
ls
 (T
ra
ck
 S
pe
ed
 >
 3
 u
m
/m
in
)
TAT-Rac
(Q61L)
TAT-Rac
(Q61L)
+ PAF
4 nmol O2
Figure 2: Rac activation in eosinophils is not sufficient to induce or enhance respiratory burst 
and migration. (A) Respiratory burst was measured as oxygen consumption by eosinophils as 
described in Materials and Methods. Cells were pre-incubated with Tat-Rac(Q61L) protein for 15 
minutes at 37°C and stimulated with or without PAF (10-6 M) for 2 minutes 37°C. Subsequently, 
STZ (1mg/ml) was added to activate the respiratory burst and oxygen consumption was continually 
measured for several min. The results shown is representative for 3 experiments. • Represents 
addition of PAF or STZ. (B) Migration of eosinophils was monitored by time lapse analysis. Cells 
were incubated with Tat-RacQ61L (20 µg/ml) and allowed to attach to fibronectine coated 
coverslips for 15 minutes. Neutrophil migration was induced by PAF (10-7M) and imaged every 20 
seconds for 10 minutes. Migration of eosinophils with a migration speed greater than 3 µm/min 
were expressed as percentage of total number of eosinophils ±SD. (n=3) 
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Rac proteins are known to regulate actin polymerization in a variety of cells, resulting in 
cell spreading and the formation of lamellipodia. Furthermore neutrophils of Rac2-
deficient mice displayed significant defects in chemotaxis (14). We investigated the role 
of constitutively active Rac(Q61L) in PAF induced migration of eosinophils. Migration of 
eosinophils on fibronectin coated coverslips was measured by timelapse imaging for 10 
minutes. Pre-treatment of eosinophils with Tat-Rac(61L) proteins had no effect on the 
migration of either the unstimulated cells, nor the PAF activated cells (Fig. 2B). These 
findings demonstrate that Rac alone was unable to induce or prime the superoxide burst or 
migration in eosinophils.  
 
Rac modulates FcαRI function 
Previously we have reported that disruption of the cytoskeleton by cytochalasin D 
treatment prevents cytokine induced binding of IgA in Ba/F3 cells (ectopically expressing 
FcαRI) and human peripheral blood eosinophils (39). Since Rac is thought to be involved 
in regulating cytoskeletal organization, we hypothesized that Rac might thus be involved 
in IgA binding. First, we investigated the effect of constitutively active Rac in 
Ba/F3_FcαRI cells, which has been proven to be a good model to study cytokine induced 
IgA binding. Ba/F3_FcαRI cells were cytokine starved, incubated with Tat-Rac(Q61L) 
protein (20 µg/ml) or with IL-3 for 15 minutes. After incubation with IgA coated beads 
for 30 minutes, IgA binding was scored under the microscope. IgA binding was strongly 
induced by IL-3 as has been reported previously (34). Ba/F3 cells transduced with Tat-
Rac(Q61L), resulted in strong IgA binding without prior-stimulation of cells with 
cytokines (Fig. 3A). These findings were confirmed by using Ba/F3_FcαRI cells 
ectopically expressing a constitutively active Rac(G12V), which had similar 
characteristics as Rac(Q61L) (27, 28). Furthermore, a role for Rac in regulating IgA 
binding of eosinophils was analysed using Tat-Rac(Q61L) protein. In these cells, IL-5 
strongly induces the IgA binding, whereas PAF is less potent. Similar to Ba/F3_FcαRI 
cells, Tat-Rac(Q61L) also activated IgA binding in eosinophils (Fig. 3B). The induction 
of IgA binding to eosinophils by Rac(Q61L) was less than for IL-5, but similar to that of  
PAF. These findings demonstrated that Rac alone is sufficient to induce IgA binding.  
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Figure 3: Constitutively active Rac induces IgA binding in eosinophils and Ba/F3_FcαR cells. 
(A) Cytokine-starved Ba/F3_FcαRI cells were incubated with Tat-Rac(Q61L) protein (20 µg/ml; 15 
min), with IL-3 (1:1000; 15 min) or with incubation buffer alone at 37°C. Furthermore, IgA binding 
of Ba/F3_FcαRI stably overexpressing Rac(G12V) gene was determined. (B) Isolated eosinophils 
were incubated with Tat-Rac(Q61L) protein (20 µg/ml; 15 min), with IL-5 (10-9 M; 15 min), with 
PAF (10-6 M; 5 min) or with incubation buffer alone at 37°C. Binding of IgA beads to these cells 
was measured and results were expressed as rosette index (number of beads of a rosette/100 cells).  
 
Rac activity is not sufficient for modulating CR3 integrin (CD11b/CD18) function. 
Similarly to Fc receptors, interactions of integrins with the cytoskeleton are thought to be 
important for their (in)activation (40, 41). Our data thus suggest that it might be possible 
that Rac proteins, are also involved in regulating integrin function. Here we investigated 
the binding of STZ particles by eosinophils. This binding is mainly mediated by CR3 
(CD11b/CD18) (42). Although we showed in Figure 2 that Rac(Q61L) protein was not 
sufficient to activate or prime STZ-stimulated superoxide production in eosinophils, it was 
still possible that Rac can regulate STZ binding to eosinophils. As previously reported, 
PAF strongly induced STZ binding to eosinophils (35), but Rac(Q61L) had no effect on 
STZ binding to unstimulated eosinophils (Fig. 4). This demonstrates that Rac alone was 
unable to activate CD11b and CD18 integrins and the effects we observed in FcαRI 
function suggest a distinct mechanism between CD11b/CD18 and FcαRI functioning. 
 
 
Figure 4: Effect of constitutively active Rac on 
STZ binding of eosinophils. Isolated human 
eosinophils were pre-incubated with Tat-Rac(Q61L) 
protein for 15 minutes at 37°C and stimulated with or 
without PAF (10-6 M) for 2 minutes 37°C. After 
adding FITC labeled STZ (1mg/ml) for 5 min, 
eosinophils were analyzed for STZ binding by flow 
cytometer. Eosinophils bound to STZ were expressed 
as percentage of total number of eosinophils ±S.D. 
(n=3) 
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Rac regulates FcαRI lateral mobility in the plasma membrane. 
The results described above demonstrate that Rac is able to modulate FcαRI function. To 
investigate this process in more detail, we measured the lateral mobility of FcαRI in the 
plasma membrane using fluorescence recovery after photobleaching (FRAP). Ba/F3 cells 
were generated ectopically expressing FcαRI fused to yellow fluorescent protein (YFP). 
Cells were cytokine starved, pre-incubated with Tat-Rac(Q61L) protein for 15-30 minutes 
and subsequently stimulated with or without IL-3 for 15 minutes. The percentage of the 
recovery of fluorescence after bleaching is significantly diminished in cells stimulated 
with IL-3 (52.3 ±7.3%) or transduced with Tat-Rac(Q61L) (52.5 ±7.7%) compared to 
unstimulated cells (69.4 ±7.9%). The recovery time constant was only slightly increased 
for IL-3 (0,064 ±0.003) and Tat-Rac(Q61L) (0,062 ±0.002) compared to unstimulated 
cells (0.056 ±0.004). These findings demonstrated that IL-3 and dominant-active Rac 
reduced the lateral mobility of FcαRI by increasing the immobile pool of FcαRI. 
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Figure 5: Mobility of FcαRI is reduced 
by Rac activation. Ba/F3 cells 
overexpressing FcαRI tagged with EGFP 
were attached to coverslips and incubated 
with Tat-Rac(Q61L), IL-3 (1:1000) or 
with incubation buffer for 15 min at 37°C. 
In each independent experiment 20 cells 
were used for FRAP measurements. FRAP 
curve and time constants were analyzed 
using Sigma plot. (n=3) 
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Discussion 
Granulocytes are critical in the first line of host defense against invading microorganisms. 
This requires activation of a series of effector functions, including degranulation, 
phagocytosis and respiratory burst to accomplish the killing and removal of pathogens. 
The small GTPase Rac of the Rho-family has been previously implicated in regulating 
these processes (10, 11). However, most of these studies have utilized in vitro systems, 
cell lines or knock-out mice, and has focused on neutrophils, whereas the role of Rac in 
eosinophils is largely unknown.  
We have investigated the role of Rac in primary human peripheral blood eosinophils. 
Overexpression of a constitutively active Rac (Q61L) in eosinophils, using the recently 
developed technique of protein transduction (21, 24, 37) has allowed us for the first time 
to manipulate Rac function in primary human granulocyte function. Due to aggregation of 
the proteins during isolation, we modified the protein isolation method performing the 
isolation under non-reducing conditions. Incubation of Tat-Rac(Q61L) with eosinophils 
resulted in fusion protein entering eosinophils rapidly and efficiently (±99%) and 
confirmed the success of protein transduction in eosinophils (21, 22).  
In this study we demonstrated that Rac activation alone is not sufficient to prime or 
activate superoxide production and migration in eosinophils. Although several studies 
have suggested that Rac plays an important role in these processes, none of these have 
investigated whether Rac alone is sufficient to modulate eosinophil functioning. As shown 
by others, the presence and activation of Rac is necessary for the fMLP induced 
respiratory burst in neutrophils (13, 19, 20). We showed here that Rac alone is not 
sufficient to induce or prime fMLP induced superoxide production (Fig. 2). Thus both 
fMLP induced migration and respiratory burst are dependent on Rac activation, but this 
activation alone is not enough to trigger these processes. Indeed, it has been reported that 
triggering of other signaling pathways, including Ca2+/Calmodulin and PI3K, are 
necessary in the activation of these processes (31, 44-46).  
Further investigation of the role of Rac in both Ba/F3_FcαRI cells and eosinophils 
demonstrated that Rac modulates FcαRI function (Figure 3). The regulation of ligand 
binding to Fc receptors and integrins is very similar. The affinity for extracellular ligands 
of both receptors are modulated in response to intracellular signals or so-called “inside-
out” signalling (40, 47, 48). Furthermore, the cytoplasmic tails of both receptors are 
targets for the modulation of the external receptor affinity state (39, 40). However, 
introducing constitutively active Rac in eosinophils demonstrated that Rac alone was 
insufficient to modulate CR3 integrin function (Figure 4).  
A possible mechanism by which Rac activated FcαRI is through modulating the 
cytoskeleton, which is crucial for correct functioning of FcαRI (39). Rac proteins are 
known to regulate actin rearrangement in a variety of cells, resulting in cell spreading and 
the formation of lamellipodia (15). Cytoskeletal rearrangement is also thought to play an 
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important role in modulation of integrin function (40, 41). Since Rac did not modulate 
integrin function it suggest that beside cytoskeletal rearangement, other pathways are 
necessary to modulate FcαR or CD11b/CD18 functioning. An explanation might be that 
Rac regulates FcαRI function through the cytoplasmic tail directly. Mutation of a C-
terminal serine (Ser263) to alanine (S263A) in FcαR, results in constitutive binding of 
IgA, whereas mutation to an aspartic acid, which mimics the phosphorylation of this 
residue, results in only a weak binding of IgA, even after cytokine stimulation (39). In 
addition, PI3K and p38 have been implicated in cytokine-induced activation of FcαRI. 
Thus it might be that Rac, which has been described to act upstream of PI3K and p38 in 
some cell systems (49), regulates FcαRI function via PI3K and p38(50). The presence of 
highly conserved tyrosine, threonine and serine residues in the integrin cytopasmic tails 
suggest that phosphorylation has also the potential to regulate integrin function. CD11b is 
constitutively phosphorylated, whereas the CD18 becomes phosphorylated after activation 
(51, 52). Threonine phosphorylation of CD18 has been recognised as being important for 
the regulation of CD11/CD18 avidity (53). Thus the phosphorylation of the cytoplasmic 
tails of FcαRI and CR3 through specific signalling pathways might allow the regulation of 
these receptors independently of each other. 
The mechanism of FcαRI modulation by cytokines and Rac was further investigated by 
determining the lateral membrane mobility of FcαRI using FRAP methodology. We were 
able to demonstrate that cytokine activation of FcαRI lead to decreased mobility, caused 
by reduction of a mobile pool of FcαRI, but not by a lower diffusion rate. Introduction of 
Rac in these cells caused a similar decrease of the mobile fraction of FcαRI. These data 
suggest that decreased mobility of FcαRI results in enhanced IgA binding. A likely 
mechanism for these findings is that the decreased mobility is associated with the forming 
of “clusters” of FcαRI receptor, and thereby increasing avidity for ligands. However, it is 
also possible that FcαRI affinity is also modulated. Further investigation is needed to 
unravel the specific role of Rac in these processes. 
In the present report, we showed that Rac activation is not in itself sufficient for activation 
or priming of the migration and respiratory burst in eosinophils. Interestingly we have 
identified a new role for Rac in eosinophils as mediator of FcαRI function. The 
observation that Rac mediates FcαRI ligand binding but not CR3, indicates that Fc 
receptor and integrin activation are not regulated by the same inside-out signalling system. 
Greater understanding of these mechanisms will result in a better insight into the 
regulation of leukocyte activation. This information might provide novel approaches to 
the design of anti-inflammatory therapies. 
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Abstract 
 
Assaying activation of signal transduction is laborious and does not allow the study of 
large numbers of samples, essential for high-throughput drug screens or for large groups 
of patients. Using phosphospecific antibodies, we have developed ELISA techniques 
enabling non-radioactive semi-quantitative assessment of the activation state of p42/p44 
MAPK, p38 MAPK, Protein Kinase B and the transcription factor CREB in 96 well 
plates. This assay has been termed PACE (Phosphospecific Antibody Cell-based ELISA) 
and was successfully used for both adherent and suspension cells. Various stimuli induced 
dose-dependent enzymatic activity of which the kinetics closely correlated with those 
measured via classical methodology. Using PACE we have now characterised for the first 
time the concentration-dependent effects of various inflammatory prostaglandins on 
CREB phosphorylation in macrophages. Hence PACE is a straightforward and novel 
technique enabling the large-scale analysis of signal transduction. 
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Introduction 
Cells must continuously adapt to external stimuli. The molecular details of most of the 
underlying signalling pathways have now partially been clarified and frequently involve the 
sequential by phosphorylation of the molecules involved. Probably the best-characterised 
cascade is the signalling pathway initiated by active p21Ras leading to the sequential 
activation of Raf, MEK and p42/p44 MAPK (1-4). Other signalling cascades, analogous to 
this pathway, lead to the phosphorylation and stimulation of p38 MAPK and SAPK/JNK, 
which both show significant sequence homology to p42/p44 MAPK. Aberrant control of 
these signal transduction pathways have been implicated in a variety of pathological 
conditions and are therefore an interesting target for both drug discovery as well as for 
research into the alterations of signal transduction in primary material isolated from 
individual patients.  
Unfortunately, current methods for assaying activation of p38 MAPK, p42/p44 MAPK, or 
SAPK/JNK, such as Western Blotting and in-gello kinase assays are labour intensive and 
do not allow the study of large numbers of samples. The situation has improved recently 
with the advent of phosphospecific antibodies, which recognise the phosphorylated forms 
of proteins but not their unphosphorylated counterparts. However, analysis still requires 
SDS-PAGE followed by Western Blotting and this will typically not allow simultaneous 
loading of more as 20 samples. Therefore, this technique is still not suited for applications 
as drug discovery or the testing of large numbers of patients, and alternatives are called 
for. 
The same situation holds true for other signal transduction components, such as c-
Akt/PKB, (5,6) which  constitutes an important cellular survival signal (7). Detection of c-
AKT/PKB activity remains dependent on kinase assays or Western Blotting. Similarly, 
cAMP-dependent transactivation of CRE-containing promoters through protein kinase A 
and phosphorylation of CREB (8,9) remains a difficult target for high-throughput 
screening.  
The above-mentioned considerations prompted us to develop an ELISA-based assay for 
measuring the activation of specific signalling pathways. We employed phosphospecific 
antibodies, which recognise the activated state of signalling components but not the 
unphosphorylated, non-active form. We used these antibodies to determine immunoreactivity 
of cells grown in 96 wells plates exposed to various stimuli and we have thus created the 
PACE (Phosphospecific Antibody Cell-based ELISA). As PACE and similar ELISA-based 
techniques provide a non-radioactive semi-quantitative read-out of signal transduction 
pathways which is suited for the investigation of large numbers of samples and allows high-
throughput screening, we suggest that the assessment of signal transduction by PACE will 
become the technique of choice for rapid analysis. 
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Materials and Methods 
 
Materials and cell culture 
fMLP, poly-L-lysine, OPD and BSA were from Sigma (St. Louis, MO, USA). HSA was 
from the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service 
(Amsterdam, The Netherlands). Ficoll-Paque was from Pharmacia (Uppsala, Sweden). 
Polyclonal antibody against p44/42 MAPK was from UBI (Lake Placid, NY, U.S.A.) and 
polyclonal anti-phospho-p44/42 MAPK, anti-phospho-p38 MAPK, anti-phospho-PKB/c-
Akt and anti-phospho-CREB antibodies were from New England Biolabs (Beverly, MA, 
U.S.A.) as were all in-vitro kinase assay kits. Swine-anti-rabbit peroxidase-conjugated 
antibody and Goat-anti-rabbit were from DAKO. PD098059 was from Biomol (Plymouth, 
PA). Murine macrophages clone 4/4  (10) were cultured according to routine procedures. 
Blood was obtained from healthy volunteers. Mixed granulocytes were isolated as 
described earlier (11).  
 
Cell-based ELISA for adherent cells 
Cultured murine macrophages were seeded in 96 wells at 50,000 cells/cm2. When 
appropriate, the cells were serum-starved for 4 hours and stimulated for 10 minutes. After 
stimulation, the cells were fixed with 4% formaldehyde in PBS for 20 minutes at room 
temperature and washed three times with PBS containing 0.1% Triton X-100 
(PBS/Triton). Endogenous peroxidase was quenched with 0.6 % H2O2 in PBS/Triton for 
20 minutes and three times washed (PBS/Triton), blocked with 10% FCS in PBS/Triton 
for 1 hour and incubated overnight with various dilutions of primary antibody in 
PBS/Triton containing 5% BSA at 4°C. Next day, cells were washed 3 times with 
PBS/Triton for 5 minutes and incubated with secondary antibody (peroxidase-conjugated 
goat-anti-rabbit, dilution 1:100) in PBS/Triton with 5% BSA for 1 hour at room 
temperature and washed thrice with PBS/Triton for 5 minutes and 2 times with PBS. 
Subsequently the cells were incubated with 50 µl of a solution containing 0.4 mg/ml OPD, 
11.8 mg/ml Na2HPO4.2H2O, 7.3 mg/ml C6H8O7.H2O (citric acid) and 0.015% H2O2 for 15 
minutes at room temperature in the dark. The reaction was stopped with 25 µl of 1 M 
H2SO4 and the OD490/650 was measured and standard error of the mean was determined 
(error bars in figures). 
 
Cell-based ELISA for non-adherent cells 
A 96-wells plate (Nunc. Maxisorp) was coated with 10µg/ml poly-L-lysine for 30 minutes 
at 37°C. After two washes with sterile PBS, 1.5×105 granulocytes were plated into each 
well and incubated for 30 minutes at 37°C. Granulocytes were stimulated with fMLP and 
fixed with 8% formaldehyde in PBS for 20 minutes at room temperature, followed by 
three washes with PBS/Triton. Quenching was performed with 1% H2O2 and 0.1% Azide 
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in PBS/Triton for 20 minutes and cells were further treated as described for adherent cells 
with the exception of the use of a 1:500 dilution of the secondary antibody (peroxidase-
conjugated swine-anti-rabbit) in PBS/Triton with 5% BSA for 1 hour at room 
temperature.  
 
Crystal-violet Cell quantification assay 
After the peroxidase reaction, the cells were washed twice with PBS-triton followed by 2× 
with demi water. After drying the wells for 5 minutes, 100 µl of crystal violet solution 
(0.04% crystal violet in 4% (v/v) ethanol/water) was added for 30 minutes at room 
temperature. Subsequently, the cells were washed at least 3 times with demineralised 
water and 100 µl of 1% SDS solution was added and incubated on a shaker for 1 hour at 
room temperature. Finally, the absorbance was measured at 595 nm with an ELISA 
reader. 
 
In-vitro kinase assays 
Murine macrophages were grown in either 6-well plates (p42/p44 MAPK assay), or 60 
mm dishes (p38 MAPK and PKB assay) and serum starved for 16 hrs. After appropiate 
stimulation cells were treated according to the protocol of the manufacturer.  
 
Western Blotting 
40 µl of cell lysate or kinase reaction mix was loaded onto SDS-PAGE and blotted onto 
PVDF membranes. After blocking and washing, bands were visualised using the 
appropriate phosphospecific antibodies (1:1000), peroxidase-conjugated goat-anti-rabbit 
(1:2000), and enhanced chemiluminescence. 
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Results and Discussion 
 
Development of a p42/p44 MAPK phosphorylation assay in 96 wells plates 
The activation p42/p44 MAPK is accomplished by phosphorylation of the protein on 
threonine183/tyrosine185 and threonine202/tyrosine204, respectively by MEK (4) and 
commercial antibodies recognising phosphorylated p42/p44 MAPK with little cross 
reactivity to the unphosphorylated form of MAPK or other cellular proteins are available 
(Fig. 1). We analysed how these antibodies would perform when used for an ELISA-
based assay. Therefore, 4/4 macrophages were challenged with different concentrations of 
TPA, a potent activator of MAPK in these cells. Subsequently, the cells were fixed, 
blocked and washed (see experimental procedures) and incubated with different 
concentrations of anti-phospho p42/p44 MAPK antibody followed by further routine 
ELISA procedures, finally culminating in oxidation of OPD by a peroxidase reaction and 
determination of absorbance at 490/650 nm. We have termed this procedure PACE 
(Phoshospecific Antibody Cell-based ELISA). As evident from figure 1, in unstimulated 
cells or in the absence of primary or secondary antibody, little enzymatic activity is 
detected. Increasing concentrations of TPA, however, yield increased levels of enzymatic 
product (Fig. 1A), the dose response curve observed in the ELISA being in strict 
accordance with the dose-response curve of TPA-enhanced MAPK activity as observed 
with Western Blots or in-vitro kinase assays (Fig. 1B and C). We found that at a 1:250 
antiphospho p42/p44 MAPK dilution combined low background with high sensitivity. 
The specificity of PACE was further established by the observation that PD98059, which 
inhibits activation of MEK, (12) blocked the TPA-induced increase in absorbance (not 
shown). We concluded that PACE is a sensitive and specific method for determining 
p42/p44 MAPK activation. 
 
PACE is useful for primary isolated suspension cells 
In the PACE-assay described above, the immunoreactive substance, i.e. phosphorylated 
p42/p44 MAPK, is immobilised via formaldehyde fixation of cells grown in 96 wells 
tissue culture plates. To adapt the assay for cell types which do not naturally attach to 
tissue culture plastic, we adhered primary-isolated human granulocytes to poly-l-lysine-
coated ELISA plates. When tested in PACE according to the procedures employed for 4/4 
macrophages we encountered a high background signal due to endogenous peroxidase 
activity. Inclusion of 0.1 % sodium azide was sufficient to quench this activity. 
Concentration and temporal-dependent, PD98059-sensitive, fMLP-induced enzymatic 
product formation was readily detected (Fig. 2). The p42/p44 MAPK activation of FMLP 
closely matched that observed in primary-isolated human granulocytes using classical 
kinase assays or Western Blot analysis (11). Thus PACE is a specific and sensitive 
method for detection of p42/p44 MAPK phosphorylation in both adherent and suspension 
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cells. Furthermore, these results show that this assay can also be useful for primary non-
transformed cells. 
 
 
 
 
Figure 1 Results of a p42/p44 
MAPK PACE. (A) 4/4 cells were 
grown in a 96 wells plate, 
stimulated with the indicated 
concentrations of TPA and 
subjected to PACE procedures. 
Results obtained with different 
concentrations of a polyclonal anti-
phospho p42/p44 MAPK antibody 
as a primary antibody are shown. 
Phosphorylation and activity of 
MAPK was determined by analysis 
on Western Blot (B) and an in-
vitro kinase assay (C) as well. 
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Figure 2: fMLP-mediated p42/p44 MAPK activation in neutrophils measured by PACE. 
Human neutrophils were isolated from peripheral blood, adhered to poly-l-lysine-coated 96 wells 
plates and stimulated for 2 min with fMLP or PD98059 and fMLP (left panel). The right panel 
shows the effects of 10-7 M fMLP for different time periods. After stimulation p42/p44 MAPK 
PACE was performed 
 
Development of a PACE for p38 MAPK, PKB/c-Akt, and CREB 
We investigated whether phosphospecific antibodies directed against other signal 
transduction components are applicable for PACE. Macrophages were challenged with 
different concentrations of LPS, a potent activator of p38 MAPK. Subsequently, the cells 
were fixed and incubated with different concentrations of anti- phosphothreonine180/ 
phosphotyrosine182 p38 MAPK antibody, followed by further routine ELISA procedures. 
Again little enzymatic product formation was detected in the absence of either the primary 
or secondary antibody or in the absence of LPS. Increasing concentrations of LPS, 
however, produced a dose-dependent increase in immunoreactivity (Fig. 3A). We found 
that at an anti-phospho p38 MAPK antibody dilution of 1:250 combined low background 
with high sensitivity. The PACE-detected increase in phosphorylated p38 MAPK 
corresponded to that observed using Western Blotting and to activity in in-vitro kinase 
assays (Fig. 3C). Although the phosphospecific p38 MAPK antibody is reported to have 
cross reactivity with other stress-activated MAPKs, we only detected one band on 
Western Blot.  
We also tested a phosphoserine 473-specific PKB/c-Akt antibody in PACE. Macrophages 
were stimulated with the PKB activator insulin. As shown in Figure 4(A), we observed a 
dose-dependent stimulation of enzymatic product formation, in agreement with the 
insulin-dependent increase of PKB/c-Akt activity observed in both Western Blotting 
(which also showed the specificity of the antibody for PKB/c-Akt; Fig. 4B) and in-vitro 
kinase assays (Fig. 4C). The optimal dilution of primary antibody (1:100) was higher than 
those observed with the p42/p44 MAPK and p38 MAPK PACE. The specificity, however, 
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of the PKB/c-Akt PACE was confirmed by the sensitivity of the insulin-induced signal to 
wortmannin. 
 
 
Figure 3: Results of a p38 MAPK PACE.  (A) 4/4 cells were grown in a 96 wells plate and stimulated 
with LPS, followed by PACE procedures. Results obtained with different concentrations of a polyclonal 
anti-phospho p38 MAPK antibody are shown. Analysis of  p38 MAPK on Western Blot (B) and an in-
vitro kinase assay (C) is also shown. 
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Figure 4: Results of a PKB/c-Akt PACE. 4/4 cells grown in a 96 wells plate were stimulated with 
insulin followed by PACE procedures. Results with different concentrations of a anti-phospho PKB/c-
Akt antibody are shown (A). The effect of wortmannin on insulin-stimulated cells was also determined 
(right panel). Phosphorylation and activity of PKB determined by Western Blot (B) and in-vitro kinase 
assay (C) are also depicted. 
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Finally we tested a phosphoserine 133 CREB antibody in PACE. To this end 4/4 
macrophages were stimulated with prostaglandin E2, prostaglandin F2α and prostaglandin 
I2, since various prostaglandins have been reported to mediate CREB-phosphorylation  
(13-16), but the effects of these important inflammatory mediators on CREB 
phosphorylation in macrophages have as yet not been assessed. As shown in Figure 5(A), 
prostaglandin E2 resulted in CREB phosphorylation in macrophages as detected by 
Western Blot (the antibody also cross reacts with ATF1). After stimulation, a CREB-
PACE was performed, whereas cAMP production was measured in a parallel experiment. 
Prostaglandin F2α did not induce cAMP production nor did it lead to the production of 
enzymatic product in a PACE assay (Fig. 5B). In contrast, prostaglandin E2 and 
prostaglandin I2 gave rise to a significant increase in cAMP production and CREB 
immunoreactivity in PACE. Increases in cAMP formation did not completely correlate 
with increases in CREB phosphorylation at lower concentrations of prostaglandins, but 
this was attributed to cAMP independent phosphorylation of CREB (14). We concluded 
that PACE is a convenient method to determine the phosphorylation state of important 
signal transduction elements and is applicable for a variety of different phosphospecific 
antibodies against both protein kinases and transcription factors. 
 
Correcting for differences in cell number 
The validity of the PACE assay critically depends on two factors: the loading of equal 
amounts of cells in different wells and the quality of the primary antibody. We 
investigated, therefore, whether it is possible to correct for the former factor using crystal 
violet staining after the PACE procedure. As shown in Figure 6, crystal violet staining 
works well under these conditions and provides the opportunity to correct the signals 
measured in PACE for cell number, as evident by the reduction in variability in the assay. 
With the respect to the latter factor, the antibodies employed may react with other cellular 
proteins. This is not a major problem if this antibody reactivity is not different between 
stimulated and unstimulated cells as this will only result in some additional background 
signal. If, however, immunoreactivity is induced by stimulation of the cells, a problem 
may arise. Western Blotting of TPA-stimulated cells using the anti phospho p42/p44 
antibody reveals, after prolonged exposure, some faint induced bands apart from the 
immunoreactivity at 42 and 44 kD, and these bands may contribute to the signal measured 
in ELISA. Nevertheless, the enhanced chemiluminescence used to detect antibody binding 
is not a very linear technique, is very sensitive, and saturates quickly. The contribution of 
phospho p42/p44 MAPK to the signal measured in PACE may therefore be even larger 
than estimated from Western Blot. Indeed, one of the major advantages of PACE over 
Western Blotting is that the enzymatic reaction underlying PACE is of a more linear 
nature and therefore produces quantitatively more accurate results. 
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Figure 5: Results of prostaglandin treatment on cAMP production and CREB. (A) 4/4 cells 
were grown in 60 mm dishes and stimulated with PGE2. CREB phosphorylation was subsequently 
measured by Western Blotting, using phospho-specific CREB antibodies. (B) Effects of PGE2, 
PGI2 and PGF2α on cAMP production and CREB phosphorylation, measured using a commercial 
enzyme-linked immuno assay for cAMP (Amersham) and PACE. 
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Figure 6: Correcting for differences in cell number by staining the wells with crystal violet 
after the PACE procedure. 4/4 cells were stimulated with TPA and subjected to PACE (upper 
panel). Subsequently cell number in the individual wells was determined using crystal violet 
staining and measuring absorbance at 595 nm, and the ratios were calculated (lower panel). The bars 
indicated by A represent background signal 
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1 Sytemic inflammatory response in COPD 
COPD is associated with an abnormal inflammatory response, which is likely to be 
reversible during the first stages of COPD. Eventually the process becomes irreversible 
during further progression of the disease (Fig 1A). The inflammatory response in COPD is 
thought to be  partly mediated by increased numbers of neutrophils in the peripheral blood 
and airways of these patients (1-4). Neutrophil activation has been demonstrated in BAL 
fluid, sputum and in the peripheral blood of COPD patients (1, 5-7). Full activation of 
neutrophils results in release of cytotoxic enzymes by degranulation and production of 
reactive oxygen species by a membrane bound NADPH-oxidase. These harmful 
molecules are thought to contribute to the damage of the lung tissue that gradually 
develops in COPD patients. The recruitment and subsequent activation of neutrophils in 
the tissue is likely to be orchestrated by the increased levels of cytokines/chemokines, 
such as IL-8 and TNFα, in the airways. These inflammatory mediators are strong 
activators of neutrophils and can be produced by epithelial cells, which are exposed to 
cigarette smoke (8-10). A direct role for cigarette smoke in the activation of neutrophils 
has also been suggested (11). Leaking of the cytokines/chemokines from the airways to 
the peripheral blood is thought to mediate the priming/activation of the peripheral blood 
neutrophil. These findings point to an important role for neutrophils in the pathogenesis of 
COPD. To gain further insight in the systemic inflammatory processes in COPD, we 
studied the activation of neutrophils from the peripheral blood of COPD patients by 
analysis of gene expression profiles.  
In Chapter 2 we demonstrated that gene expression profiles of peripheral blood 
neutrophils from moderate to severe COPD (Class IIB and III) patients exhibited an 
“activated” phenotype. These findings are in agreement with data from others 
demonstrating that neutrophils from COPD patients show some features of activation (6). 
Furthermore we demonstrate that activation of neutrophils correlates with the severity of 
COPD, suggesting that the progress of COPD is accompanied by an increasing systemic 
response (Fig 1A). The increase in systemic inflammation is, however, only significant in 
the more severe patients (class IIB and III). This finding suggest that systemic 
inflammation is probably initiated in moderate COPD patients (class II). This hypothesis 
is supported by a previous study demonstrating an enhanced neutrophilic response in 
COPD patients (class II), but not in healthy smokers (5). However, a start of a systemic 
response in the COPD classes 0 and I can not be excluded.  
A recent report demonstrated that levels of IL-8 and sTNF-R55 in the airways 
correlated with the severity of COPD (12, 13). The hypothesis that the local inflammation 
communicates with the systemic compartment via cytokines/chemokines would also 
suggest that the levels of cytokines/chemokines in the peripheral blood correlate with the 
severity of COPD. These findings have so far not been substantiated. Levels of systemic 
inflammatory mediators are likely too low to be measured due to a short half-life and 
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clearance in the peripheral blood (14). Another explanation is suggested in Chapter 4. 
Here it was shown that neutrophil activation is variable within individual COPD patients 
compared to healthy volunteers. Assuming that neutrophil activation can be used as a read 
out of the systemic inflammation, this response cannot be considered as a stable, but more 
as a variable process, with a production of pro- and anti-inflammatory 
cytokines/chemokines. So the variability in cross sectional studies of COPD might be 
caused by a continuous imbalance between different inflammatory processes in the 
neutrophils.  
Besides the fluctuations of the systemic inflammatory response in the stable phase, a 
consistent change in systemic inflammatory response was demonstrated in COPD patients 
with an acute exacerbation (Chapter 3). Peripheral neutrophils from COPD patients with 
an acute exacerbation showed no “activation phenotype” compared to the stable phase. 
This change in neutrophil activation might be caused by a change in levels and/or 
combination of inflammatory mediators (Chapter 3). This may result in the migration of 
neutrophils to the tissue, leaving mainly unstimulated or recently matured neutrophils 
from the bone marrow in the peripheral blood. These findings suggest that inflammatory 
responses in mild to moderate to severe COPD patients are continually changing. These 
changes result not in clear clinical symptoms in moderate COPD patients due to excess of 
lung capacity. In more severe COPD patients, in which the excess of lung capacity is not 
large enough to compensate for changes in inflammatory responses, these changes can 
lead to an exacerbation of the disease (Fig. 1C).  
 
Fig. 1: Model for disease progression 
in COPD. (A) The subclincial stage of 
COPD which can last up to 20 years or 
more is characterized by a mainly 
reversible inflammation (GOLD 
severity stages at risk to mild COPD), 
which gradually becomes irreversible 
due to a chronic inflammatory reaction. 
(B) During the progression of COPD a 
systemic activation of neutrophils is 
initiated in the moderate stage of 
COPD. (C) The high but variable 
activation of neutrophils represents 
changes in the systemic inflammation. 
Hyperactivation of neutrophils and a 
subsequent sequestering in the airways 
represent a change in the sytemic and 
local inflammation. This change can 
lead to acute exacerbations in severe 
COPD patients, if the decrease in the 
lung function cannot be compensated 
by excess lung capacity.  
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Similar findings for the activation and migration of circulating neutrophils were found in 
patients with multiple organ failure (MOF). A two step model has been suggested for this 
disease, in which circulating neutrophils are highly primed in the first step due to a major 
trauma (15). The underlying mechanisms of this priming are not clear, but there are 
indications that increased production of several cytokines/chemokines are involved (15-
18). Priming of circulating neutrophils results in some sequesteration in organs, but 
sequesteration alone is not sufficient for the development of organ injury (16, 19, 20). The 
priming of neutrophils last for about 24 hours and during this time, neutrophils are 
responsive to additional stimuli, such as surgery, resulting in enhanced migration to the 
organs and subsequently full activation. This full activation is required to cause tissue 
damage. It is tempting to speculate that in more severe COPD patients circulating 
neutrophils are in a primed state, which will lead to sequesteration to the airways. This 
priming of neutrophils makes these cells prone to activation by additional stimuli, such as 
an infection, leading to hyperactivation of the neutrophils with subsequent lung damage. 
Although infection is a cause of exacerbation in many COPD patients (21) not all 
exacerbations are associated with viral or bacterial infections (22), suggesting that other 
factors are present to induce exacerbations.  
In addition, hyperactivation of neutrophils during an exacerbation might also lead to 
migration of neutrophils to other tissue than the lungs which might lead to injury of these 
organs. This might explain why COPD patients often develop systemic effects, such as 
muscle wasting and weight loss during later stages of their disease. Thus activation of 
circulating neutrophils can be useful as a read-out for variable systemic inflammatory 
responses. Further analysis of longitudinal studies of the expression profiles of neutrophils 
and other cells are required to define the changes in systemic inflammatory responses in 
COPD patients. This will result in a better understanding of the pathogenesis of COPD.  
The finding that neutrophils themselves can express several inflammatory 
cytokines/chemokines (Chapter 2) (23) suggests that neutrophils are not only effector 
cells, but that these cells can also act as pro-inflammatory immune cells. Indeed, several 
inflammatory genes regulated in patients with COPD correlate with the severity of the 
disease. Since the increase in gene expression of inflammatory cytokines/chemokines in 
peripheral blood neutrophils correlated with the severity of COPD, and is particularly 
prominent in severe COPD patients (Chapter 2), it is tempting to speculate that the 
peripheral neutrophils play a role in the switch to a chronic more severe disease.  
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An explanation for the underlying mechanisms of this hypothesis might be a change in the 
balance of expression of anti- and proinflammatory mediators by circulating neutrophils. 
Indeed, Chapter 2 we reported that expression of the anti-inflammatory mediator IL-1RA 
is much higher than that of the pro-inflammatory mediator IL-1β in neutrophils stimulated 
with TNFα, compared to neutrophils from severe stable COPD patients. Apparently, the 
balance between the IL-1β and IL-1RA is disturbed in patients with severe stable COPD. 
Thus it might be that in the reversible smoking induced inflammatory reaction, 
neutrophils are activated by cytokine/chemokines and control the inflammatory reaction 
by expression of large amounts of IL-1RA (Fig.2A). In an abnormal inflammatory 
reaction, such as that observed in severe COPD patients, neutrophils cannot produce 
enough anti-inflammatory molecules leading to a self-perpetuating inflammatory response 
(Fig. 2B). It would also be interesting to investigate the activation of monocytes in COPD 
patients, since these cells can express large amounts of inflammatory mediators. This 
model is supported by data from another chronic inflammatory disease where neutrophils 
play a role in the chronic phase of rheumatoid arthritis. In contrast to COPD, in 
rheumatoid arthritis much more is known concerning the function of IL-1 family proteins. 
It has been shown that in rheumatoid synovium an imbalance exists in the pro- and anti-
inflammatory mediators since the levels of production of IL-1RA are inadequate to 
effectively block the pro-inflammatory effects of IL-1 (24). Injection of IL-1RA in the 
synovium, significantly reduced the signs and symptoms of rheumatoid arthritis at 24 
weeks (25). Recently it has been suggested that soluble IL-1R2, which is increased on day 
one of an acute exacerbation of COPD may may be associated with the clinical 
improvement (26). Thus applying an anti-IL-1 therapy to COPD patients might improve 
clinical symptoms. It would be necessary to investigate the expression of pro- and anti-
inflammatory mediators by neutrophils in a acute or reversible inflammatory response, 
since our data on normal inflammation is based on in vitro data. Further development and 
thorough investigation of gene expression profiles of neutrophils, and other inflammatory 
cells might give further insight in the underlying mechanism of chronic inflammation.  
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Fig. 2: Model for the switch between reversible to irreversible inflammation in COPD. (A) 
Release of cytokine/chemokines by tissue cells by smoke inhalation, results in the recruitment and 
pre-activation of neutrophils and other inflammatory cells to the tissue. Full activation of 
neutrophils by stimuli such as infection or unknown factors results to degranulation and production 
of reactive oxygen species, leading to tissue damage. The inflammation is controlled by the 
production of anti-inflammatory mediators produced by (pre)activated neutrophils and other 
inflammatory cells, resulting in a temporal or reversible inflammation. (B) Irreversible inflammation 
is characterized by its independence on smoke inhalation. Long term reversible inflammation in the 
tissue leads to a decrease in the expression of anti-inflammatory mediators by (pre)activated 
neutrophils, resulting in an increase in pro-inflammatory mediators in the tissue. This loss of 
control, leads to an increase of pro-inflammatory mediators, which might leak into the peripheral 
blood and (pre)activated inflammatory cells. These cells in turn produce more pro- than anti-
inflammatory mediators, and thereby enhancing the chronic effects. Thus the loss of control on the 
increase of pro-inflammatory mediators lead to a positive feedback loop for the tissue and other 
inflammatory cells, resulting in an irreversible inflammation.  
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2 Function of signaling proteins in granulocytes 
Granulocytes are critical effector cells in killing invading microorganisms. The killing is 
mediated by specific effector functions, such as phagocytosis, degranulation and 
production of reactive oxygen species. Correct control of these effector functions is 
necessary, since abnormal regulation, or a defect in these processes can lead to severe 
infections or inappropriate tissue damage. The control of these processes is mediated by 
inflammatory mediators, such as cytokines and chemoattractants. Upon binding to their 
receptors, these mediators trigger a large variety of intracellular signaling molecules, 
resulting in the correct functioning of the granulocytes. Understanding of the activation of 
intracellular signaling molecules and their role in granulocyte functioning is important, as 
it might provide novel insights in regulating and controlling inflammation. In this thesis 
we have focused on two distinct signaling molecules, Src kinase and the small GTPase 
Rac, which are known to be activated by diverse stimuli in granulocytes, however their 
precise role in granulocyte functioning is not clear.  
 
2.1 Role of Src kinases in neutrophil function 
Src kinases were one of the first kinases families identified, however it has only been in 
the last decade that advances have been made in understanding the regulation and function 
of these proteins. It is has been well established that Src kinases are involved in diverse 
signal transduction pathways, regulating a broad spectrum of physiological responses, 
including cell cycle, cell proliferation, differentiation, adhesion and survival (reviewed by 
(27)). Although several Src kinases, including Lyn, Hck, and Fgr are activated by both 
cytokine and GPCRs, little is known about their role in granulocyte functioning. It might 
be that the Src kinases play a role in regulating distinct signaling events between the 
chemokine and cytokine receptors. In Chapter 5, we investigated the role of Src kinase 
using a pharmacological inhibitor. In several other cell types, Src kinases have been 
implicated in the regulation of various intracellular signaling pathways. In neutrophils, we 
found that Src kinases mediate both fMLP and GM-CSF induced activation of PKB, but 
not that of p38MAPK and ERK1/2 (Fig. 3). These findings are supported by a report 
showing that Src kinases are not involved in fMLP induced Ras activation (28). 
Investigation of several neutrophil functions, revealed that Src kinases as well as PI3K are 
involved in the superoxide production, survival and f-actin polymerization (Chapter 5) 
(29). These findings demonstrate that Src kinases mediate both fMLP and GM-CSF 
induced activation of PKB, probably through PI3K activation. This is supported by data 
showing that a member of the Src kinase family, Lyn, associates with both the GM-CSF 
receptor and the p85 subunit of PI3K in neutrophils (30, 31). Src kinases are thought to 
recruit Class I PI3Ks (p110α/β/δ) via their adaptor subunits, (p85), which contain Src 
homology-2 (SH2) domains that are able to bind to phosphorylated tyrosine residues (32). 
The observation that Src kinases are involved in fMLP-mediated activation of PKB is 
 
General Discussion 
 158 
supported by data showing that in neutrophils stimulated with agonists of G-protein-
coupled receptors, PI3K is activated through a genistein-sensitive target, presumably a 
protein tyrosine kinase (33-35). However, other reports have suggested that GPCRs act 
solely via PI3Kγ to activate PKB in neutrophils (36, 37). PI3Kγ, which is associated with 
the adaptor molecule p101 (38), is stimulated by G-protein βγ subunits (39, 40), which do 
not interact with SH2 domain containing adaptors, excluding tyrosine kinases from direct 
activation of PI3Kγ. In addition, recent data also demonstrate that PI3Kγ can be activated 
by pathways independent of G-proteins such as those initiated by exposure of neutrophil 
to LPS (41). Furthermore, it has recently been shown that the G-proteins Gαs and Gαi 
directly stimulate the kinase activity of c-Src, Lck, and Hck (42, 43). Since the GPCRs, 
such as fMLP receptor or IL-8 receptor, are coupled to Gαi proteins (44), this suggests 
that the activation of Src kinases by fMLP may be directly mediated by G-proteins. Taken 
together, these findings suggest that besides the direct regulation of PI3K by G-proteins, 
GPCRs can also regulate PI3K via Src kinases. So the regulation of PI3K by GPCRs is 
more complicated than previously thought. In conclusion, Src kinases are important 
signaling molecules, linking GPCRs and cytokines to PI3K/PKB, in neutrophils. This 
pathway is necessary, but not sufficient for activation of the respiratory burst, since GM-
CSF, which does not activate the respiratory burst, also activates this pathway.   
The finding that both inhibitors of Src kinases and PI3K inhibit GM-CSF mediated 
survival suggest that GM-CSF may act through Src kinases, and subsequently via PI3K, to 
regulate neutrophil lifespan (Chapter 5). In several cell types, activation of the PI3K/PKB 
pathway has been shown to be associated with cell survival. One of the mechanisms by 
which PI3K/PKB can mediate cell survival, is via phosphorylation of the pro-apoptotic 
Bcl-2 family member BAD. Phosphorylation promotes its association with the 
cytoplasmic protein 14-3-3, which in turn prevents the association of BAD with anti-
apoptotic Bcl-2 family members, effecting prolonged survival (45, 46). This data is 
supported by a recent study in neutrophils demonstrating a role for Lyn in GM-CSF 
delayed apoptosis (47) and by studies showing that the PI3K inhibitor LY294002 blocked 
GM-CSF dependent PKB and BAD phosphorylation in neutrophils (48, 49). GM-CSF 
induced survival is also mediated by reducing the levels of BAD mRNA, which is also 
sensitive to PI3K inhibition (49). It has been shown in other cell types that cytokines can 
inhibit the transcription factor FKHR-LI via PI3K/PKB pathway, resulting in reduced 
expression of pro-apoptotic members, such as Bim (50). It would be interesting whether 
transcription of BAD is also under control of FKHR-L1. Besides downregulation of pro-
apoptotic proteins, cytokines also upregulate the expression of anti-apoptotic proteins. The 
major cytokine induced anti-apoptotic proteins found in neutrophils are Mcl-1 and A1 (51, 
52). However it is unclear how cytokines regulate the expression of these anti-apoptotic 
proteins in neutrophils. Thus cytokines induce survival in neutrophils by several 
mechanisms, in which the Src/PI3K/PKB pathway play central role.  
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Fig. 3: Possible mechanisms by which Src kinases regulate neutrophil functioning. 
GPCRs and cytokine receptors, such as GM-CSF/IL-3/IL-5 receptors, can both activate PI3K/PKB 
pathway via Src kinases and thereby modulate several neutrophil functions including production of 
superoxide, survival and actin polymerization. Actin polymerization and production of superoxide is 
also modulated by Rac, which is involved in the induction of these processes, while Src kinases 
mediate the duration. 
 
Furthermore, we found that Src kinases may act through PI3K-PKB to regulate fMLP 
induced respiratory burst, since a similar inhibition of fMLP induced respiratory burst 
with inhibitors of PI3K and Src kinase were found (Chapter 5). These findings are in 
agreement with data showing that PI3K is involved in the superoxide production in 
neutrophils (29, 36, 37, 53). It has been shown that PI3K and subsequent PKB activation 
is involved in the phosphorylation of p47phox, which is required for the correct 
translocation of NADPH oxidase components (54, 55). Recently it has been reported that 
the phox proteins, such as p40phox and p47phox, are able to bind to the products of PI3K 
including phosphatidylinositol-3,4-bisphosphate (PtdIns(3,4)P(2)) and 
phosphatidylinositol-3-phosphate (PtdIns(3)P), respectively (56, 57). Thus Src kinases 
may act through PI3K/PKB to regulate the phox proteins and thus modulate superoxide 
production. Besides the phox proteins, Src kinases might regulate fMLP-induced 
respiratory burst through maintenance of actin polymerization (Chapter 5). The kinetics of 
inhibitors of Src kinases and PI3K on the inhibition of actin polymerization are very 
similar to that of inhibition of the respiratory burst. In both cases, the inhibitors do not 
block the initiation of the response, but rather the maintenance of the signal. This is 
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further based on a recent report showing that neutrophil NADPH oxidase could be 
deactivated by actin depolymerization agents in a cell-free system, suggesting that actin 
filaments, which grow during the activation of NADPH oxidase, prolong the lifetime of 
the oxidase complex (58). In addition, the membrane cytoskeleton is involved in 
recruiting Rac, p47phox and p67phox during oxidase activation (59). These findings suggest 
a role for Rac, which is known to be involved in actin polymerization, however in 
neutrophils it has been shown that fMLP induced Rac activation is not mediated by Src 
kinases or PI3K (60). Thus it might be that Rac and Src/PI3K/PKB act in parallel 
regulating fMLP induced actin polymerization and superoxide production, whereby Rac is 
inducing the processes and Src/PI3K/PKB is mediating the stabilization and duration (Fig. 
3).  
  
2.2 Role of Rac in granulocyte function 
In contrast to Src kinases, Rac is activated by GPCRs and not by cytokine receptors. Most 
of the Rac data are based on cell lines using ectopic over-expression of mutants of Rac or 
are from mice deficient in Rac (61-66). Disadvantages of these methods are that 
transformed cell lines, are not truly representative of primary cells and that Rac may also 
influence the embryonic development of mice, or the differentiation of granulocytes. The 
only data concerning a role of Rac in human granulocytes are from a patient bearing a 
dominant negative mutant of Rac2 (67, 68). Several processes such as fMLP induced 
migration and respiratory burst are diminished in neutrophils from these patients (67). In 
human neutrophils, however is not known which cellular functions can be mediated by 
activation of Rac alone.  
In Chapter 6 we investigated the role of Rac in eosinophil functioning, by transducing 
these cells with a constitutively active mutant of Rac. We found that activation of Rac is 
not required for activation or enhancement of the respiratory burst. We also showed that 
constitutively active Rac did not induce or enhance the superoxide production induced by 
STZ. This is supported by reports showing that although superoxide production in 
response to fMLP, or fMLP/PAF and IgG-opsonized particles stimulation was greatly 
diminished in neutrophils from patients bearing the dominant negative Rac2 or in Rac2 
deficient mice, opsonized zymosan and PMA induced superoxide production was almost 
normal (62, 63, 67, 68). In addition, PMA stimulation results in a strong activation of the 
respiratory burst without activating Rac in neutrophils (60). These findings suggest that 
the requirement of Rac in superoxide production is not absolute and is selective for 
specific signaling pathways. Although studies have shown that Rac is present in the 
NADPH oxidase complex, conflicting data exist on the precise role of activation of Rac in 
the superoxide production (69-72). It might be that some stimuli use the activation of Rac 
to enhance the superoxide burst, while others pathways only need the presence of Rac in 
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the NADPH complex and regulated the stability of the NADPH complex through 
alternative means.  
We observed that Rac activation is sufficient to modulate IgA binding, to eosinophils, 
whereas STZ binding, which is mainly dependent on CD11b/CD18 intergrins, is not 
sensitive. Furthermore, we could demonstrate that FcαRI lateral mobility in the membrane 
was diminished by activation of Rac. Our findings suggest that decreased lateral mobility 
of FcαRI, results in clustering of the FcαRI and subsequent enhanced IgA binding. 
Although it is likely that the enhanced IgA binding by activation of Rac is the result of an 
increase in avidity, a subsequent change in affinity cannot be excluded. Furthermore, 
these findings demonstrate that functioning of FcαRI and CD11b/CD18, can be 
modulated by distinct inside-out signaling pathways. Functioning of both receptors are 
known to be dependent on cytoskeletal rearangements (73, 74), which has been reported 
to be mediated by Rac via F-actin polymerisation (75). However, our data suggest that 
besides cytoskeletal rearangement, an alternative pathway is necessary to modulate 
receptor functioning. Indeed, the function of FcαRI, is also modulated by the 
phosphorylation of the intracellular tail. Mutation of a C-terminal serine (Ser263) to 
alanine (S263A) in FcαR, results in constitutive IgA binding, whereas mutation to an 
aspartic acid (S263D), which mimics the phosphorylation of this residue, greatly reduced 
IgA binding, even after cytokine stimulation (73). Besides the regulation of FcαRI by 
phosphorylation, phosphorylation also has the potential to regulate integrin function, since 
the presence of highly conserved tyrosine, threonine and serine residues in the integrin 
cytopasmic tails. CD11b is constitutively phosphorylated, whereas the CD18 becomes 
phosphorylated after activation (76, 77). Furthermore it has been reported that threonine 
phosphorylation of CD18 plays a role in CD11b/CD18 avidity (78). For β1 integrin it has 
been shown similarly to FcαRI that phosphorylation of a serine residue leads to 
inactivation of the integrin (79). Thus, although phosphorylation of β1 integrin and FcαRI 
leads to similar regulation of both receptors, the pathway mediating the phosphorylation 
of FcαRI is modulated by a distinct mechanism than that of modulating integrin 
functioning.  
Inhibitor studies implicated PI3K and p38, respectively, in IL-3 and IL-4 induced 
activation of FcαRI. In addition, both IL-3 and IL-4 mediate IgA binding via PKC, which 
has been shown to act downstream of PI3K in regulating IgA binding (80). Thus it might 
be that IL-3 and IL-4 signalling converge at the level of PKC. Possibly Rac, which has 
been described to act upstream of PI3K and p38 in some other cell systems (81), regulates 
FcαRI function via PI3K and p38 (82) or that Rac acts in parallel with PI3K and p38 to 
modulate PKC. The involvement of PI3K in activation of FcαRI, might also suggest a 
role for Src kinases in this process (Chapter 5). In neutrophils, there is no link between 
Rac and Src kinases, since a pharmacological inhibitor of Src kinases did not inhibit 
GPCRs induced activation of Rac, and cytokines cannot induced Rac activation (60), 
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however we can not exclude the possibility that Rac is upstream of Src kinases. In 
addition, it has been described that Src kinases are physical associated with the FcαR (83), 
and play a role in FcαRI induced release of IL-1RA and IL-8. Although this finding 
suggests a role for Src kinases downstream of FcαRI, it would be interesting to investigate 
whether the Src kinases that are bound to the FcαRI are also involved in linking cytokine 
signaling with FcαRI functioning.  
Of interest are the observations that Rac is involved in NAPDH oxidase activation upon 
stimulation of FcγR, but not with serum treated zymosan, which stimulate neutrophils 
mainly via CD11b/CD18 (Chapter 6) (62). Consistent with these observations, in 
macrophages, Rac and Cdc42 regulate the uptake of Ig-opsonized particles via FcγR, 
whereas Rho, and not Rac or Cdc42, plays a prominent role in CD11b/CD18-mediated 
phagocytosis (84). These findings together with our finding that Rac is modulating the 
FcαRI functioning and not CD11b/CD18, suggest an important and specific role for Rac 
in the functioning of Fc receptors (Fig. 4). To make the picture more complete, it would 
be interesting to determine whether Rho is modulating CD11b/CD18 integrin avidity. 
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Fig. 4: Rac mediated inside out signaling. (1) Inside out signaling can be mediated via Rac, which 
modulates FcαRI functioning via two distinct pathways. (2) One pathway is through regulation of 
cytoskeletal rearangement, which is involved in both FcαRI and integrin functioning. Besides this 
general pathway, (3) Rac mediates FcαRI functioning via a specific pathway, which might be 
mediated by PI3K, p38 MAPK, PKC or by other signaling proteins. (4) Activation of both pathways 
leads to a decrease in lateral membrane mobility, resulting in clustering of the FcαRIs  and 
subsequent enhanced binding of IgA, followed by activation of FcαRI. (5) Activation of FcαRI 
leads to activation of Rac and Src kinases, which mediate FcαRI responses such as production of 
superoxide and phagocytosis. 
 162 
 
Chapter 8 
 163 
Concluding remarks 
In this thesis, we have investigated via molecular/cellular tools, including gene array and 
real time RT-PCR, the activation of peripheral blood neutrophils in COPD patients 
(Chapter 2-4). These findings demonstrate that investigation of the transcriptional 
program of cells give insight into their activation state, and thus on the processes, in 
which they play an important role. Here we demonstrate that the activation state of 
neutrophils can be determined through various approaches including gene expression 
profiling, activation of intracellular signaling pathways and priming. In addition in 
Chapter 7 a new methodology was developed to determine activation of intracellular 
signalling pathways in a high-throughput assay. Understanding the molecular mechanisms 
regulating cellular function under distinct conditions (Chapter 5 and 6) is important to 
define the processes underlying activation of inflammatory cells. Furthermore, 
understanding how granulocyte function is perturbed can provide new therapeutic drug 
targets, that will restore proper neutrophil functioning. The ideal therapy would prevent 
unnecessary tissue damage while preserving the adaptive and benefical aspects of the 
inflammatory response.  
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Een aanhoudende ontsteking als reactie op ingeademde externe prikkels, zoals bij roken, 
wordt gezien als een belangrijke kenmerk voor chronisch obstructief longlijden (COPD). 
Deze ontsteking wordt onderhouden door een continue migratie van witte bloedcellen 
naar het longweefsel, waarbij speciale extracellulaire signaal eiwitten (cytokines en 
chemokines) betrokken zijn. Neutrofiele granulocyte is één van die witte bloed cellen die 
naar het longweefsel migreert en waarvan men denkt dat het daar een rol speelt in weefsel 
beschadiging. Neutrofiele granulocyten zijn belangrijke cellen voor het immuunsysteem 
omdat ze het lichaam verdedigen tegen micro-organismen. Ze kunnen namelijk bacteriën 
onschadelijk maken door ze “op te eten”. Dit “opeten” wordt ook wel fagocytose 
genoemd. Tijdens fagocytose komen veel schadelijke stoffen vrij die bedoeld zijn voor het 
vernietigen van de bacteriën. Bij onjuiste productie van deze schadelijke stoffen kunnen 
deze cellen ook veel schade toebrengen aan weefsels. Daarom bestaat de volledige 
activatie van deze cellen uit twee stappen. Tijdens de eerste stap worden de cellen in staat 
van paraatheid gebracht (pre-activatie), waarna een tweede activatie (bijvoorbeeld een 
infectie) resulteert in fagocytose en productie van toxische stoffen (zie ook Fig. van 
hoofdstuk 1).  
In dit proefschrift is onderzocht of circulerende neutrofiele granulocyten zijn geactiveerd 
in patiënten met COPD. Neutrofiele granulocyten kunnen na activatie verscheidene 
nieuwe eiwitten maken, zoals cytokines, chemokines, intracellulaire signaal eiwitten en 
eiwitten die in de wand van de cel zitten. Dus onderzoek naar de expressie van deze 
eiwitten kan duidelijk maken of deze cellen geactiveerd zijn. Eventuele expressie patronen 
zouden meer inzicht kunnen geven door welke stimuli deze cellen zijn geactiveerd. 
Daarnaast zouden deze expressie patronen ook meer inzicht kunnen geven in de ernst van 
COPD. Het maken van nieuwe eiwitten gebeurt via de processen transcriptie en translatie. 
Van het DNA dat als een mal fungeert, wordt een tijdelijke copie gemaakt tijdens het 
proces transcriptie. Deze tijdelijk copie van een gen wordt messenger RNA genoemd en 
fungeert weer als mal voor het maken van het desbetreffende eiwit. Dit proces wordt 
translatie genoemd. Activatie van deze cellen is onderzocht doormiddel van messenger 
RNA expressie patronen van de neutrofiele granulocyten. 
Hoofdstuk 2 toont aan dat neutrofiele granulocyten, gestimuleerd met enkele cytokines, 
verschillende gen expressie patronen laten zien. Dus aan de hand van deze gen expressie 
patronen zouden we kunnen bepalen op welke manier neutrofiele granulocyten zijn 
geactiveerd in COPD patiënten. Inderdaad, de gen expressie patronen van neutrofiele 
granulocyten van ernstige COPD patiënten vertonen een patroon van activatie die 
overeenkomt met die van neutrofiele granulocyten geactiveerd met signaal eiwitten zoals 
TNFα of LPS. Deze activatie is significant bij de meer ernstige COPD patiënten en 
correleert met de ernst van COPD. Uit het gen expressie patroon van neutrofiele 
granulocyten blijkt dat deze cellen ook cytokines en chemokines kunnen produceren, 
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waardoor deze cellen naast het aanbrengen van weefselschade ook de ontstekings reactie 
kan reguleren. Deze regulatie wordt bepaald door een balans van remmende en 
stimulerende cytokines/chemokines. Het lijkt dat deze balans in ciruclerende neutrofiele 
granulocyten van COPD patiënten is verstoort in het nadeel van remmende 
cytokines.chemokines. Door deze mindere productie van ontstekings remmende cytokines 
zouden neutrofiele granulocyten een rol kunnen spelen bij de handhaving van de 
ontsteking. Verder blijkt dat naast deze verhoogde activatie van neutrofiele granulocyten, 
de activatie variabel is binnen een patiënt (Hoofdstuk 4). Dit is vooral zichtbaar bij een 
een acute aanval (exacerbatie) van COPD (Hoofdstuk 3). Hierbij verandert het gen 
expressie patroon van neutrofiele granulocyten vergeleken met de meer stabiele periode. 
In plaats van een verhoogde activatie tijdens de meer stabiele periode van COPD, lijken 
de neutrofiele granulocyten weer vrij normaal tijdens een exacerbatie. Een verklaring kan 
zijn dat de geactiveerde neutrofiele granulocyten migreren naar de luchtwegen door 
hyperactivatie, terwijl de cellen die achterblijven in het bloed bestaan uit niet geactiveerde 
cellen of uit net geproduceerde cellen door het beenmerg. Het is bewezen door andere 
studies dat de instroom van neutrofiele granulocyten, maar ook dat van andere witte bloed 
cellen, toeneemt tijdens een exacerbatie van COPD. Verder is het waarschijnlijk dat 
hyperactivatie van neutrofiele granulocyten vooral in ernstige COPD patiënten, die al een 
lage longfunctie hebben, lijdt tot een verdere daling in longfunctie. Deze daling in 
longfunctie zal dan eerder tot ernstige klachten lijden of te wel resulteren in een 
exacerbatie, terwijl bij een mildere COPD patiënt, deze daling in longfunctie nog niet zal 
resulteren in ernstige klinische symptomen of een exacerbatie. Dus het volgen van de 
activatie van neutrofiele granulocyten kan helpen bij een beter diagnose van een 
exacerbatie en kan leiden tot een betere afstemming van het toedienen van medicatie.  
Verder hebben we de activatie van intracellulaire signaal eiwitten door cytokines en 
chemokines in granulocyten vergeleken met de functie van deze cellen. Cytokines en 
chemokines activeren beide de intracellulaire signaal eiwitten, Src kinases, die op hun 
beurt een ander signaal eiwit, Protein Kinase B (PKB) kunnen activeren (Hoofdstuk 5). 
Activatie van Src kinases door cytokines en chemokines spelen een belangrijke rol in het 
functioneren van neutrofiele granulocyten. Cytokines en chemokines reguleren de 
overleving van neutrofiele granulocyten en zijn belangrijk voor het maken van schadelijke 
stoffen zoals zuurstof radicalen. Een ander intracellulair signaal eiwit, Rac, wordt ook 
geactiveerd door chemokines, maar niet door cytokines. In Hoofdstuk 6 hebben we 
gevonden dat activatie van Rac resulteert in een verandering in binding van een 
extracellulair signaal eiwit, IgA. Het is bekend dat binding van IgA resulteert in 
fagocytose en productie van toxische stoffen door deze cellen. Dus activatie van Rac 
maakt de cel veel gevoeliger voor IgA oftewel Rac pre-activeert de cel zodat IgA de cel 
volledig kan activeren.  
Verder is er in samenwerking met het Academisch Medisch Centrum te Amsteram een 
nieuwe techniek ontwikkeld om op een snelle en eenvoudige manier de activatie van 
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intracellulaire signaal eiwitten te kunnen meten (Hoofdstuk 7). Door deze techniek is het 
een stuk eenvoudiger om veel patiënten te screenen op de activatie van intracellulaire 
signaal eiwitten. De combinatie van de activatie van intracellulaire signaal eiwitten en de 
gen expressie patronen zou een nog beter inzicht kunnen geven op welke manier cellen 
zijn geactiveerd. 
Samenvattend kan gezegd worden dat naast een beter inzicht in de rol van deze cellen in 
abnormale ontstekings reacties, zoals die zich afspeelt bij COPD, het ook belangrijk is om 
het onderliggende mechanisme van activatie van granulocyten te begrijpen. Aan de hand 
van deze informatie kunnen nieuwe specifieke remmers worden ontwikkeld, die eventuele 
weefsel schade zouden kunnen voorkomen. 
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